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ABSTRACT 
 
Rebecca R. Klatzkin: Prior Depression, PMDD, and Pain: Biological Mechanisms 
(Under the direction of Susan S. Girdler) 
 
The purpose of this study was to examine the extent to which premenstrual dysphoric 
disorder (PMDD) and major depressive disorder (MDD), two depressive disorders unique or 
more common to women, exhibit distinct alterations in stress-responsive measures and 
experimental pain sensitivity.  A total of 38 women completed all aspects of testing.  Of these 
women, 17 met strict Diagnostic and Statistical Manual of Mental Disorders criteria for 
PMDD and were compared with 21 non-PMDD women for PMDD-related differences.  For 
analyses regarding the influence of MDD on dependent measures, a history of MDD was 
used to model clinical MDD.  In our sample, 13 women had a history of MDD and 25 
women were classified as never depressed.  All women were tested for pain sensitivity to 
cold pressor and tourniquet ischemic tasks, sympathetic nervous system (SNS) (blood 
pressure, heart rate, norepinephrine) and hypothalamic pituitary adrenal (HPA)-axis (cortisol 
and β-endorphin) functioning at baseline, and SNS responses to mental stress tasks. 
PMDD women displayed decreased threshold and tolerance to the cold pressor task 
(i.e. greater pain sensitivity), and blunted SNS reactivity to speech stress when compared to 
non-PMDD women.  In addition, while Non-PMDD women showed a more consistent 
relationship between higher BP levels and decreased pain sensitivity, PMDD women showed 
a more robust relationship between greater β-endorphin levels and decreased pain sensitivity.  
Women with prior MDD showed persistent biological disturbances beyond the remission of 
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the depressive episode, reflected in increased cold pressor tolerance (i.e. decreased pain 
sensitivity), increased premenstrual mood symptoms, greater diastolic blood pressure (BP) 
responsivity to stress, and an enhanced relationship between BP and pain than never 
depressed women.  Finally, no diagnosis-related differences were found for any baseline 
HPA-axis factor. 
These results indicate that dysregulation in pain mechanisms and SNS stress 
reactivity, as well as in the relationship between pain and stress-related factors in PMDD and 
prior MDD, may be underlying physiological mechanisms contributing to the etiology of 
both disorders.  
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CHAPTER 1 
 
INTRODUCTION 
 
Mood Disorders in Women 
 Mood and anxiety disorders are highly prevalent in women throughout their lifetime.  
Female gender is substantially related to increased risk for affective disorders [1], since 
lifetime prevalence rates for affective disorders in the United States are 24% for women 
compared to 15% for men [2].  Specifically, mood disorders such as major depression, 
dysthymia, seasonal affective disorder, and generalized anxiety disorder are more prevalent 
in women than men [1, 3, 4], making the diagnosis and treatment of these disorders a strong 
focus in women’s health research [5].   
 The importance of gender in mood disorders is further emphasized by the fact that 
although the prevalence of affective disorders does not discriminate between prepubescent 
boys and girls, the risk for mood disorders increases in females upon puberty [6].  
Additionally, increased rates of affective disorders in females during the reproductive years, 
as well as menstrually-related mood disturbances such as premenstrual dysphoric disorder 
(PMDD) and perimenopausal and postpartum depression provide fuel for the notion that 
women are distinct in their susceptibility to psychiatric illness [1].   
 Not only do women suffer from affective disorders at a greater rate than men, they 
may experience a more severe form of these disorders.  Korstein et al. [7] studied both males 
and females with chronic MDD and found that women experienced more psychomotor 
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retardation, reported increased psychosocial impairment, and were therefore more severely 
depressed than men.  Furthermore, the World Health Organization named major depressive 
disorder (MDD) the number one cause of disease burden for women aged 18 to 44 [4].  Thus, 
the present study seeks to explore the potential biological and psychosocial mechanisms 
underlying women’s mood disorders in order to inform the development of future treatments. 
 
Major Depressive Disorder  
In 1990, Major Depressive Disorder (MDD) was ranked as the 4th leading cause of 
disability worldwide by the World Health Organization, and is projected to rise in the 
rankings by 2020 [8].  Since the disorder places such a great burden on societies around the 
world [8], it is important to fully understand MDD by recognizing the diagnostic criteria and 
the heterogeneous nature of the mood disorder.  The major criterion for MDD, as stated by 
the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV) [9], is 
the presence of at least one major depressive episode.  This is characterized by at least a two 
week period during which an individual experiences no less than 5 key components of major 
depressive symptomatology.  Specifically, one symptom must be either: 1) depressed mood 
and 2) loss of pleasure in normal activities, while the others may include insomnia or 
hypersomnia, psychomotor agitation or retardation, significant weight fluctuation, 
considerable fatigue, indecisiveness, feelings of worthlessness or excessive guilt, and 
recurrent thoughts of death or suicide [9].   
It is important that MDD is distinguished from other depressive disorders such as 
minor depressive disorder, dysthymia, and adjustment disorder with depressed mood, due to 
the similarities between the disorders and the need for accurate diagnoses to guide treatment.  
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Minor depressive disorder is differentiated from MDD by the lifestyle impact and number of 
symptoms, although both disorders are identical in duration [9].  For minor depression, two, 
but no more than five of the same symptoms listed for MDD must be present over a two 
week period.  A more chronic depressive disorder is dysthymia, which is characterized by 
dysphoric mood present during the majority of days in at least a two year period, with no 
incidence of a major depressive episode during that time.  Finally, adjustment disorder with 
depressed mood occurs in response to a significant psychosocial stressor, causing emotional 
and behavioral symptoms that develop within three months of the stressor onset.  The 
symptoms of adjustment disorder must either be above and beyond what would normally be 
expected in response to the stressor, or must significantly interfere with day to day 
functioning.  Symptoms must not persist for more than 6 months after an acute stressor has 
terminated, but may last longer if the stressor was chronic or had enduring consequences.  
Specifically, the subtype of adjustment disorder with depressed mood is diagnosed when the 
symptoms are predominantly depressed mood, feelings of hopelessness, and tearfulness [9].  
In order to achieve greater homogeneity regarding histories of DEP, the current study 
excluded women with prior minor depressive disorder, dysthymia, and adjustment disorder 
with depressed mood if no history of MDD had ever been present. 
Within the category of MDD, two distinct subtypes of the disorder are distinguished 
from one another, melancholic and atypical DEP [10].  Melancholic DEP is characterized by 
a general state of hyperarousal, commonly displayed in self-loathing that invades all thoughts 
and emotions, severe anxiety, insomnia, and loss of appetite, as well as a hyperactive 
hypothalamic-pituitary-adrenal (HPA) axis.  Atypical DEP is distinguished not only by a 
reversal of most melancholic symptoms, but also by a reversal of HPA-axis functioning.  
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Patients with atypical DEP are generally hypoaroused, reflected in low anxiety, increased 
food intake and sleep, feelings of emptiness, disconnectedness from their emotions, and a 
downregulated HPA-axis and sympathetic nervous system (SNS) [10].  Despite the opposing 
nature of atypical and melancholic DEP, many patients with MDD present with a variety of 
symptoms that do not clearly fit into either category.  Both subgroups of DEP are 
characterized by anhedonia and dysphoria, and only 25-30% of patients with MDD have 
purely melancholic features, while 15-30% present with purely atypical feature [10], making 
it difficult to distinguish between the two.  However, due to the opposing neuroendocrine and 
sympathetic profiles, all subsequent literary references to the diagnosis of MDD will include 
only the melancholic subtype of the disorder.   
 The current study also focuses exclusively on women, since data show a great divide 
between the genders in terms of the prevalence, etiology, and burden of MDD [11, 12].  
MDD is the leading cause of disease-related disability in women, affecting a greater 
percentage of females (21.3%) versus males (12.7%) [12], and this gender gap can be 
partially accounted for by endocrine control of the female reproductive system and hormonal 
fluctuations throughout the menstrual cycle.  Hormone changes during a woman’s life cycle, 
such as during the menstrual cycle, during the postpartum period, and during the menopausal 
transition, are associated with increased vulnerability to mood disturbances [1, 3, 4].  
Moreover, depressive disorders such as PMDD, postpartum depression, and menopausal 
depression are all associated with these hormonal fluctuations.   
 Further understanding of the biological determinants underlying the greater 
prevalence of MDD in women comes from studies on genetics [13], a major contributor to 
the onset of this highly heritable disorder [6-8].  Kendler et al. [13] found that the heritability 
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of liability to lifetime MDD was 30% greater in women than in men.  The study also 
determined that the genetic risk factors for MDD in males and females are positively 
correlated, but do not overlap completely, and thus contribute to the gender gap in MDD.  
Replication of this study in a Swedish sample yielded similar results, showing that the 
proportion of population risk in MDD ascribed to genetics is greater in women than in men 
[14].  This study [14], as well as a recent meta-analysis [15], found that genetic risk factors in 
men and women were positively correlated, but not identical.  Thus, the correlational data 
suggests that men and women share some, but not all, of the genetic determinants for MDD.  
In contrast, this sizeable meta-analysis [15] as well as a recent review [16] report no 
consistent sex difference in heritability of MDD, indicating that the gender differences in the 
prevalence of this disorder may not be explained by genetic factors.  Despite the 
inconsistencies in the literature on the genetics of MDD, the greater prevalence of this 
disorder in women and the various mechanisms underlying this difference provide cause to 
examine this disorder separately in women, as we do in the present study.  
 Irrespective of the biological, psychosocial, and personality factors underlying the 
gender difference in prevalence rate of MDD, the disorder is an encumbrance that both men 
and women are likely to carry for the duration of their lives.  The chronic nature of the 
disorder does not discriminate on the basis of gender, since the risk of a recurrent episode is 
similar for both men and women [17].  Over 75% of individuals who have had an episode of 
MDD will battle with remissions and recurrences of the disorder over their lifetime, with 
some estimates showing that after an individual experiences a second major depressive 
episode, the risk of a third becomes 70% within three years [18].  Furthermore, the degree of 
stress or disturbance necessary to trigger an episode of major depression decreases as the 
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number of recurrent episodes increases [19].  One possibility suggested by the statistics is 
that the high recurrence rate in MDD may be due to persistent disturbance in endogenous 
stress [20-26] and pain [27, 28] -related factors, indicating underlying neurobiological 
mechanisms involved with the disorder.  The current study focuses on women with a history 
of MDD who do not currently suffer from the disorder in order to avoid the inclusion of 
PMDD women with co-morbid MDD, a group that is biologically and clinically distinct from 
PMDD [29-34].  The goals of the current study include confirming our earlier work and that 
of others suggesting persistent biological and psychosocial disturbances beyond the 
remission of the depressive mood disturbance, and determining the special relevance prior 
MDD may have to PMDD. 
 
Premenstrual Dysphoric Disorder  
Premenstrual symptoms in women have been described for centuries, with one of the 
earliest accounts written by the Greek writer, Semonides, 2600 years ago stating, “One day 
she is all smiles and gladness.  A stranger in the house seeing her will sing her praise.... But 
the next day she is dangerous to look at or approach: she is in a wild frenzy... savage to all 
alike, friend or foe.”  Although it is not for certain, Semonides may have been describing the 
debilitating mood swings that coincide with the menstrual cycle in women with severe 
premenstrual symptoms.  In the same vein, Hippocrates believed that many psychological 
and behavioral problems were due to “retained menstrual blood”, and the ancient Greeks 
used the word “hysteria” to describe the belief that the uterus could “wander around” inside 
the body looking for a baby, causing mental illness that would remit upon menstruation [35].  
In 1847, Dr. Ernst von Feuchtersleben wrote “Menstruation is always attended, in sensitive 
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individuals, with mental uneasiness, which manifests itself according to the temperament, as 
irritability or sadness [36],” and taking the description of premenstrual symptoms further was 
the 11th century Italian gynecologist, Trotula of Salerno, who not only described the distress 
felt by these “sensitive” women but also the cyclic nature that characterizes the disorder: 
“There are young women who suffer in the same manner and are relieved when the menses 
are called forth [37].” 
It was not until the Great Depression in 1931 that New York physician Robert Frank 
coined the term “premenstrual tension” and gave the first modern biological description of 
cyclic variations in mood associated with the menstrual cycle [38].  Frank [38] described 
premenstrual tension as a syndrome comprising edema, weight gain, feelings of restlessness, 
irritability, and indescribable tension, in which women engaged in “foolish and ill-considered 
actions” (p. 1054) before menses, and also documented the remission of symptoms shortly 
after menstruation.  Although this description was a breakthrough in the medical literature, 
the symptoms listed were wide ranging emotional and physical ones, and thus did not clearly 
state the criteria for the disorder of premenstrual tension.   
In 1953, Dr. Katharina Dalton coined the term “premenstrual syndrome” [39] but it 
was not until 1986 that the British endocrinologist defined specific diagnostic criteria for the 
disorder that included premenstrual psychological and physical symptoms as well as the 
remittance of these symptoms with the onset of menstruation [40].  It was at this time that the 
American Psychiatric Association (APA) added Late Luteal Phase Dysphoric Disorder 
(LLPD) to the Diagnostic and Statistical Manual III Revised Edition (DSM III-R) under the 
heading “Proposed Diagnostic Categories Needing Further Study” [41].  After the addition to 
the DSM III-R was made, Spitzer and colleagues [42] described the rationale behind the 
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decision to give a precise and universally accepted definition to this syndrome.  They 
reasoned that mental health professionals were not properly informed about LLPD and 
therefore could not accurately diagnose and treat the disorder in their clients.  Furthermore, 
researchers studying the syndrome had difficulty differentiating women with the strict set of 
cyclic symptoms that would qualify as LLPD with women who only reported physical or 
mild emotional premenstrual symptoms or presented with chronic psychiatric disturbance 
that worsened premenstrually.  After the standardized diagnostic criteria for LLPD was 
published, clinicians were then able to accurately diagnose and treat women with the 
disorder, and researchers studying premenstrual symptoms were then able to follow the same 
diagnostic criteria to promote the generalizability of their findings [42].    
In 1994, the APA revised the operational definition of LLPD by reordering the 
symptoms and adding a new symptom (a subjective sense of being overwhelmed or out of 
control) and renamed it Premenstrual Dysphoric Disorder, the title which is currently used 
today.  PMDD, categorized by the DSM-IV [9] as a depressive disorder not otherwise 
specified, is described as the cyclic recurrence of a variety of emotional and physical 
symptoms of sufficient severity to interfere with function during the luteal phase of the 
menstrual cycle.  Such symptoms include irritability, anxiety, fatigue, mood swings, 
headache, and dysphoric mood, causing significant impairments to marital, parental, social, 
and work relationships [43].   
Strictly defining PMDD in the DSM-IV was also important in distinguishing the 
disorder from the commonly used generic term Premenstrual Syndrome (PMS) [43].  The 
distinction between PMS and PMDD lies in the severity of the premenstrual symptoms and 
in the diagnostic criteria, with the criteria for PMDD being more well-defined and stringent 
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(e.g. excluding symptom profiles consisting only of physical symptoms) [44].  However, 
Johnson et al. [29] points out that a common misconception is that PMS is characterized by 
strictly physical symptoms, whereas PMDD is strictly emotional.  She asserts the clinical 
reality to be that emotional, behavioral, and somatic premenstrual symptoms are experienced 
by women with PMDD and PMS, but the distinguishing factor is symptom severity, 
classified as mild, moderate, or severe.  Simply stated, PMDD is severe, functionally 
impairing PMS [29], with every PMDD woman experiencing PMS, but only a small 
percentage of PMS women meeting diagnostic criteria for PMDD [35]. 
Similarly, only approximately 35% of all women presenting as PMDD will meet 
DSM prospective criteria [45, 46], while the percentage of potential PMDD women meeting 
retrospective criteria is much larger [47] due to the unreliability of the method [45].  Women 
completing daily ratings in a retrospective fashion have been shown to report more 
significant symptoms and greater functional impairment than women prospectively reporting 
their PMDD symptoms [45].  Thus, obtaining prospective daily ratings in order to confirm 
strict, accurate PMDD diagnoses is an important methodological component in PMDD 
research, and is the practice employed by the current study.  
In order to meet PMDD criteria as outlined in the DSM-IV [9], there must be clear 
evidence of at least 5 of 11 specified symptoms during most of the last week of the luteal 
phase, accompanied by complete symptom remission shortly after the onset of menstruation 
during most menstrual cycles in a given year.  One of these 5 symptoms must be either 1) 
feeling sad, hopeless, or self-deprecating; 2) feeling tense, anxious, or on edge; 3) marked 
lability of mood interspersed with frequent tearfulness; or 4) persistent irritability, anger, and 
increased interpersonal conflicts.  Finally, these symptoms must markedly interfere with 
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work, school, social activities, and relationships with others, must be confirmed by 
prospective daily symptoms records over a minimum of two menstrual cycles, and because 
symptoms must be absent the week following menses, must be differentiated from the 
premenstrual exacerbation of a chronic depression, dysthymia or other mood disturbance [9].  
Although the DSM-IV [9] does outline strict diagnostic criteria, there is still the need for 
each research study to operationally define PMDD, since the DSM-IV [9] does not specify 
the use of any particular instrument for the completion of daily symptom ratings, nor does it 
provide threshold levels for symptom severity. 
In the general population, community-based studies that have prospectively assessed 
symptoms have shown that PMDD afflicts 4.6 – 6.7% of women in their reproductive years 
[48], and although the symptoms of PMDD are of shorter duration than those of other 
depressive disorders, the impact of PMDD symptoms on quality of life during the 
premenstrual luteal phase is equivalent to that seen with MDD, post-traumatic stress disorder, 
and panic disorder [31].  PMDD may begin at puberty and continues until menopause, lasting 
on average 37 years [30], with the disorder being most severe in the twenties to mid-thirties 
[43].  Thus, the burden of illness of PMDD is great due to the chronic nature of the disorder, 
as well as the functional impairment of work productivity, social and family relationships, 
and health related quality of life [48, 49].  For instance, during their reproductive years, 
women with the disorder have been estimated to suffer approximately 3.8 years of disability 
[30], and experience an economic burden of $4333 of indirect costs per year in the form of 
loss of productivity at work and missed work days [50]. 
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Histories of Depression and Premenstrual Dysphoric Disorder 
A strong association between histories of depression (DEP) and PMDD has been 
documented, indicating a high comorbidity of PMDD and a history of mood disorders, with 
lifetime estimates of mood disorders in PMDD women ranging from 30-70% [45, 51, 52].  
Harrison et al. [53] used the DSM-III-R [41] criteria to diagnose women with LLPD, and 
found that 70% of the 86 women with the disorder had a prior episode of MDD lasting at 
least four weeks.  Subsequent studies have found much lower prevalence rates, although the 
association between PMDD and prior DEP remains strong [54].  Pearlstein et al. [51] 
assessed the prevalence of prior MDD in prospectively diagnosed PMDD women and found 
36 of the 78 women (46%) to have experienced MDD in their lifetime.  Furthermore, Cohen 
et al. [45] assessed the prevalence and predictors of PMDD in a large community-based 
sample of women and, using prospective daily ratings as a diagnostic tool, and found that 19 
of the 33 women (57.6%) with PMDD had a prior history of DEP, and that PMDD women 
were significantly more likely to have had prior DEP than non-PMDD women (58% vs. 
28%) [45].   
Due to the high prevalence rate of a history of DEP in PMDD, it has been suggested 
that histories of DEP may play a role in the etiology of the disorder [55].  Kendler et al. [55] 
performed a longitudinal population-based twin study and found that premenstrual 
symptomatology and MDD share environmental and genetic risk factors, but the biological 
processes influencing the risk for premenstrual symptoms are only modestly related those 
affecting the risk for MDD.   
Women with PMS [56] and PMDD [57, 58] are also more likely to develop a future 
episode of MDD than are non-PMS or non-PMDD women.  Graze et al. [59] showed that 
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PMDD women with the highest depression scores on the Premenstrual Assessment Form 
were the most likely to develop an episode of MDD in the two to four year follow-up period, 
while Hartlage et al. [58] found that a small sample of women with PMDD were 14 times 
more likely to develop MDD in a two year follow up period than women without PMDD.  It 
is important to note that PMDD may also co-occur with other axis I disorders such as MDD, 
although the symptoms must be clinically distinct from the 11 symptoms associated with 
PMDD [60].   
Distinguishing between PMDD with a coexisting mood disorder and premenstrual 
exacerbation of a current mood disorder is a difficult but significant task, since treatment 
outcomes differ based on diagnosis [61].  Such differences in pharmacological treatment 
outcomes between PMDD and premenstrual exacerbation of MDD serve to support the 
biological distinction between the two disorders.  For instance, SSRIs are efficacious in 
relieving emotional, behavioral, and physical symptoms much more quickly [32-34] and at a 
lower dosage [31, 48] in PMDD than other psychiatric disorders, including MDD.  
Additionally, there is evidence that in women diagnosed with both atypical MDD and 
PMDD, the symptoms specific to PMDD may remain after successful pharmacological 
treatment of the major depressive symptoms [62]. Thus, these data suggest that while PMDD 
and MDD have higher then expected rates of comorbidity, they are clinically and 
pathologically distinct disorders.  
Moreover, a recent study by Pincus et al. [63] confirmed that the temporal pattern of 
symptoms in PMDD is distinct from that of a similar disorder, recurrent brief depression 
(RBD).  Specifically, the study used pulse detection algorithms, augmented by the statistical 
technique Approximate Entropy [64], to diagnose women with either PMDD, RBD, or 
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healthy controls based on defining characteristics of both disorders without reference to the 
menstrual cycle, by identifying the presence and degree of regularity in random prospective 
daily mood ratings.  Findings revealed that the symptom pattern of PMDD has more 
regularity, less brief or staccato spikes, and a greater standard deviation than that of RBD and 
control subjects, distinctions that can assist in more accurate diagnosis, and enhance the 
prediction and evaluation of treatment outcomes [63]. 
Although a distinct disorder, a prior history of DEP may have special relevance in 
PMDD symptomatology and biological responses to mental stress.  Examination of daily 
ratings made by women prospectively diagnosed with PMDD from an existing study 
performed in our laboratory led to the finding that for PMDD women, prior DEP was 
associated with greater luteal phase somatic severity ratings compared with never depressed 
PMDD women.  Furthermore, in that study, we reported that only in PMDD women with 
prior DEP did alterations in the progesterone-derived neurosteroid response to stress predict 
worse premenstrual symptoms, while neurosteroid reactivity failed to predict symptoms in 
PMDD women with no prior DEP [65].  
 
Etiology of PMDD 
The characterizing component to PMDD is its cyclic nature, since the ebb and flow of 
symptoms coincide with the menstrual cycle.  An idealized menstrual cycle is 28-days in 
length and is composed of three phases: follicular, ovulatory, and luteal.  The follicular 
phase, starting on day one of menstruation and ending at approximately day 12, is 
characterized by low progesterone levels and a lack of symptoms.  At the end of the follicular 
phase, gonadotropin releasing hormone (GnRH) released from the hypothalamus causes the 
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pituitary gland to release greater concentrations of follicle stimulating hormone (FSH) and 
luteinizing hormone (LH), signaling the ovulatory phase.  Ovulation occurs mid-cycle and 
lasts up to 48 hours, followed by the luteal phase of the menstrual cycle, in which high levels 
of both reproductive hormones estradiol and progesterone are present.  Thus, the 
distinguishing feature of the luteal phase is the presence of elevated progesterone.  The 
symptomatic luteal phase begins at approximately day 15 and continues until day 28, with 
the onset of menses marking the beginning of the next cycle.  Although women with PMDD 
only experience severe symptoms during the luteal phase of the menstrual cycle, this 
symptomatic phase causes a lasting detriment on their social and parental relationships 
during the remaining weeks of the menstrual cycle as well [43]. 
Due to the cyclical nature of the mood disturbance in PMDD, much early attention 
was paid to the pathophysiological role of the gonadal steroid hormones, particularly 
progesterone [66].  These studies determined, however, that women with or without 
premenstrual symptoms do not differ in their absolute levels of gonadal hormones [67], 
finding little evidence to support the view that either an excess or deficiency in progesterone 
or estradiol concentrations are etiologically relevant to the disorder [68].  Moreover, the 
majority of controlled trials have failed to find that progesterone administration is efficacious 
in PMDD [69, 70].   
Consequently, researchers suggested that premenstrual symptoms are most likely 
caused by aberrant reactions to normal fluctuations in hormone levels throughout the 
menstrual cycle [66, 71] and that PMDD women may be more sensitive to the mood 
modulatory effects of gonadal hormones [72].  Studies have shown evidence against a causal 
role for the fluctuating levels of estradiol and progesterone specifically during the late luteal 
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phase, however [48].  Specifically, findings have shown that a number of PMDD women are 
symptomatic with ovulation and during the early luteal phase prior to any significant change 
in progesterone concentration, that administration of progesterone during the luteal phase is 
ineffective in treating the disorder [66, 73], and that characteristic symptoms of PMDD are 
still present in the follicular phase of the next menstrual cycle after elimination of the mid- 
and late luteal phase via a progesterone receptor antagonist [46].  The latter study supports 
the notion that changes occurring prior to the mid- to late luteal phase, such as ovulation, 
influence PMDD symptomatology [46].   
Many studies have supported the importance of ovulation in PMDD, finding an 
absence of symptoms during non-ovulatory cycles, after ovariectomy, and following 
treatment with ovulation inhibitors [66].  Thus, GnRH agonists are highly effective at 
alleviating mood symptoms and somatic symptoms in PMDD women [74], since they induce 
a menopausal-like state of anovulation and amenorrhoea via decreased LH and FSH and 
consequently estrogen and progesterone concentrations [48, 73].  Long term use of GnRH 
agonists, however, has been shown to cause negative medical effects such as osteoporosis, 
increased risk of cardiovascular problems, menopausal symptoms, and hypoestrogenism, the 
last of which can be reversed with “add-back” estrogen-progesterone supplementation [29, 
73].  Unfortunately, some, but not all studies have shown that exogenous hormone 
replacement causes reinstatement of mood and anxiety symptoms in PMS and PMDD 
women, but not in controls [71, 75, 76].  In contrast, one study found that the reinstatement 
of symptoms in PMDD women remitted within four weeks of add-back treatment [71], 
suggesting that exogenous hormone replacement may only cause a short-term reinstatement 
of negative mood symptoms.  The fact that exogenous hormone treatment is eventually 
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needed to counteract the negative health effects of GnRH agonists, yet may reverse the 
positive effect on symptoms, supports the etiological theory that PMDD women display an 
abnormal response to normal hormone levels [71, 77], and also points to the idea that GnRH 
agonists may only be a short-term solution to the lifelong problem of PMDD [48].   
Despite the strict diagnostic criteria and more than 60 years of research into this 
disorder, the underlying pathophysiologic mechanisms underlying PMDD are only beginning 
to be determined.  The lack of a consensus on the biological determinants of PMDD and the 
subsequent failure to find a treatment that is efficacious in all women suffering with disorder 
speaks to the heterogeneity of PMDD and suggests that there may be certain subgroups of 
PMDD women, based on genetic predisposition or environmental factors, as well as a history 
of psychiatric conditions such as MDD, who do not respond to available treatments and for 
whom underlying biological mechanisms need to be identified.  Thus, one goal of the present 
study is to explore stress-responsive measures in PMDD women as well as in women with 
and without a history of MDD, since PMDD women have a high likelihood of having 
experienced a prior depressive episode [45, 51, 53, 54].  Our study intends to yield findings 
that will be important in clarifying the nature of PMDD as well as identifying subgroups of 
the disorder that may have a specific neurobiology and thus respond differently to treatments.   
 
Hypothalamic Pituitary Adrenal Axis and Sympathetic Nervous System Function in 
Response to Stress  
There is consistent evidence that women with histories of DEP and PMS experience 
increased daily stress [78-82].  Based on the findings for a major role of life stress in the 
pathophysiology of psychiatric illness [83], the assessment of neurobiological responses to 
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stress in patients versus controls has been used as an approach to elucidate the stress-illness 
relationship [84].  Furthermore, since both MDD and PMDD are either triggered or 
exacerbated by stressful life events [83], it is possible that long-term dysregulation in stress 
responsive systems contributes to both mood disorders as well as to the high comorbidity 
rates [45, 51-55]. 
The concept of stress dates back to the beginning of medical history itself, with 
Hippocrates referring to both the suffering associated with disease (pathos) and to the toil 
(ponos) that the body had to endure to restore homeostasis [85].  In more recent history, both 
Walter Cannon [86] and Claude Bernard [87] described the ability of all organisms to 
maintain a constancy of their internal milieu or homeostasis.  Seventy years ago, an 
individual’s response when faced with a significant physical or emotional stressor was 
referred to by Hans Selye [88] as the general adaptation syndrome (GAS).  The GAS is 
characterized by an integrated response involving multiple systems contributing to enhanced 
focus on the perceived threat, accelerated cardiac output (CO) and respiration, as well as 
blood flow to brain, heart and muscles to provide the fuel necessary to react to the potential 
threat [89].  Selye described the GAS as consisting of three distinct stages: 1) an initial brief 
alarm reaction, 2) a prolonged period of resistance, and 3) the final stage of exhaustion and 
death. The first stage is now referred to as the “fight or flight” response, during which the 
sympathetic nervous system (SNS) acts to combat the stressor through mechanisms such as 
increased BP, HR, and respiration.  If the stressor persists, the second stage of resistance 
begins, increasing the potential for overuse of the body's defense mechanisms.  In this stage, 
the SNS as well as the HPA-axis work even harder to maintain the heightened state of 
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arousal and sustained energy. Exhaustion or death finally ensues if the body runs out of its 
reserve of energy and immunity [88].  
 The SNS and the HPA-axis constitute the two major stress axes that work in concert 
to render the body capable of reacting to stressful stimuli and to bring the body back to 
homeostatic levels once the stress is terminated [90].  When a stressor arises, many counter-
regulatory systems are activated, but one of the primary stress response systems is the HPA-
axis, beginning with the activation of the hypothalamus.  The paraventricular nucleus of the 
hypothalamus releases corticotrophin releasing hormone (CRH), which travels in the 
hypophyseal portal circulation to the anterior pituitary gland, signaling the pituitary to release 
adrenocorticotropic hormone (ACTH) into the peripheral circulation.  ACTH then binds to 
receptors on the adrenal cortex to release glucocorticoids such as cortisol [91].  Cortisol then 
binds to postsynaptic glucocorticoid receptors (GRs), inducing a G-protein second messenger 
cascade and influencing gene protein expression.   
As an integral part of the stress response, cortisol acts throughout the body to inhibit 
the gonadal axis as well as inflammatory and immune responses, maintain muscle function 
and CO, and most importantly, elevate blood glucose to provide the body with the necessary 
fuel for the increased metabolic demands of stress [90, 92].  Under resting conditions, 
approximately two to three pulsatile bursts of CRH are secreted into the blood stream per 
hour, and these pulses follow a circadian pattern with greater amplitude in the morning.  
Under stressful conditions, however, the amplitude of CRH secretory bursts increases, which 
therefore also causes increases in ACTH and cortisol secretions [89]. 
The initial “fight or flight” reaction of the body to a stressor is only half the battle, 
since it is also necessary to shut off the body’s stress response when the threat is no longer 
                                                                                                                                        
 19
present.  Cortisol, as well as other stress hormones, acts as part of the negative feedback 
system of the HPA-axis that serves to regulate hormone levels produced in response to stress.  
Receptors on brain regions such as the hypothalamus and pituitary sense the excess, and less 
often deficiency, of stress hormones, and respond by either decreasing or increasing 
production of those hormones, respectively [90].  The endogenous opioid β-endorphin, 
released from both the hypothalamus and the pituitary gland, also plays a key role in the 
negative feedback loop by acting on the hypothalamus to inhibit the release of CRH, while 
additionally suppressing pain sensations in response to a stressor [92].  The negative 
feedback system is essential, since it allows the body to return to baseline levels of hormone 
secretion and helps to maintain homeostasis. 
The SNS, the other major player in the stress response, is comprised of preganglionic 
neurons that originate in the spinal cord and synapse with postganglionic neurons that 
innervate many muscles, organs, and glands throughout the body.  When a stressor arises, the 
SNS directly and indirectly causes the release of the catecholamines norepinephrine (NE) and 
epinephrine (EPI).  The locus coeruleus, the primary noradrenergic network in the central 
nervous system located in the mid-pons region of the brain stem, is activated and directly 
causes the secretion of the neurotransmitter NE from nerve endings innervating the heart, 
vasculature, and muscles among others [10].  The nerve endings of the SNS also innervate 
the adrenal medulla, thereby indirectly causing the release of NE and EPI from this region 
into the blood stream.  NE acts as a neurotransmitter in the SNS, and as a hormone when 
released from the adrenal medulla as part of the HPA-axis.  However, since EPI is the 
primary catecholamine released from the adrenal medulla in response to stress, plasma 
concentrations of NE mostly reflect SNS rather than HPA-axis functioning [93].  NE acts 
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primarily at α1- adrenergic receptors to increase smooth muscle contraction and 
vasoconstriction, and β1- adrenergic receptors in the heart to increase contractility, together 
causing increased HR, CO, and BP [94].  Thus, the SNS is the primary mediator of 
cardiovascular responses to stress. 
Although both systems are distinctly important entities, the SNS and HPA-axis work 
together in responding to a challenge.  Neural connections exist between the HPA-axis and 
the locus coeruleus, enabling both CRH and NE to stimulate the release of the other.  For 
example, the HPA-axis production of CRH not only stimulates the release of ACTH from the 
pituitary, but also activates the locus coeruleus to release NE in response to a stressor.  The 
SNS is also capable of activating the HPA-axis at the level of the hypothalamus, causing 
CRH release and consequently ACTH secretion, while it is also capable of suppressing the 
HPA-axis by inhibiting glucocorticoid activity through negative feedback [89, 94].  
Integration of the stress systems allows behavioral and peripheral changes that improve the 
ability of the organism to maintain homeostasis and increases the likelihood of survival [89]. 
 
Hypothalamic Pituitary Adrenal and Sympathetic Nervous System Function in 
Depression 
Dysregulation of the HPA-axis is well established in DEP, reflected in elevated 
baseline cortisol [95-102], CRH [97, 100], ACTH [96, 103], β-endorphin [101, 104], as well 
as diurnal cortisol [105, 106], NE [106] and ACTH [107, 108] compared to healthy controls.  
In response to stress, DEP is associated with decreased ACTH responses to CRH challenge 
[98, 99, 109, 110], and decreased ACTH [96] and cortisol [20, 96, 111] responses to mental 
stress, each reflecting CRH hypersecretion and thus an overactive HPA-axis at rest.  
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Furthermore, the majority of patients with DEP show cortisol non-suppression in response to 
dexamethasone (DEX) [102] and to a combined DEX/CRH test [103, 112-115], reflecting 
HPA-axis negative feedback dysfunction.  The SNS is also hyperactive in DEP, with patients 
showing elevated baseline NE [116-118], systolic BP (SBP) [119], and HR [106, 118, 120], 
stress-induced HR [117, 120, 121] and NE [117], as well as diurnal NE [105, 106], BP [105, 
122], and HR [105, 122, 123], indicative of heightened sympathetic activation.   
 
HPA-axis Dysfunction in Depression 
Basic biological mechanisms 
Despite the fact that the upregulation of the HPA-axis in DEP is one of the most 
common findings in the field of biological psychiatry [124-126], some variation in the 
literature regarding neuroendocrine as well as SNS functioning in DEP still exists in part due 
to the heterogeneity of the disorder.  Specifically, variations in biological mechanisms (e.g. 
hypercortisolimia and DEX non-suppression) and timing (acute vs. chronic), as well as 
differences between the two main subtypes (i.e. melancholic vs. atypical) of the disorder [10, 
97, 127-130] contribute to the difficulty in characterizing HPA-axis and SNS dysregulation.  
A recent review reported that at any given time, only 40-60% of medication-free patients 
with MDD display hypercortisolism, or an upregulation in cortisol secretion, which was once 
thought to be a fundamental attribute of the disorder [130].  Similarly, another biological 
marker once thought to signify a depressive disorder was the non-suppression of cortisol in 
response to DEX [131].   
The DEX suppression test (DST), in which a synthetic glucocorticoid is administered 
to provide negative feedback to the pituitary and consequently suppresses the release of 
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ACTH and cortisol in normal controls, was classically used as the major assessment of HPA-
axis functioning in DEP.  However, since DEX non-suppression of cortisol is now known to 
be present in only approximately 20-50% of depressed patients [113, 132], this once 
universal test is no longer a diagnostic tool for DEP nor widely used in the assessment of 
HPA-axis functioning [131].  DEX non-suppression, indicative of dysfunction in negative 
feedback control of the pituitary gland, does however have predictive power in that the 
response is associated with a more severe course of DEP and enhanced risk for relapse [133-
135] (see below).  
In 1981, CRH was discovered [136], and the production of a synthetic version of this 
hormone allowed further exploration into HPA-axis functioning in DEP, since administration 
of CRH causes the release of ACTH and cortisol [131].  Using this CRH challenge paradigm, 
many studies have found diminished ACTH but normal to elevated cortisol responses in DEP 
compared to healthy controls [10, 130, 137, 138].  A plausible explanation for this finding is 
the downregulation of pituitary CRH receptors in response to CRH overproduction, coupled 
with adrenal hypertrophy due to chronic stimulation.  This in turn leads to enhanced adrenal 
responsiveness to the diminished ACTH, explaining the increased cortisol response to CRH 
[10, 130, 137, 138].   Support for this explanation comes from a recent study by Newport and 
colleagues who found reduced ACTH secretion in response to CRH in women with MDD, 
and estimated that almost 60% of the variance in the blunted CRH/ACTH response in women 
with MDD was accounted for by CRH hypersecretion [109].  Enhanced cerebrospinal fluid 
(CSF) CRH levels in DEP is a common finding in the literature, and is considered a state 
marker of the disorder, as is adrenal hypertrophy and adrenal hyperresponsiveness to ACTH, 
since normalization occurs with successful treatment [97, 133, 137, 139-141]. 
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Changes in pituitary and adrenal responsiveness to heightened CRH over time and in 
accordance with DEX suppression status may provide an explanation for the multiple 
theories regarding the underlying mechanisms of HPA-axis upregulation in DEP.  For 
example, Parker at al [130] explains that acute DEP is characterized by an upregulated HPA-
axis at baseline coupled with normal pituitary and adrenal responsiveness to CRH and 
ACTH.  However, over time, chronic DEP is associated with elevated glucocorticoid 
negative feedback as well as blunted ACTH and normal cortisol responses to CRH due to 
adrenal hypertrophy [130].  Additionally, blunted ACTH responses to CRH infusion have 
been shown to occur in DEX non-suppressors, but not in those depressed subjects with 
normal DEX suppression [142].  Thus, variations in the length of the depressive state as well 
as the presence of DEX suppression may explain some of the discrepancies in the literature 
[130], and further studies controlling for these factors while assessing HPA-axis dysfunction 
in DEP are indicated.                                                                                                                                                                                               
Regardless of the inconclusive nature regarding the long-term, downstream 
consequences of enhanced CRH production, there is consistent evidence for heightened CRH 
concentrations in DEP [122, 166, 168, 170-172], for which animal studies have discovered 
important behavioral implications relating to the disorder.  Keen-Rhinehart et al. [143] 
discovered that female rats who show continuous production of CRH display increased 
depression-like behavior in response to the forced swim test compared to control females, 
and Holsboer and colleagues [144] found that CRH causes depression-like symptoms such as 
impaired sleep and motor behavior, decreased food consumption and sexual activity, and 
increased anxiety in animals.  The results of animal studies have further clinical implications, 
since CRH1 receptor antagonists have been shown to cause anxiolytic and anti-depressive 
                                                                                                                                        
 24
behaviors in pre-clinical animal models, and are currently being tested as potential treatments 
for melancholic DEP [132, 138, 145].  Thus, enhanced CRH production in DEP, reflecting 
heightened HPA-axis activity, has meaningful clinical implications.  
 
Impairment of HPA-axis negative feedback in depression 
Chronic CRH hypersecretion, and overall hyperactivity of the HPA-axis in MDD are 
thought to be strongly related to impairment or downregulation of GRs affecting negative 
feedback to the hypothalamus [131, 132, 137, 139].  Negative feedback is crucial for the 
proper regulation of the HPA-axis, since endogenous glucocorticoids must be able to bind to 
GRs at the level of the hypothalamus and the pituitary gland in order to slow the release of 
CRH and ACTH, otherwise causing a major disruption of the natural homeostatic 
mechanisms of the stress axis [131, 146, 147].   
A study by Wong et al. [106] supports the hypothesis that downregulated GR 
functioning, leading to impaired negative feedback, may cause of HPA-axis upregulation in 
DEP.  The study reported an absence of a negative correlation between CSF levels of CRH 
and plasma cortisol in depressed subjects, a correlation seen in controls, indicating an 
abnormal HPA-axis negative feedback system in DEP.  More recently, support for this 
hypothesis comes from studies using the combined DEX/CRH challenge, in which the once 
common CRH challenge paradigm is enhanced to include pretreatment with oral DEX one 
day in advance of CRH administration [148, 149].  The addition of DEX pretreatment allows 
the test to be more sensitive (greater than 80%) in detecting HPA-axis dysfunction, 
particularly in negative feedback control to the pituitary gland [112].  Studies using the 
combined DEX/CRH test support HPA-axis overdrive in MDD, since in controls, 
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pretreatment with DEX results in the expected suppression of ACTH and cortisol responses 
to CRH, but depressed patients respond to DEX pretreatment with an increased hormonal 
response to CRH [103, 112-115, 125, 138, 150].   
Studies using this DEX/CRH paradigm have given clinical relevance to the disruption 
of the HPA-axis negative feedback system in DEP.  Kunzel at al. [125] found a positive 
correlation between cortisol reactivity to the DEX/CRH test, reflecting non-suppression, and 
number of previous episodes of a depressive disorder, as well as with overall score on the 
Hamilton Depression Scale.  The combined DEX/CRH test has also been found to predict the 
clinical response to treatment.  Ising et al. [128] found that DEX suppression on admission 
and persistent non-suppression of cortisol to DEX/CRH at follow-up predicted unfavorable 
responses to antidepressant treatment.  Thus, the literature points to dysfunction in negative 
feedback mechanisms in DEP that are associated with HPA-axis upregulation and contribute 
to the depressive symptoms associated with the disorder. 
 
HPA-axis responses to psychological stress in depression 
In contrast to DEX/CRH challenges and GR manipulations, mental stressors have 
yielded less conclusive observations of HPA-axis hypo-responsivity in DEP, reflecting 
heightened basal output, which may be due to variability in the type of psychological stressor 
used [151].  However, a recent meta-analysis by Burke and colleagues [127], assessed eight 
methodologically sound studies for cortisol responses to psychological stress in MDD and 
found that in patients with MDD compared to controls, higher baseline cortisol levels were 
associated with blunted cortisol stress responses [127].  The relationship between increased 
baseline and decreased stress-induced cortisol is consistent with physiological research 
                                                                                                                                        
 26
showing that heightened baseline cortisol has an inhibitory effect on stress levels [95].  Thus, 
the meta-analysis supports the findings of the CRH and DEX/CRH challenge literature for 
HPA-axis upregulation in DEP, since blunted cortisol in response to psychological stress 
reflects HPA-hyperactivity at baseline.  
One study assessed in the meta-analysis [127] was a one by Gotthardt and colleagues 
[96], who found increased levels of ACTH, cortisol, BP, and HR prior to a signal-detection 
task stressor in MDD patients compared to controls.  In response to the stressor, depressed 
subjects showed no significant increase in ACTH and cortisol, while control subjects showed 
a normal stress-induced increase [96].  The meta-analysis [127] not only included studies 
using laboratory stressors, but daily life stressors as well.  For example, Peeters et al. [111] 
assessed cortisol responses in subjects with MDD and found that although cortisol was 
significantly elevated in response to negative life events in controls, those with MDD 
experienced no cortisol response.  Furthermore, manipulation of participants’ feelings of 
control via induction of success and failure in a number addition test was used as the stressor 
in a study by Croes and colleagues [152].  Although there were no differences at baseline, the 
study found that while controls showed the expected decrease in cortisol to controllable 
success and an increase in cortisol in response to the uncontrollable failure stressor, 
individuals with MDD showed an average decrease in saliva cortisol in response to both 
conditions, reflecting HPA-axis dysregulation [152].   
Additionally, Young et al. [95] found partial support for HPA-axis hyperactivity in 
MDD in a study assessing cortisol and β-endorphin levels in subjects with MDD both before 
and after a mental stress battery.  The study replicated previous findings for heightened 
baseline levels of both cortisol and β-endorphin in DEP [101, 104] which would be expected 
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to inhibit the HPA-axis stress response.  The heightened baseline cortisol and β-endorphin in 
MDD did inhibit the β-endorphin response to mental stress, since MDD patients showed a 
blunted β-endorphin response compared to controls, but did not inhibit the cortisol stress 
response in MDD patients, since both MDD patients and controls exhibited normal cortisol 
responses to mental stress.  Thus, baseline and post-stress cortisol levels were inversely 
correlated in controls, but not in patients with MDD.  These results are clinically relevant, 
since repeated heightened cortisol responses to continuous life stressors may be involved 
with the etiology of DEP and the mood changes that exacerbate the disorder [95].   
Patients with Cushing’s disease, a condition characterized by cortisol overproduction, 
also give evidence for the negative mood consequences of chronic cortisol exposure, since 
the condition is associated with a high rate of mood disorders that resolve following 
successful treatment with metyrapone, adrenalectomy, and pituitary irradiation [124].  
Moreover, chronically enhanced cortisol levels due to long term stress can have detrimental 
consequences such as loss of bone mineral density, hippocampal suppression resulting in 
deficient short-term memory, as well as neuronal death in the hippocampus [153].   
In summary, the majority of studies in current DEP point to a hyperactive HPA-axis, 
reflected in heightened levels of β-endorphin, cortisol, and ACTH at baseline, levels 
hypothesized to inhibit the stress response and contribute to the blunted HPA-axis 
responsiveness to stress seen in DEP.  HPA-axis overdrive manifested in a reduced stress 
response in women with MDD may at first seem counterintuitive, but is consistent with the 
allostatic load model of chronic stress [153-155].  In humans, the price of repeated biological 
adaptations to stress has been termed allostatic load and refers to the long-term effect of 
physiologic responses to stress.  Allostatic load may be expressed as repeated elevations of 
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neurohormonal stress mediators (e.g. cortisol, NE) over long periods, as a failure to adapt to 
the same stressor, as a failure to shut off the normal stress response, or as an inadequate 
hormonal response to stress that may allow other systems that are normally counter-regulated 
to become overactive (e.g. inadequate secretion of glucocorticoids resulting in increased 
levels of inflammatory factors that are normally regulated by the glucocorticoids).  It has 
been suggested that such hypoactivation of stress responses may result from a wearing out or 
exhaustion of the stress-responsive system due to long-term allostatic load [153-155].   
 
SNS Dysregulation in Depression 
Upregulation of the SNS in addition to the HPA-axis has been found in current DEP.  
A strength of the present study is our assessment of both SNS and HPA-axis factors in MDD, 
since there is a comparative lack of SNS versus the HPA-axis assessments in DEP.  Existing 
studies that have in fact measured SNS factors report that patients with DEP show heightened 
baseline [116-118], diurnal [105, 106], and stress-induced NE [117], elevated baseline [119] 
and diurnal BP [105, 122], along with heightened baseline [106, 118, 120], diurnal [105, 122, 
123], and stress-induced [117, 120, 121] HR.   
Even elevated depressive symptoms in the absence of clinical DEP are associated 
with increased 24 hour urinary NE and HR in daily life [156], as well as increased BP, HR, 
CO, and NE in response to a speech stressor [157], and heightened systolic BP in response to 
an exercise challenge [104].  A meta-analysis of 11 studies on the relationship between 
cardiovascular reactivity and depressive symptoms found reasonable support for a positive 
relationship between SBP, DBP, HR reactivity and severity of depressive symptoms, with 
moderate to small effect sizes reported in the literature [158].  A recent study [159] assessed 
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caregivers of spouses with Alzheimer’s disease for plasma NE concentrations at baseline and 
in response to a speech stressor, and found that depressive symptoms was a positive predictor 
of post-stress NE levels.   
Despite the literature showing increased SNS measures in current DEP, opposing 
results have been reported.  Two recent studies [160, 161] found a negative correlation 
between depressive symptoms and SNS factors, specifically systolic BP and HR during 
psychological stress in medically healthy controls [160], and both systolic and diastolic BP at 
psychological stress, and change in HR and diastolic BP from baseline to stress in coronary 
artery disease (CAD) patients [161].  However, in the latter study, in addition to having 
CAD, many participants had multiple co-morbid health conditions and were taking 
antidepressant medication [161], while the former study reported only small effect sizes 
[160].  Despite these contradictory findings, the majority of the available evidence suggests 
that current DEP, or elevated depressive symptoms in the absence of clinical DEP, are 
associated with heightened sympathetic as well as HPA-axis functioning, though it must be 
acknowledged that this pattern may reflect melancholic DEP only [129, 162].   
 
HPA-axis and SNS Dysregulation in Individuals with a History of Depression 
HPA-axis and SNS functioning in prior depression compared to current and no prior 
depression 
One aim of the current study is to examine whether altered sympathetic and HPA-axis 
activation persists in women who are currently free of depressive illness but who have a 
history of MDD.  Possible SNS and HPA-axis dysregulation in healthy subjects with a 
history of DEP may contribute to the risk for development of subsequent mood disorders, 
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due to the high rate of recurrence of the depressive disorders and the negative correlation 
between episodes of DEP and amount of stress needed to trigger an episode of major 
depression [18].  Although many intervention studies have been performed assessing SNS 
and HPA-axis functioning both before and after successful antidepressant treatment (see 
below) [128], only a handful of studies have made these assessments in euthymic individuals 
with a history of MDD without using a pre- versus post-treatment design.   
One such study was performed by Young et al. [21] using a cohort of monozygotic 
twins, finding higher diurnal salivary cortisol in currently euthymic participants with a 
history of MDD, compared to individuals without a history of MDD.  Additionally, Kathol 
and colleagues [22] found that individuals recently in remission from MDD had greater 
diurnal mean urinary cortisol levels than those who had no history of MDD.  Similarly, 
Broadley et al. [24] found greater resting diastolic BP and HR in euthymic participants with 
prior recurrent MDD compared to controls with no history of psychiatric illness.  Recently, 
Davydov et al. [23] conducted a study in which resting SNS factors in patients in partial 
remission from MDD (as defined by scores between 7 and 18 on the Hamilton Depression 
Scale) and taking various antidepressant medication were examined and compared to healthy 
controls.  The study found heightened systolic BP and low-frequency HR variability in the 
patients compared to controls, indicative of increased SNS activity, after partial remission of 
the depressive illness [23], though the current use of psychotropic medications limits the 
conclusions that can be drawn.   
Stress-responsive SNS and HPA-axis measures have also been assessed in individuals 
with prior DEP, with results supporting the notion of sustained dysfunction of the HPA-axis 
and SNS following remission.  For example, in a study comparing patients with current and 
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prior MDD and controls for HPA-axis responses to a mental arithmetic stressor, findings 
showed a blunted cortisol response in current and former MDD patients compared to 
controls, reflecting an inhibition of the stress-response due to heightened baseline HPA-axis 
factors [20].  Additionally, Pintor et al. [163] found no differences between outpatients in 
recovery from MDD and those who were currently depressed in their cortisol and ACTH 
responses to CRH challenge, with depression groups showing lower ACTH coupled with 
greater cortisol responses compared to healthy controls.  Since 72% of those patients with 
current MDD had at least one previous depressive episode, and those in recovery from MDD 
had, on average, 2.75 previous episodes, it follows that these results are consistent with the 
literature in chronic DEP for heightened cortisol but reduced ACTH versus acute DEP [130].   
It is important to note, however, that the majority of subjects in both groups were taking 
tricyclic antidepressants, which have been shown to directly regulate the HPA-axis by 
increasing GR concentrations [25], and thereby enhancing GR-mediated negative feedback 
capabilities.   
In contrast, a recent study compared women with remitted MDD to those with no 
history of affective disorders for SNS and HPA-axis factors at baseline and in response to 
mental stressors, finding overall hypoactivity in the remitted subjects [26].  Specifically, 
Ahrens et al. [26], found decreased mean arterial pressure (MAP), serum cortisol and NE at 
baseline as well as a blunted serum cortisol and ACTH response to the stressors in remitted 
subjects compared to controls.  However, the results are far from consistent, since no 
differences between groups were seen in ACTH at baseline, HR and heart rate variability 
(HRV) at any time point, as well as in the NE and MAP response to stress.  Furthermore, the 
results may be skewed by the presence of other current or past mood disorders such as 
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anxiety and post-traumatic stress disorders, which were not assessed via formal interview.  
The present study controls for these factors, and thus holds the opposing hypothesis that 
women with prior MDD will show upregulation of the HPA-axis and SNS, the former 
reflected  by heightened baseline levels serving to inhibit the HPA-axis stress response, as 
supported by the vast majority of the literature [124, 126].  Thus, the present investigation 
extends previous literature by being the first, to our knowledge, to assess SNS measures of 
BP and HR in response to mental stress in euthymic women with a history of MDD. 
Strengthening the notion of persistent HPA-axis hyperactivity in individuals with 
prior DEP are studies assessing euthymic first degree relatives of depressed patients [114, 
164].  In these reports, this high risk group showed cortisol release in response to the 
DEX/CRH test that was between healthy controls and currently depressed patients [164], 
which was maintained over a four year follow up period [114] and suggests a stable genetic 
component contributing to HPA-axis dysregulation, possibly affecting the vulnerability for 
development of a depressive disorder [114, 131].  The genetic link between HPA-axis 
hyperactivity and DEP is enlightened by the fact that DEP is highly heritable [6-8] and 
family and twin studies show that a genetic predisposition is a major contributor to the 
development of an affective disorder [114].  Thus, it is possible that women who show 
persistent, non state-dependent HPA-axis upregulation beyond the remission of the 
depressive disorder may be more likely to have a genetic predisposition for the disorder. 
 
Post-treatment HPA-axis and SNS dysregulation 
Studies examining HPA-axis and SNS dysregulation in patients in remission from 
DEP after successful antidepressant treatment have yielded mixed results.  A minority of 
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studies have found evidence for an elevated HPA-axis that endures beyond antidepressant 
treatment and remission of the depressive episode.  For example, Banki et al. [165] showed 
persistently heightened CSF-CRH levels both before and after antidepressant treatment 
despite symptom improvement, while Deuschle et al. [166] found that saliva cortisol 
concentrations remained high compared to pretreatment levels after treatment of MDD with 
the SSRI paroxetine, despite a decrease in depressive symptoms.  However, this study [166], 
along with two others [103, 148] also treated MDD patients with another type of 
antidepressant, tricyclics, and found mixed results.  Although cortisol concentrations and 
responses to the DEX/CRH challenge normalized as DEP symptoms improved, ACTH levels 
and responses to DEX/CRH remained higher than controls.   
Further support for dysregulation beyond the remission of the depressive disorder 
comes from a study by Veith et al. [116] who found heightened NE concentrations at 
baseline in MDD patients being treated with tricyclic antidepressants compared to controls.  
Although the antidepressant reduced NE levels initially in all subjects, this effect was 
reversed after 28 days of treatment.  These results should be interpreted with caution, as 
should any findings from antidepressant treatment studies assessing SNS functioning by 
measurement of NE, since upregulated NE activity may be indicative of a reduction of NE 
synaptic clearance and not SNS activity per se [116, 167].  Overall, these studies show 
persistently heightened HPA-axis and sympathetic functioning even after successful 
treatment of the depressive disorder.  
In contrast, the majority of studies have reported normalization of HPA-axis and SNS 
parameters following antidepressant treatments [103, 146, 149, 166, 168-171], vagus nerve 
stimulation [110], and cognitive behavioral therapy [172].  These studies show a reduction of 
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high pretreatment levels of HR [172] ,CSF-CRH [168, 170], β-endorphin [170], arginine 
vasopressin [168], and saliva cortisol [166], as well as a decreased ACTH [110, 169] and 
cortisol [103, 148, 169, 171] responses to DEX/CRH challenge.  Ising and colleagues [128] 
argued that HPA-axis normalization, specifically GR functioning, is a key factor in the 
success of antidepressant drugs, and that the degree of normalization of the HPA system 
correlates with and predicts clinical efficacy of antidepressants [173].  These results support 
the theory that GR dysregulation is crucial for HPA axis hyperactivity in DEP, as do further 
reports that antidepressants increase GR expression and function, as well as GR-mediated 
HPA axis feedback inhibition, thus downregulating baseline and stress-induced HPA axis 
functioning [146, 147].   
A limitation of many of the abovementioned studies finding normalization of SNS 
and HPA-axis hyperactivity after successful treatment is the relatively short length of time 
between baseline and post-treatment testing.  The majority of studies scheduled the follow-up 
testing 6 weeks or less after baseline [103, 112, 166, 168, 169], while others scheduled their 
post-treatment assessment 3-4 months after the initial visit [110, 172].  Therefore, 
normalization of HPA-axis as well as SNS factors after treatment may be a short-term 
phenomenon that initially overrides the “trait” characteristic of heightened HPA-axis and 
SNS activity, but returns over time and becomes uncoupled from symptom improvement.  
The current study addresses this issue by assessing baseline and stress-induced SNS activity 
in women with prior MDD who have been free of the disorder for at least one year, 
irrespective of the type of treatment or cause of remission, and therefore is an important 
addition to the existing literature.  
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Relationship between risk of depression relapse and persistent HPA-axis upregulation 
The inconsistencies in the literature regarding HPA-axis dysregulation after 
antidepressant treatment may be due to individual variation in the risk for relapse and poor 
outcomes [134, 146].  Aubry and colleagues [174] assessed cortisol suppression in response 
to the combined DEX/CRH test in controls and in subjects with prior MDD taking various 
antidepressants, and proceeded to follow those with prior MDD for one year to determine 
relapse rates.  Cortisol concentrations in response to the DEX/CRH challenge were 
significantly greater in the subjects who relapsed than in controls, although there was no 
difference in cortisol suppression between controls and those in prolonged remission [174].  
This study showed the ability of heightened cortisol responses to the DEX/CRH test to 
predict MDD relapse.  This predictive outcome of non-suppression after successful treatment 
was verified by Ribeiro et al. [134], who performed a meta-analysis of seven 
methodologically sound studies assessing patients with DEP for non-suppression of cortisol 
after DST, and found that overall, the persistent non-suppressors had worse outcomes, such 
as hospitalization, suicide, and symptom recurrence, than did suppressors.   
More recently, Zobel et al. [175, 176] discovered that inpatients in remission from 
MDD whose plasma cortisol responses to the combined DEX/CRH test remained high or 
increased after various antidepressant medications, were more likely to have relapsed within 
six months of discharge than those remitted patients with low cortisol reactivity.  Similarly, 
Appelhof and colleagues [177] showed that regardless of treatment strategy for patients with 
MDD (antidepressant, thyroid hormone, or placebo), cortisol non-suppressors to DEX/CRH 
challenge after successful remission were at higher risk for relapse than suppressors. These 
studies showing patient variation in risk for relapse may explain the discrepancies in the 
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literature regarding baseline HPA-axis dysregulation as well as sustained HPA-axis overdrive 
after symptom remission, since studies failing to find upregulated HPA-axis factors at either 
time point may only be assessing those patients who will never develop a future depressive 
episode.  Systematic studies are needed to specifically address this notion by assessing 
cortisol non-suppression in response to DEX/CRH challenge in controls and MDD patients at 
baseline, after successful antidepressant treatment, and at long-term follow-up.   
Many explanations for the predictive abilities of HPA-axis non-suppression at post-
treatment have been proposed.  It may be that the phenomenon is indicative of an active but 
resolving depressive state that changes with severity of the disorder, or that persistent non-
suppression only occurs in a specific population of patients with certain demographics or 
characteristics of the disorder, or finally that persistent non-suppressors and suppressors 
differ on the pathophysiological mechanisms underlying the disorder [134].   Future studies 
are needed to address these theories in order to determine the potential for HPA-axis non-
suppression to be a predictive tool for the development of future MDD episodes as well as 
the effectiveness of treatment.   
In conclusion, despite some discrepancies in the literature and various plausible 
explanations regarding HPA-axis dysfunction in DEP, the clinical relevance of this 
phenomenon cannot be discounted.  Due to the predictive abilities of the combined 
DEX/CRH test to determine antidepressant treatment outcome, the test may become a 
surrogate marker providing information at the pre-treatment stage regarding the potential for 
antidepressants to be clinically efficacious by normalizing GR signaling.  Studies assessing 
this exciting possibility are underway, and will no doubt have a profound effect on improving 
treatment for this debilitating disorder [128, 145].  
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Hypothalamic Pituitary Adrenal and Sympathetic Nervous System Function in 
Premenstrual Dysphoric Disorder 
Despite the longstanding interest in menstrually related mood disorders and their 
prevalence, experimental studies examining sympathetic and HPA-axis function in PMS and 
PMDD women have been scant.  A review of the literature on physiological stress responses 
in PMDD and PMS [178] reported that existing studies have yielded inconsistent results but, 
when considered together, the majority of available evidence points toward downregulated 
HPA and SNS axes.  For instance, PMS women have been shown to display reduced 
peripheral β-endorphin levels during the luteal, symptomatic phase of the menstrual cycle 
compared to their own follicular phase [179], and also compared to non-PMS women during 
the luteal [179-181] and follicular [182] phases.  Low β-endorphin levels have been found to 
significantly increase with the alleviation of premenstrual symptoms with hormone 
replacement therapy in PMS women [183], results that signify a putative role for the 
neurotransmitter in the etiology of the disorder.   
In addition to any pathophysiological role of estradiol or progesterone in PMDD, 
dysregulation in GABAergic progesterone-derived neurosteroids, or a differential sensitivity 
to these metabolites, has also been implicated in the disorder [65, 184, 185].  Of particular 
relevance to PMDD may be the neuroactive steroid allopregnanolone (ALLO), a metabolite 
of progesterone produced by the ovaries, adrenals, and de novo in brain [186], since plasma 
levels of ALLO follow closely those of progesterone during the symptomatic luteal phase 
[187].  ALLO is a potent modulator of GABAA receptors, enhancing inhibitory 
neurotransmission by increasing the time during which Cl- ion channels are open [188, 189], 
and it is through this mechanism that it exerts profound anxiolytic effects [190-192].  While 
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the literature on baseline ALLO concentrations in PMDD is quite mixed [187], it has been 
hypothesized that an increase in ALLO after successful SSRI treatment is an important 
source of symptom improvement [48], supporting studies showing associations between 
symptom improvement after SSRI treatment and ALLO increases in MDD [193-195].  
Additionally, ALLO attenuates stress-induced HPA-axis activity [196, 197] and can be used 
as a measure of HPA-axis activity since it is released by the adrenal gland.  Lombardi et al. 
[198] found that PMDD women had a significantly blunted adrenal ALLO response to an 
ACTH stimulation test following DEX suppression compared to controls during the luteal, 
but not the follicular phase.  Since ACTH normally elicits an increase in ALLO production 
by the adrenals [199], blunted ALLO in this study may reflect adrenal hyporesponsitivity to 
stress in PMDD women during their symptomatic phase of the menstrual cycle [198].  
Exercise stress paradigms have also been used to assess HPA-axis downregulation in 
PMS.  Roca et al. [200] physically challenged both PMS and control women with a treadmill 
exercise and found that PMS women did not show the luteal phase enhancement of HPA-axis 
factors compared to follicular phase levels, a menstrual cycle effect normally seen in controls 
[201].  Specifically, Roca et al. [200] found that controls showed a luteal phase increase in 
arginine vasopressin, ACTH, and cortisol compared with the follicular phase, while PMS 
women failed to show this difference.  Also observed was a trend towards a lower exercise-
induced cortisol/ACTH ratio in PMS women across the menstrual cycle, indicating a 
diminished adrenal responsivity to exercise stress.   
Blunted HPA-axis responses to serotonergic agents have also been documented in 
PMS [34, 202].  Su et al. [34] found reduced ACTH responses to m-Chlorophenylpiperazine, 
a serotonin receptor agonist, in PMS women compared to controls in both the follicular and 
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luteal phases of the menstrual cycle, as well as blunted cortisol responses to m-
Chlorophenylpiperazine in PMS versus controls in the luteal phase only.  Additionally, 
Bancroft et al. [202] found reduced cortisol responses to L-tryptophan, a serotonin precursor, 
in women with PMS versus controls in both menstrual cycle phases.  In another challenge 
paradigm, Facchinetti et al. [181] compared women with severe PMS and asymptomatic 
controls for plasma cortisol responses to naloxone, an opioid receptor antagonist, and CRH 
during the symptomatic luteal phase of the menstrual cycle and found conflicting results.  
The expected increase in cortisol in response to naloxone occurred in the controls, but was 
significantly blunted in the PMS women, supporting HPA-axis downregulation in PMS.  In 
contrast, the expected release of cortisol in response to the CRH challenge was heightened in 
PMS women compared to controls, which the authors suggest may be a compensatory 
mechanism for the reduced HPA-axis negative feedback from endogenous opioids [181].    
Further discrepancies in the literature regarding stress responses in PMS come from 
studies showing no PMS related differences in the biological stress response.  For example, 
Van den Akker and Steptoe [203] found no differences in HR at baseline and in response to 
mental stress between women with PMS and healthy controls.  Methodological factors 
potentially contributing to these inconsistencies concerning SNS and HPA-axis functioning 
in PMS include small samples, differences in the timing of cycle phase, and lack of hormonal 
verification of phase.  Another important factor involves the lack of prospective symptom 
assessment to classify PMS women in many of these studies [204-208], increasing the 
likelihood of false positive diagnoses [209].  Thus, the PMS cohorts were likely to have been 
heterogeneous with respect to symptom severity, ranging from mildly symptomatic, to 
PMDD.   
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Earlier work from our laboratory using prospective ratings to confirm DSM criteria 
for PMDD and which excluded women with current Axis I disorders, did find evidence for 
reduced sympathetic activation in response to stress in PMDD women in both cycle phases 
[78].  Although no differences were found at baseline, PMDD women showed blunted HR 
and diastolic BP reactivity, as well as a trend toward reduced CO and systolic BP reactivity 
to a variety of laboratory psychological stressors relative to non-PMDD women [78].  
Additionally, in a separate cohort of women, our laboratory found lower stroke volume, CO, 
and cortisol both at baseline and in response to mental stress in PMDD women versus 
controls [79].  More recently, in a 3rd cohort of PMDD women with or without prior abuse, 
evidence showed that never abused PMDD women have lower stress-induced systolic and 
diastolic BP and HR than never abused non-PMDD controls [210].   The present study builds 
on these findings by introducing prior MDD status, a disorder that is prevalent in PMDD [45, 
51-54], as a potential moderator of the relationship between SNS and HPA-axis 
dysregulation and PMDD. 
 
Stress Response Dysregulation In PMDD May Be Due To Higher Prevalence Of Depression 
History 
A factor that was not accounted for in the vast majority of these earlier studies on 
SNS and HPA-axis functioning in PMDD, and which research from our laboratory suggests 
would impact biological responses to stress [65], concerns the impact of histories of 
psychiatric disorders.  Our research in women with PMDD indicates that histories of 
affective illness can result in persistent dysregulation in stress-responsive biological 
measures, including measures reflecting HPA-axis and SNS dysfunction, even in the absence 
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of current psychiatric illness [65].  As described above, studies from our laboratory as well as 
others assessing stress responses in women with PMDD have shown distinct SNS and HPA-
axis profiles in PMDD versus non-PMDD women.  However, more recent studies from our 
laboratory have revealed that these differences may have reflected, at least in part, the higher 
prevalence rates of prior DEP in PMDD [39, 40].  Thus, this earlier work was limited by its 
failure to recognize the special relevance that prior DEP may have for PMDD women.   
Consequently, our laboratory went on to examine whether histories of DEP in PMDD 
were associated with alterations in the ALLO response to stress in 26 PMDD women (14 
with prior DEP) and 39 non-PMDD controls (17 with prior DEP) tested in the luteal phase of 
the menstrual cycle [65].  In this study, all women with prior DEP, regardless of PMDD 
status, showed a decrease in ALLO in response to stress compared with a moderate ALLO 
increase in never depressed women, and also failed to show the expected decrease from 
venipuncture to baseline rest compared to never depressed women [65].  Results suggested 
that in women with histories of DEP, even in the absence of current DEP, there is a failure of 
ALLO mechanisms to respond appropriately to challenge as evidenced by lack of an increase 
in response to mental stressors found in never depressed women.  Furthermore, regression 
analyses revealed that only in PMDD women with prior DEP did greater ALLO 
concentrations at extended baseline rest, reflecting failure to recover from venipuncture 
stress, and more blunted ALLO reactivity to mental stress predict worse premenstrual 
symptoms of depression, irritability and labile mood.  ALLO failed to predict symptoms in 
PMDD women with no prior DEP, indicating special relevance of prior DEP to PMDD 
symptomatology [65].  The association of ALLO concentrations with a history of DEP, but 
not with PMDD status per se, provides additional support for the evidence that PMDD is 
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biologically and clinically distinct from other forms of DEP, a distinction that has been 
repeatedly debated in the literature [56, 61]. 
In our prior research in the same cohort of PMDD and prior DEP women described 
above [65], using a placebo-controlled design, we measured plasma ALLO concentrations 
following progesterone administration.  We reported that, over a 255 minute period 
consisting of periods of resting and mental stress tasks, women with prior DEP had 
consistently lower ALLO levels compared to never depressed women, and that this was 
especially evident in the non-PMDD women [184].  These results are consistent with the 
hypotheses that there may be persistent dysregulation in stress-responsive measures in 
women with prior DEP, even after complete remission (>1 year).  Since ALLO readily 
crosses the blood brain barrier and is produced by the adrenals [186], the finding of a 
decrease in plasma ALLO in response to stress in women with prior DEP is consistent with 
prior research finding a reduced HPA-axis response to mental stress in women with current 
[127] and prior MDD [20].   
In the present study, strict criteria to define and confirm cycle phase was used in 
assessing PMDD women for SNS and HPA-axis functioning at baseline and SNS 
responsivity to mental stress during the luteal phase, and thus addresses the methodological 
concerns from the existing literature as well as those regarding the impact of psychiatric 
histories in PMDD.   
 
Depression: Influence on Clinical and Experimental Pain  
Investigations into the physical, or somatic, components of both MDD and PMDD 
allow for a broader understanding of these disorders by incorporating the less publicly 
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emphasized, yet clinically significant, symptoms contributing to functional impairment.  
Somatic symptoms such as headache, fatigue, and back pain are core components of 
depressive illness, since over 75% of depressed patients report chronic or recurring pain to 
their primary care physician [211].  Furthermore, a study of 685 patients from a family 
medicine clinic found that 75%–80% of depressed patients reported somatic symptoms such 
as headache, stomach, neck, back, and generalized pain [212].  Additionally, a positive 
correlation between clinical pain intensity and the severity of MDD has been reported, as 
well as a trend towards a positive correlation between clinical pain intensity and number of 
depressive episodes in premenopausal women [213].   
Despite the fact that laboratory-based methods of assessing pain sensitivity, 
specifically ischemic and cold pressor threshold and tolerance used in the present study, are 
positively related to clinical pain in both healthy adults [214, 215] and chronic pain patients 
[216-218], few studies have explored the relationship between experimental pain sensitivity 
and clinical DEP.  A systematic review and meta-analysis examined the effect of current 
DEP on experimental pain perception, concluding that pain threshold was higher in 
depressed individuals than healthy controls [219].  However, only 2 of the 6 studies in the 
meta-analysis assessed pain tolerance, which may be especially relevant for mood disorders 
since pain tolerance reflects the affective experience of pain, while pain threshold reflects the 
sensory experience [220].  More recent studies have assessed both threshold and tolerance to 
multiple pain stimuli in depressed patients, and although findings have been mixed, they 
indicate a reduced sensitivity to experimental pain in depressed subjects compared to controls 
[221-225].   
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For instance, a recent study found increased threshold and tolerance to thermal and 
electrical pain stimuli in patients with adjustment disorder, a mild form of DEP associated 
with a life stressor [223].  A different approach was taken by Lautenbacher and colleagues 
[221], who were not only interested in determining the differences in pain thresholds between 
depressed patients and controls, but whether these differences were in fact due to 
dysregulated perceptual processing speed or reaction time.  Results showed that subjects with 
current DEP had increased heat pain thresholds compared to controls, regardless of whether 
or not subjects were required to rely on perceptual processing speed.  Depressed subjects and 
controls also did not differ significantly on their skin sensitivity for non-noxious warmth, 
cold, and vibration stimuli, indicating that the decreased sensitivity in DEP is specific to pain 
perception [221].  Giesecke et al. [226] also provides evidence against overall perceptual 
processing as a mechanism underlying pain perception in DEP in their study assessing neural 
activation to pressure pain sensitivity using functional magnetic resonance imaging (fMRI) in 
fibromyalgia patients with or without MDD.  Self-reported depressive symptoms and 
diagnosis of MDD were not correlated with pain-evoked neuronal activation in brain areas 
associated with the sensory-discriminative aspects of pain (e.g. somatasensory cortices), but 
were associated with neuronal activations in brain regions associated with the motivational-
affective dimension of pain (e.g. amygdala).  
What has yet to be thoroughly examined is whether there is persistent dysregulation 
in experimental pain perception and underlying pathophysiological mechanisms in women 
with prior MDD, since this may have implications for risk for subsequent MDD.  Bar et al. 
[27] assessed thermal pain sensitivity in women who were in full clinical recovery from 
MDD and found significantly increased pain threshold and tolerance in women with prior 
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MDD compared to controls.  However, most of the women in recovery from MDD were 
taking antidepressant medication, which could be a confounding factor due to its analgesic 
effects [72, 73].  Moreover, for the purposes of the present study, examination of existing 
symptom calendar data collected in a prior study in our laboratory led to the finding that 
women with prior DEP, irrespective of PMDD status, experienced elevated daily somatic 
symptoms.  Specifically, women with a history of DEP reported more severe headache, 
fatigue, bloating, cramping, swelling, and breast tenderness than women with no prior DEP 
[unpublished data].  These pilot data are consistent with the hypotheses of the current study 
regarding persistent effects of prior MDD on somatic complaints for all women, and support 
the aims to confirm this finding and also investigate biological mechanisms that may 
contribute to somatic symptoms.   
Another more recent study from our laboratory was among the first to compare 
women with or without prior mood disorders (diagnosis of prior minor DEP, major DEP, or 
bipolar mixed episode) for experimental pain threshold and tolerance to heat, ischemic, and 
cold pressor pain [28], in women who were not taking any medications.  The study showed 
that women with prior mood disorders were less sensitive to ischemic pain than women with 
no prior mood disorders, although no significant differences were seen for heat or cold 
pressor pain.  These results support persistent disturbance in pain modulatory mechanisms in 
women with a history of mood disorders, which may have implications for the development 
of future mood disturbances. The present study seeks to aid in clarifying the underlying 
mechanisms contributing to alterations in pain sensitivity in women with a history of MDD.    
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Premenstrual Dysphoric Disorder: Influence on Clinical and Experimental Pain 
While the literature on pain sensitivity in current and past MDD is lacking, there are 
even fewer studies assessing pain sensitivity in PMDD [182, 204, 205, 227], despite the fact 
that somatic symptoms such as breast tenderness, bloating, and joint or muscle pain are 
important features of PMDD and contribute to overall dysfunction [228].  Examining the 
percentage of PMDD women reporting luteal phase somatic complaints based on daily 
prospective ratings from a previous study in our laboratory determined that a full 100% of 
the confirmed PMDD women endorsed at least one somatic symptom in the luteal phase (e.g. 
headache, cramping) severe enough to interfere with function, while 63% of the PMDD 
women had at least one somatic symptom severe enough to be temporarily disabling 
[unpublished data].   
Despite the evidence for the role of physical symptoms in PMDD, studies assessing 
pain sensitivity in women with this disorder are scant.  Prior studies from our laboratory 
show that women with PMDD exhibit shorter ischemic pain threshold and tolerance times 
compared with controls in both the follicular [227] and luteal phases [182, 227], and other 
studies have shown that PMDD women endorse higher pain intensity ratings in response to 
pressure pain irrespective of menstrual cycle phase [204, 205].  Additionally, using a non-
traditional means of assessing experimental pain threshold,  Chae and colleagues [229] 
recently compared middle school girls with high and low PMS scores on the Menstrual 
Distress Questionnaire for pressure pain threshold at a targeted acupuncture point known to 
be associated with gynecological and obstetric dysfunctions, and also at various other 
acupuncture and non-acupuncture points on the body.  The study found significantly lower 
pressure pain threshold in girls with severe PMS compared to girls with mild to moderate 
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PMS at the targeted acupuncture point, as well as a trend in the same direction at the majority 
of other body points, thus supporting the hypothesis that PMS is associated with heightened 
pain sensitivity [229].  What has yet to be established, however, is whether prior MDD, 
which is more prevalent in PMDD [45, 51-54], distinguishes subgroups of PMDD women in 
terms of their sensitivity to pain.  Studies comparing PMDD and non-PMDD women, as well 
as women with and without prior MDD, for sensitivity to experimental pain stimuli may 
clarify the nature of the clinical pain experience in these disorders.   
 
Stress-Responsive Endogenous Pain Regulatory Mechanisms 
The relevance of altered SNS and HPA-axis responses to stress may not only have 
implications for mood disorders, but for clinical pain syndromes as well.  Clinical pain is an 
associated feature of both MDD [211, 212, 230] and PMDD [228, 231], and cardiovascular 
and neuroendocrine responses to stress exert profound antinociceptive effects in both animals 
and humans [232].  The phenomenon is known as stress-induced analgesia (SIA).  For 
example, higher resting and stress-induced NE levels are associated with reduced pain 
sensitivity to ischemic, cold pressor, and heat pain, at least in Caucasian non-smokers [233, 
234].  In rats, adrenal medullary transplants have been shown to increase CSF catecholamine 
levels, thereby reducing pain sensitivity [235].   
The most well-documented relationship in SIA, however, is between high BP and 
reduced pain sensitivity [233, 235-246], which has been shown in individuals with 
hypertension, a familial risk for hypertension, as well as in healthy normotensives [247].  For 
instance, Sheps and colleagues [238] showed support for the BP-pain association by finding a 
positive association between MAP and thermal pain threshold (pain onset) and tolerance 
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levels in both normotensive and hypertensive male subjects. Zamir and Shuber [237] also 
examined pain threshold in normotensive and hypertensive males, and found that 
normotensive subjects showed a reduced threshold to tooth pulp stimulation compared to 
hypertensives, indicating a relationship between high BP and reduced pain sensitivity.  
Similarly, Bruehl et al. [244] administered a pressure pain task to the fingers of normotensive 
males and found an inverse relationship between resting systolic BP and pain ratings 
throughout the 60 second pressure stimulus.  Further support for the BP/pain relationship can 
be found in a study by Bragdon et al. [242] that assessed thermal pain sensitivity both at 
baseline and after a mental stress battery.  The study observed that both pre- and post-stress 
thermal pain tolerance was positively related to both pre- and post-stress systolic BP.  
Breuhl and Chung [247] outlined three potential mechanisms that may underlie the 
relationship between blood pressure and pain.  The first is the arterial baroreceptors, which is 
a negative feedback system that acts like pressure sensors to regulate BP through reflex 
changes in autonomic activity [248].  When BP rises in response to the experience of pain, 
baroreceptors are activated, causing descending pain inhibitory activity intended to bring the 
body back to homeostatic cardiovascular levels.  Noradrenergic activity, specifically α2-
adrenergic mechanisms, may also play a role in the BP/pain relationship, since central 
noradrenergic pathways are an essential part of the descending pain inhibitory system, and 
are crucial to maintaining stable cardiovascular functioning [247].   
In addition to baroreceptors and adrenergic factors, the HPA-axis is also involved 
with SIA.  Many studies have reported increased concentrations of β-endorphin to be 
associated with reduced pain sensitivity in humans [182, 233, 245, 249-252].  Specifically, 
Guasti et al. [245] found a negative correlation between baseline β-endorphin levels and pain 
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sensitivity to the pulpar test, which involves the administration of intermittent bursts of 
electrical stimuli to the tooth.  McCubbin and Bruehl [240] examined the relationship 
between BP, pain, and β-endorphin from a different view, using a within-subjects design to 
administer either saline or naloxone to normotensive males prior to a cold pressor pain task 
and measured BP.  After saline pretreatment, resting systolic BP was negatively associated 
with cold pressor pain ratings, and although this association became non-significant 
following naloxone administration, the drug did not completely eliminate the inverse 
relationship between systolic BP and pain ratings, indicating potential for non-opioid as well 
as opioid mediators.  This study [240], as well as others [245, 250-252], suggests that the 
relationship between BP and pain sensitivity is at least partially mediated by endogenous 
opioids such as β-endorphin.  
Although many studies report correlations between high BP with high β-endorphin 
and low pain sensitivity, β-endorphin levels are often not associated with the degree of pain 
responsiveness [247].  Breuhl and Chung [247] also cite endogenous opioids, such as the 
HPA-axis factor β-endorphin, as potential mediators of the relationship between BP and pain, 
although they acknowledged that results are mixed and point to an important but not 
sufficient role.  Finally, while animal studies find strong substantiation for opioid 
involvement in the BP/pain association, human studies fail to provide consistent support.   
Similarly, studies have implicated another HPA-axis factor, cortisol, as a partial yet 
insufficient mediator of SIA [233, 234, 243, 249].  For example, Al’absi et al. [243] found 
that salivary cortisol concentrations at baseline predicted lower self-reported pain during and 
after the cold pressor task, however only in men.  CRH, which is released from the 
hypothalamus in response to a stressor, has also been shown to be a mediating factor of SIA, 
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since intravenous, intradermal, intracranial, and subcutaneous administration of CRH 
produces analgesia in animal models, although the effect is primarily due to the release of β-
endorphin as well as the anti-inflammatory effects of cortisol [253].  Additionally, previous 
studies from our laboratory reported that greater cortisol in response to mental stress was 
associated with greater pain tolerance in nonsmokers [233] and in Caucasians [234].  In 
summary, these relationships between the SNS and HPA-axis and pain are thought to reflect 
an integrated response during the defense reaction, which is characterized by increases in 
SNS activity such as BP, HR and the release of catecholamines, and increases in HPA-axis 
activity such as the release of ACTH, endogenous opioids (β-endorphin), and cortisol [254].   
While the perception of pain is adaptive, the suppression of pain might prove adaptive 
in the short term as part of the fight or flight response.  Recent studies from our laboratory 
found that higher systolic BP, NE, and cortisol were associated with higher pain tolerance to 
ischemic, cold pressor, and thermal heat pain in healthy men and women [234], and that β-
endorphin levels were positively associated with higher pain tolerance to cold pressor pain 
[249].  To date, only one group of researchers has recently assessed whether alterations in 
sympathetic and HPA-axis mechanisms are related to increased pain sensitivity in women 
with current depressive disorders.  Frew and Drummond [255] determined the BP/pain 
relationship to be initially absent in patients with MDD, but when the opioid antagonist 
naltrexone was administered, the inverse relationship between BP and cold pressor pain 
sensitivity emerged.  Thus, endogenous opioids, such as β-endorphin, seem to mask the 
BP/pain relationship in MDD, but mediate the relationship in non-depressed controls.  The 
present study seeks to further examine stress-responsive endogenous pain regulatory 
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mechanisms in euthymic women with prior MDD, as well as be the first to investigate these 
mechanisms in PMDD women.  
 
Primary Hypotheses: 
1. Women with prior MDD will be less sensitive to experimental pain stimuli compared to 
women with no prior MDD, and PMDD women will be more sensitive to experimental 
pain stimuli than non-PMDD women.  Thus, it is hypothesized that there will be a main 
effect of both PMDD status and prior MDD for experimental pain sensitivity.  
2. All women with prior MDD will experience greater severity of daily somatic symptoms 
than women with no prior MDD (Main effect of MDD).  It is fully expected that all 
PMDD women will have greater daily somatic symptoms, especially in the luteal phase 
relative to all non-PMDD women (Main effect of PMDD). 
3. All women with prior MDD will show increased HPA-axis factors at rest, and thus a 
main effect of prior MDD for HPA-axis factors is hypothesized.  Also, all women with 
MDD will show increased sympathetic activity both at baseline and in response to stress 
relative to never depressed women.  Therefore, it is hypothesized that there will be a 
main effect of prior MDD for SNS factors, irrespective of condition (baseline or stress), 
since prior MDD will have increased SNS factors compared to never depressed subjects.   
4. All women with PMDD will have decreased SNS factors both at baseline and in response 
to stress.  Thus, it is hypothesized that there will be a main effect of PMDD status for 
SNS factors, irrespective of condition, since PMDD will show decreased SNS factors 
compared to non-PMDD controls.  Additionally, all women with PMDD will have 
decreased HPA-axis factors at baseline, and thus a main effect of PMDD status for HPA-
axis factors is hypothesized. 
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Secondary Hypotheses: 
1. Since it is well established that increased SNS factors are associated with reduced 
sensitivity to experimental pain, it is hypothesized that group differences in SNS 
activation will predict group differences in pain sensitivity.   
2. Although the literature associating HPA-axis factors and pain sensitivity in humans is 
limited, it is hypothesized that group differences in HPA-axis activation will predict 
group differences in pain sensitivity.  
  
 
 
 
 
 
CHAPTER 2 
 
RESEARCH METHODS 
 
Participants:  
A total of 38 women (19-50 years of age) completed all aspects of testing.  Of these 
women, 17 met strict DSM-IV [9] criteria for PMDD and were compared with 21 non-
PMDD women for PMDD-related differences.  For analyses regarding the influence of MDD 
on dependent measures, a history of MDD was used to model clinical MDD.  In our sample, 
13 women had a history of MDD and 25 women were classified as never depressed.  The 
current study enrolled and prospectively screened 74 potential PMDD women to yield the 17 
confirmed PMDD women (23%) (See Appendix A: Enrollment Statistics), reflecting the 
employment of strict diagnostic criteria, since the literature shows that approximately 35% of 
potential PMDD women actually meet DSM prospective criteria [45, 46].  As seen in 
Appendix A (Enrollment Statistics), the current study enrolled and prospectively screened 46 
potential non-PMDD women to yield 21 non-PMDD women who met study criteria.  
Approximately 35% of the PMDD sample had prior MDD, a percentage that falls slightly 
lower than the expected rates for PMDD women [45, 51].  As for the non-PMDD sample, 
since only approximately 24% of women have a history of MDD [256], targeted 
advertisements enabled the recruitment of 33% of this group to have prior MDD (see 
Appendix A).    
Excluded was any subject with a current Axis I psychiatric disorder, however subjects 
who met this criteria were referred for treatment.  Also excluded was any woman who was 
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pregnant or breastfeeding, had irregular menstrual cycles, was taking prescription medication 
(including oral contraceptives and psychotropics), had a cardiovascular disorder, a history of 
or a current chronic or acute pain condition, an endocrine disorder including diabetes or 
thyroid disorder, or other chronic medical illness.  A history of MDD was based on interview 
(see below) with one year in full remission required.  Because of the relatively small sample, 
in order to achieve greater homogeneity regarding DEP histories, excluded from the MDD 
groups were women with a history of minor DEP, dysthymia, or adjustment disorder with 
depressed mood, if they did not also have at least one episode of MDD.  The never depressed 
groups were free of any lifetime depressive illness, including minor DEP or adjustment 
disorder.  Although not a focus of this study, the four groups were closely matched for abuse 
histories due to the aims of the overarching parent project focused on histories of sexual and 
physical abuse in women. 
  
Procedures: 
Screening and Enrollment: After an initial phone-screening interview, each subject 
was scheduled for their enrollment session.  During this session, informed consent was 
obtained, a medical history questionnaire, Beck Depression Inventory, and Spielberger Trait 
Anxiety Inventory were administered and reviewed, a series of stethoscopic blood pressures 
was taken, and subjects underwent a diagnostic interview using the MINI International 
Neuropsychiatric Interview for Axis I disorders as well as a validated structured interview to 
assess previous abuse experiences [257].  Once determined to be eligible, subjects were 
introduced to the Daily Record of Severity of Problems (DRSP) [258], which they were 
asked to fill out daily for 2-3 consecutive menstrual cycles.  Once the subjects had completed 
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the DRSP ratings and they were reviewed to determine eligibility, subjects were called to 
schedule a second screening visit.  During the second screening visit, subjects were 
instructed on how to use the ovulation testing kits, which enabled the approximation of the 
late luteal phase and the proper scheduling of the laboratory testing protocol.  
 Confirming PMDD Diagnosis: The Daily Record of Severity of Problems (DRSP) 
[258] was used to confirm PMDD and non-PMDD status for all subjects.  This form allows 
for quantification of the severity of physical, emotional, and behavioral symptoms.  The 
DRSP incorporates measures of life-style impact together with information on life events that 
may modify symptomatology.  In order to discourage retrospective reporting, calendars were 
mailed back weekly.  To classify subjects with PMDD, each met the DSM-IV criteria for 
‘Premenstrual Dysphoric Disorder’: 1) at least a 30% increase in symptom severity during 
the seven days preceding menses (premenstrual days) compared with follicular days 4-10; 2) 
rating of symptoms as moderate and/or severe (as opposed to mild) on at least three of the 
seven premenstrual days; 3) a total of five or more symptoms premenstrually; 4) at least one 
severe emotional symptom on three of seven premenstrual days; 5) symptoms severe enough 
to impact/disrupt normal activities or interpersonal relationships; 6) complete remission of 
symptoms within three days of menses onset followed by a clear symptom free period (≥ six 
consecutive days) during the early-to-mid follicular phase and 7) criteria 1-6 met on two 
menstrual cycles.   
 Non-PMDD women met the following criteria: 1) no more than mild emotional 
symptoms occurring during the premenstrual days; 2) no evidence for functional impairment 
associated with emotional symptoms; 3) these criteria will be met on two menstrual cycles.   
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 Since up to 50% of women with MDD report a premenstrual exacerbation of 
symptoms [43, 259], and premenstrual depressive changes independently predict the 
development of MDD [59], the following strategies were in place to insure accuracy of the 
PMDD differential diagnosis: 1) we also interviewed subjects for medical conditions that 
may present with a pattern of premenstrual exacerbation (e.g. thyroid); 2) Dr. Susan Girdler’s 
nearly 20 years of experience in reviewing daily ratings for determining PMDD criteria, 
including the criteria for a symptom free period in the follicular phase, further ensured the 
exclusion of dysthymia or premenstrual exacerbation of chronic dysphoria or functional 
impairment; 3) we excluded women with both a premenstrual and menstrual pattern (i.e., 
symptomatic throughout menses) even if a symptom free period follows in the follicular 
phase since this pattern may reflect refractory underlying DEP [260]; and 4) we required 
three years in full remission for any Axis I disorder (other than MDD, for which 1 year was 
requited) as to reduce further the likelihood that premenstrual symptoms reflect underlying 
current Axis I psychopathology.  
 Diagnostic Interview:  During the enrollment session, subjects underwent the MINI 
International Neuropsychiatric Interview for Axis I disorders.  Any woman meeting criteria 
for a current Axis I disorder was excluded and referred for treatment.  As mentioned above, a 
minimum of one year in full remission from MDD, and three years in full remission from 
other Axis I disorders were required.  Number of MDD episodes and time since last MDD 
episode were carefully evaluated.  Any individual exhibiting significant psychological 
distress, currently in crisis, or currently suicidal were not enrolled into protocol but instead, 
immediately referred for treatment.  Following the MINI Plus, using a validated structured 
interview [257], subjects were asked about previous abuse experiences.   
                                                                                                                                        
 57
Test Session:  Each of the subjects were tested once during the luteal phase of the 
menstrual cycle, 5-12 days after home urine testing reveals the LH surge that precedes 
ovulation.   Cycle phase were be confirmed to be ovulatory based upon serum progesterone.   
We tested in the luteal phase only since this is the phase in the menstrual cycle when PMDD 
women suffer from clinical levels of distress.  Thus, this is a good comparison phase to 
determine diagnosis-related differences between PMDD and prior MDD.  Furthermore, there 
is little consistent evidence that the menstrual cycle influences blood pressure and heart rate 
in healthy controls [261, 262] as well as blood pressure, heart rate, and neuroendocrine 
differences between PMDD and non-PMDD groups at rest or during stress [34, 78, 79, 182].  
Lastly, a recent report from our laboratory determined that the menstrual cycle does not 
influence experimental pain perception in all women [263].  Hence, this would be the best 
phase to investigate relationships involving endogenous pain regulatory factors and 
hyperalgesia without jeopardizing our ability to detect group differences. 
All laboratory testing began between the hours of 7:00am and 9:30am.  The 
laboratory visit lasted approximately three hours and thirty minutes and followed a fixed 
sequence.  The order of testing was as follows: 1) Instrumentation for blood pressure 
monitoring (Suntech 4240 Exercise blood pressure monitor) and stethoscopic blood pressure 
assessments to ensure reliable cuff placement and microphone position; 2) I.V. setup; 3) 
Baseline 1 Rest (10 min); 4) Administration of the Beck Depression Inventory and The 
Spielberger State Anxiety Inventory; 5) Pain Testing (approximately 30 min); 6) Recovery 
and Baseline 2 Rest (10 min); 7) Trier Social Stress Test (20 min)  
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I.V. Setup: A research nurse inserted a butterfly needle into a forearm vein.  A non-
heparinized, multi-stop-cock system was employed, which allowed the nurse to draw blood 
samples without the added stress involved in multiple venipunctures.  
Baseline 1 Rest:  Quiet rest ensued for 10 minutes and served as recovery from any 
stress effects associated with I.V. setup.  BP and HR measures were taken at minutes 1, 3, 6, 
and 9, and averaged.  Blood was sampled at min 10 for NE, β-endorphin, cortisol, and for 
progesterone.  
Pain Testing Procedures:  Subjects were exposed to two pain tests.  The tests were 
chosen to differ along several dimensions, including quality of pain sensation (i.e., sharp vs. 
dull) and underlying endogenous pain modulatory systems (i.e., opioid vs. non-opioid).  One 
of two task orders were used, insuring that each pain task is in the 1st and 2nd position, and 
that order was matched across groups. 
The Submaximal Effort Tourniquet Procedure: This procedure produces graded 
increases in BP, forearm vascular resistance, and HR [264] and activates intrinsic opioid 
systems [265-267].  The tonic nature of this stimulus produces a deep, aching pain, similar to 
many clinical pain syndromes [268].  In this procedure, a tourniquet cuff was positioned on 
the subject’s arm.  Subjects verbally indicated when the sensations in their arm first become 
painful (threshold) and when they were no longer willing or able to tolerate the task 
(tolerance), though there was a maximum time (unspecified) at which they will not be 
allowed to continue (20 mins).  Using a Visual Analog Scale (0-100), subjects rated both the 
intensity and unpleasantness of the pain at tolerance (see Appendix A).  Before the tourniquet 
cuff was rapidly inflated to 200 mmHg, each subject’s arm was raised for 30 seconds to 
promote venous drainage, the tourniquet cuff was inflated, the experimenter’s stopwatch 
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started, and subjects engaged in 20 handgrip exercises at 30% of maximum force.  Time (sec) 
to pain threshold and time to pain tolerance constituted the primary dependent measures.  
The Hand Cold Pressor:  This task is also characterized by a deep, tonic aching 
sensation but, unlike the tourniquet test, the cold pressor elicits much larger increases in BP, 
which are mediated solely via increases in total systemic vascular resistance [269].  A 
container was filled with ice and water maintained at 4° C.  At the onset of the test, subjects 
submerged their hand to a marked line on their wrist and kept their hand still.  The use of a 
water circulator prevented the water from warming near the subject’s hand.  Subjects 
indicated when the sensations in their hand first became painful (threshold) and when they 
were no longer willing or able to tolerate the pain (tolerance).  Immediately before removing 
their hand, subjects rated the pain for intensity and unpleasantness using the Likert scale.  A 
maximum time limit of 5 min was imposed.  
Recovery and Baseline 2 Rest:  Quiet rest ensued for 10 minutes, serving as a 
baseline from which to calculate reactivity.  BP and HR measures were taken at minutes 1, 3, 
6, and 9 and averaged.  Blood was sampled at min 10 for NE, β-endorphin, and cortisol.   
 The Trier Social Stress Test (TSST):  The TSST reliably induces large and consistent 
HPA-axis, cardiovascular, and NE responses [270-273] and involves four parts:  
Pre-Task Instructions (5 min): Subjects were introduced to 3 people (the ‘selection 
committee’) after which the experimenter asked the subject to take over the role of a job 
applicant who is invited for a personnel interview with the company’s staff managers (the 
selection committee).  Subjects were instructed that after a preparation period, they should 
introduce themselves to the committee in a free speech of 5 minutes duration and convince 
the committee that they would be the perfect applicant for the position.  Subjects were 
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instructed that they would be tape-recorded and that the committee members were specially 
trained to monitor nonverbal behavior and that tape-recorded speech will be analyzed for 
performance. 
Speech Preparation (5 min): Subjects were provided with paper and pencil for 
outlining their talk but were not allowed to use these notes during the talk. 
Job Speech (5 min): The selection committee returned and asked the subject to deliver 
her talk describing to the committee why she would be the perfect applicant for the position.  
If the subject finished before five minutes, the committee responded with prepared questions 
to ensure that the subject spoke for the entire period.   
Paced Auditory Serial Addition Task (PASAT; [274]) (8.5 min): Immediately 
following the end of the speech, the same committee of individuals asked the subject to listen 
to a tape-recorded presentation of numbers from 1 to 9.  Participants added each number 
presented on the tape to the immediately preceding number and stated the answer aloud.  
There were four series of numbers, with progressively shorter interdigit intervals.  The 
experimenter remained in the room to monitor performance. 
Task Assessments (see Appendix A): Task assessment questionnaires were 
administered after the cessation of each pain task, as well as at the end of the TSST (i.e. a 
separate assessment for the speech task and the PASAT given at the end of stress testing).  
The questionnaire asks the individual to draw a vertical line on a continuum from 0-10 
indicating 1) how difficult they found the task; 2) how tense they were during the task; 3) 
how well they were able to concentrate during the task; and 4) how much effort they put into 
the task. 
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Cardiovascular and Neuroendocrine Sampling During TSST:  BP and HR measures 
were taken at minutes 1, 3, and 5 of the Speech Preparation Period, minutes 1, 3, and 5 of the 
Job Speech, and minutes 2, 4, 6, and 8 of Serial Addition and averaged to constitute task 
levels.  NE was sampled at the end of minute 2 of Speech and minute 2 of Serial Addition 
since catecholamines peak within the first minutes of stress and have a short half-life (3 min).   
 
Measurements: 
MINI International Neuropsychiatric Interview: We used the MINI International 
Neuropsychiatric Interview to screen all subjects for current and lifetime psychiatric 
symptomatology for DSM-IV psychotic, mood, substance use, anxiety, and eating disorders. 
Validation and reliability studies have been done comparing the M.I.N.I. to the Structured 
Clinical Interview for DSM-III-R (patient edition) and the Composite International 
Diagnostic Interview.  The results of these studies show that the M.I.N.I. has acceptably high 
validation and reliability scores, but can be administered in a much shorter period of time 
than the above referenced instruments [275]. 
All interviews were performed by Rebecca Klatzkin.  The results of the interview 
were reviewed with clinical psychologist, Dr. Catherine Forneris, at a diagnostic conference.  
At the end of this interview, subjects were asked about sexual and physical abuse experiences 
using a structured interview developed by Dr. Leserman and colleagues [257].  As stated 
earlier, for present purposes, these data were only used to ensure equivalency of abuse across 
the four groups.  
Beck Depression Inventory (BDI [276]): This 21-item scale comprehensively 
assesses dysphoric symptoms, including affective, cognitive, somatic, overt behavior and 
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interpersonal symptoms of depression.  The BDI possesses a high degree of internal 
consistency with a mean alpha coefficient of .81 for nonpsychiatric populations [277], and a 
reasonable amount of validity with mean correlations of the BDI with clinical ratings and 
other questionnaires being 0.60 and 0.74 respectively in nonpsychiatric populations [277]. 
Spielberger Trait Anxiety Questionnaire (STAI-Y2 [278]): The STAI-Y2 is a 
questionnaire that measures symptoms of anxiety, and was used to measure how anxious the 
subject felt “in general”.  The questionnaire has 20 statements, and the participant chose if 
they felt a certain way almost never, sometimes, often, or almost always. 
Spielberger State Anxiety Questionnaire (STAI-Y1 [278]): The STAI-Y1 is a 
questionnaire that measures symptoms of anxiety, and was used to measure how anxious the 
subject felt at the very moment the questionnaire was administered.  The questionnaire has 
20 statements, and the participant chose if they felt a certain way almost never, sometimes, 
often, or almost always.     
Blood Pressure and Heart Rate: The Suntech Exercise BP monitor, Model 4240 
(SunTech Medical Instruments, Inc., Raleigh, NC) provided automated measurement of BP 
and HR during the sessions.  The Suntech Exercise BP monitor uses the auscultatory 
technique, with R-wave Gating.  This BP monitor is accurate within +/- 2 mmHg between 0 
mmHg and 300 mmHg.  Prior to initiating the baseline rest period, five standard stethoscopic 
blood pressures were taken simultaneously with the automated pressures in order to ensure 
correct microphone placement and cuff positioning. 
Plasma Norepinephrine: Norepinephrine concentrations were determined using the 
high performance liquid chromatography technique.  All high performance liquid 
chromatography procedures were conducted at the Core Laboratory of the UNC Hospitals 
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General Clinical Research Center.  The lower limit of quantification with this system is 25 
pg/ml, and the intra- and interday coefficients of variation are less than 10%.   
Plasma cortisol and serum progesterone: Plasma cortisol and serum progesterone 
were determined using radioimmunoassay techniques commercially available from ICN 
Biomedical, Inc.  The specificity of the antiserum for P is very high, showing only 0.01-2.5% 
cross-reactivity with other steroid compounds.  Luteal phase P levels <3 mg/ml were 
considered reflective of an anovulatory cycle.  The specificity of the antiserum for estradiol 
is high, showing only 0.01-1.45% cross-reactivity with steroid hormones with the exception 
of estrone, for which there is up to 6% cross-reactivity.  For cortisol, the sensitivity of the 
assay is excellent at 0.07 µg/dL and the specificity high, showing 0.05-2.2% cross-reactivity 
with similar compounds, except prednisolone, where 94% cross-reactivity is obtained.   
Plasma β-endorphin: Plasma β-endorphin levels in EDTA plasma were determined 
following extraction by radioimmunoassay using a kit from INCSTAR Corporation 
(Stillwater, Minnesota).  The intra- and inter-assay coefficients of variation from the assay 
are approximately 10% and 15%, respectively, and the assay sensitivity is 3 pmol/L.   
 
Data Analysis: 
Total Recruitment and Screening: 
 In the present study, 479 women (PMDD = 325; Non-PMDD = 154) completed a 
phone screening interview (see Appendix A: Enrollment Statistics) that served as a 
preliminary screening tool for the study.  Three hundred and fifty nine of these respondents 
did not meet phone screen criteria (due to medical, psychiatric, or other exclusion criteria) 
and thus did not participate in the study (PMDD = 108; Non-PMDD = 251).  The remaining 
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122 women (PMDD = 76; Non-PMDD = 46) met phone screen criteria and subsequently 
signed a consent form in order to begin the protocol.  For data analysis purposes, these 122 
women were placed into various groups (outlined below and depicted visually in the 
Appendix A: Enrollment Statistics) in order to address the multiple aims of the present study.  
The full sample of 122 women who signed a consent form were used to assess predictors of 
study retention (see Appendix A: Enrollment Statistics [highlighted in green]), yet only 38 of 
these women completed the laboratory study protocol (PMDD = 17; Non-PMDD = 21), and 
therefore comprise the main data set used for analyses in the present study.   
The other 84 out of these 122 women (PMDD = 59; non-PMDD = 25) failed to 
complete the laboratory study protocol, 15 of whom completed the 2-3 months of daily 
ratings required for a PMDD (N = 8) or non-PMDD (N = 7) diagnosis, but did not complete 
the laboratory study protocol due to voluntarily dropping out of the study prior to completion 
(PMDD = 3; non-PMDD = 5) or due to various reasons outside of their control (i.e. had not 
yet completed the laboratory study protocol at the time of data analysis or were unable to 
complete the laboratory study protocol due to medical issues: PMDD = 5; non-PMDD = 2).  
Although they did not complete the laboratory study protocol, these 15 women did receive a 
PMDD or non-PMDD diagnosis and were thus included in the daily ratings analyses based 
on both PMDD and prior MDD status along with the abovementioned 38 women who 
comprise the main data set (Total N = 53; see Appendix A: Enrollment Statistics [highlighted 
in red]). 
Furthermore, 69 of the 84 women who failed to complete the laboratory study 
protocol also failed to complete the 2-3 months of daily ratings required for a PMDD (N = 
51) or non-PMDD (N = 18) diagnosis.  These 69 women either chose to drop out of the study 
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(presenting as PMDD = 20; non-PMDD = 9), or were excluded from the study based on daily 
ratings criteria (PMDD = 25; non-PMDD = 7) or enrollment criteria (presenting as PMDD = 
6; non-PMDD = 2).  Thirty six (13 plus 23; see Appendix A: Enrollment Statistics) of these 
69 women completed both the psychiatric interview and at least one month of daily ratings, 
while 26 (16 plus 9; see Appendix A: Enrollment Statistics) failed to do so.  These 36 women 
(13 plus 23; see Appendix A: Enrollment Statistics) were thus included in the analyses of 
daily ratings examined as a function of prior MDD status along with the 53 women who 
received a PMDD or non-PMDD diagnosis (N = 89; see Appendix A: Enrollment Statistics 
[highlighted in blue text]). 
 
Demographics: 
Group differences in demographic factors, trait anxiety scores assessed during 
enrollment, state anxiety and depression scores assessed during the laboratory protocol, and 
baseline SNS and HPA-axis factors were examined using a one-way analysis of variance 
(ANOVA) or chi square analysis separately for PMDD (yes vs. no) and for Prior MDD (yes 
vs. no).  In order to assess whether the proportion of PMDD women as well as the proportion 
of women with a history of MDD differed by race, a 2 (PMDD) x 2 (Race: Non-Hispanic 
Whites vs. Minorities: African American, Hispanic, Asian, or Multi-racial) chi square 
analysis, and a 2 (Prior MDD) x 2 (Race) chi square analysis were utilized.  Similarly, a 2 
(PMDD) x 2 (Abuse: yes vs. no) chi square analysis as well as a 2 (Prior MDD) x 2 (Abuse) 
chi square analysis were performed to determine whether the proportion of women with an 
abuse history differed by PMDD and by Prior MDD status.  For women with prior MDD, 
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PMDD and non-PMDD groups were compared on months since last depressive episode and 
number of prior MDD episodes with a one way ANOVA.   
 
Pain Sensitivity and Task Assessments for Cold Pressor and Tourniquet Ischemic Tasks: 
In order to determine whether pain sensitivity to the tourniquet ischemic and cold 
pressor task differed by PMDD and by Prior MDD status, a 2 (PMDD) x 2 (Period: 
Threshold vs. Tolerance) repeated measures ANOVA with Period as the repeated factor was 
performed, followed by a 2 (Prior MDD) x 2 (Period) repeated measures ANOVA with 
Period as the repeated factor.  The subjective experiences of each pain task (difficulty, 
tension, inability to concentrate, effort) as measured by the task assessment questionnaire 
(see Appendix A) was analyzed separately by PMDD and by Prior MDD status using a one 
way ANOVA.  The analyses were performed separately for each pain task and for each of the 
4 items on the task assessment.  For the first 3 questions assessing difficulty, tension, and 
inability to concentrate, higher scores indicated a more negative subjective experience, while 
for the fourth question assessing effort put into the pain task, higher scores indicated greater 
effort.  Lastly, pain intensity and unpleasantness ratings from 0-100 (see Appendix A) given 
immediately following voluntary tolerance for each pain task were analyzed separately by 
PMDD and by Prior MDD status using a one way ANOVA.   
 
Daily Symptom Ratings: 
Daily Symptom Ratings as a Function of Prior MDD Status (N = 89): 
The goal of the next analyses were to explore group differences in Daily Record of 
Severity of Problems (DRSP) symptoms in women (N = 89) who were assessed for prior 
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MDD via structured psychiatric interview (Prior MDD = 42; No Prior MDD = 47), and 
completed at least one month of daily mood ratings (see Appendix A: Daily Record of 
Severity of Problems).  This group of 89 women was comprised of participants who 
completed the laboratory study protocol (N = 38), those who received a PMDD or non-
PMDD diagnosis but were unable to complete the laboratory study protocol (N = 15), and 
those who did not complete the 2-3 months of daily ratings necessary to receive a PMDD or 
non-PMDD diagnosis (N = 36).   
For each of the 24 symptoms on the DRSP (depressed, hopeless, worthless or guilty, 
anxious, mood swings, more sensitive, angry or irritable, conflict, less interest, difficulty 
concentrating, fatigue, increased appetite or overate, food cravings, slept more, trouble 
sleeping, overwhelmed, out of control, breast tenderness, breast swelling or bloating, 
headache, joint or muscle pain, less productivity or efficiency due to above problems, 
interference with hobbies or social activities due to above problems, and interference with 
relationships due to the above problems), a follicular (days 1 through 10) and luteal (days -7 
through -1) phase average was calculated for cycle one and cycle two.  For each of the 24 
symptoms, cycle one and cycle two were averaged to create an overall follicular and an 
overall luteal phase average.  Next, each symptom was placed into one of five core symptom 
categories [258]: 1. Somatic (fatigue, breast tenderness, breast swelling or bloating, 
headache, joint or muscle pain); 2. Depression: (depressed, hopeless, worthless or guilty, 
slept more, trouble sleeping, overwhelmed); 3. Anger/Irritability: (anger or irritability, 
conflict); 4. Anxiety: (anxiety); and 5. Impairment: (less productivity or efficiency, 
interference with hobbies or social activities, interference with relationships), and averaged 
to yield one total follicular and luteal score for each of the five categories.  
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All 89 women were assessed for differences in the five core symptom categories 
based on prior MDD diagnosis using a 2 (Prior MDD) x 2 (Menstrual Cycle Phase) repeated 
measures ANOVA with Menstrual Cycle Phase as the repeated factor.  Where significant 
interactions emerged, simple effects analyses and/or least square means comparisons were 
conducted to explore the source of the interaction.  
 
Daily Symptom Ratings as a Function of PMDD (N = 53): 
Similar analyses to determine group differences in symptom severity based on PMDD 
status were next performed in a smaller group of women (N = 53) comprised of those who 
completed the laboratory study protocol (n = 38), and women who did not complete the 
laboratory study protocol, but who completed the 2-3 months of daily ratings necessary to be 
given a PMDD or non-PMDD diagnosis (N = 15) (see Appendix A: Enrollment Statistics).  
The entire group (N = 53) underwent a formal assessment of prior MDD via structured 
psychiatric interview (Yes = 18; No = 35) and PMDD via the daily mood ratings (Yes = 25; 
No = 28).  Although many participants filled out daily ratings for three consecutive menstrual 
cycles in order to determine PMDD or non-PMDD diagnosis, daily ratings from only two 
menstrual cycles in which PMDD or non-PMDD criteria were met were used in the analyses.   
Group differences in the five somatic symptom categories means were explored using 
a 2 (PMDD) x 2 (Menstrual Cycle Phase) repeated measures ANOVA with Menstrual Cycle 
Phase as the repeated factor.  Where significant interactions emerged, simple effects analyses 
and/or least square means comparisons were conducted to explore the source of the 
interaction.  
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Hypothalamic Pituitary Adrenal (HPA)-Axis and Sympathetic Nervous System (SNS): 
For the 38 women who completed the laboratory study, group differences in baseline 
HPA-axis factors of cortisol and β-endorphin were analyzed separately by PMDD and by 
Prior MDD status using a one way ANOVA.  Next, stress responsivity of the SNS factors of 
systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), and 
norepinephrine (NE) based on PMDD and Prior MDD status were explored by calculating 
delta scores (Speech task – Baseline), and using separate one way ANOVAs for PMDD and 
for Prior MDD.  SNS factors from the speech task were used to calculate the delta score since 
this task has been show to elicit a greater SNS stress response than the math task [234, 279].   
 
Relationship Between SNS and HPA-axis Factors and Pain Sensitivity and Pain Intensity and 
Unpleasantness Ratings: 
To examine the relationship between SNS and HPA-axis factors and pain sensitivity, 
consistent with other published reports [280], a median split for baseline and speech stress 
SBP was conducted separately, first by PMDD status (PMDD vs. non-PMDD), and then by 
prior MDD status (prior MDD vs. no prior MDD).  In order to reduce the number of separate 
analyses, only SBP at baseline and speech stress, as well as baseline cortisol and β-
endorphin, were examined for their relationship to pain sensitivity.  For each physiological 
measure, a 2 (Group: High vs. Low) x 2 (Time: Threshold vs. Tolerance) repeated measures 
ANOVA was conducted first as a function of PMDD status and then as a function of prior 
MDD status for each pain task.   
Next, the relationship between SNS and HPA-axis factors and pain intensity and 
unpleasantness was examined using the median splits analytic approach mentioned above.  
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Speech and Math Task Assessments: 
The subjective experiences of each stress task as measured by task assessment 
questionnaires (see Appendix A) regarding difficulty, tension, inability to concentrate, and 
effort were analyzed separately by PMDD and by Prior MDD status using one way 
ANOVAs.  Analyses were performed separately for the speech and math task and for each of 
the 4 items on the task assessment.  For the first 3 questions assessing difficulty, tension, and 
inability to concentrate, higher scores indicated a more negative subjective experience, while 
for the fourth question assessing effort put into the pain task, higher scores indicated greater 
effort.   
 
Study Retention: 
Demographic Variables as a Function of Dropout Status (‘Completion’ vs.‘Dropouts’) (N = 
75): 
In the following analyses assessing study retention, ‘completers’ refer to women who 
completed the laboratory study protocol (N = 38), while ‘dropouts’ refer to women who 
voluntarily dropped out of the study at any time prior to completion (N = 37; see Appendix 
A: Enrollment Statistics [highlighted in dotted pattern]).  Multiple stepwise regression 
analyses were performed in order to examine the degree to which certain demographic 
variables (BDI, trait anxiety, age, race [Non-Hispanic Whites = 1 vs. Minorities = 0], self-
reported psychological history [Yes = 1 vs. No = 0], self-reported psychological treatment 
history [Yes = 1 vs. No = 0], self-reported alcohol consumption [number of drinks per 
month], and self-reported PMDD or non-PMDD diagnosis [Yes = 1 vs. No = 0]) served as 
independent predictors of voluntary dropout status (Completion = 1 vs. Dropout = 0).   
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In stepwise regression each independent variable specified is entered into the 
regression one at a time until all variables have been added with the provision that each 
meets a specified criterion.  The criterion employed by SAS, the statistical software used for 
these analyses, was one of significance level p < .15.  Furthermore, the stepwise approach 
involves an additional procedure in which all variables are reexamined after the addition of 
other variables to verify that each remains a significant and independent predictor.  Thus, this 
approach helps to circumvent the problem of multicolinearity of independent variables. 
 
Demographic Variables as a Function of Completion Status (‘Completion’ vs. ‘Non-
Completion’) (N = 122): 
In the following analyses assessing study retention, ‘completers’ refer to women who 
completed the laboratory study protocol (N = 38), while ‘non-completers’ refer to women 
who signed a consent form but did not complete the laboratory study protocol (N = 84).  
These 84 women consist of ‘dropouts’ as described above (N = 37; see Appendix A: 
Enrollment Statistics [highlighted in dotted pattern]), in addition to women who did not 
complete the laboratory study protocol due to various forces outside of their control (i.e. 
presence of medical issues (N = 2), had not completed the laboratory study protocol at the 
time of data analysis (N = 5), ineligibility based on inclusion criteria (N = 7) or daily ratings 
(N = 32); see Appendix A: Enrollment Statistics).  Multiple stepwise regression analyses 
were performed in this sample (N=122) in order to examine the degree to which the 
demographic variables (BDI, trait anxiety, age, race [Non-Hispanic Whites = 1 vs. Minorities 
= 0], self-reported psychological history [Yes = 1 vs. No = 0], self-reported psychological 
treatment history [Yes = 1 vs. No = 0], self-reported alcohol consumption [number of drinks 
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per month], and self-reported PMDD or non-PMDD diagnosis [Yes = 1 vs. No = 0]) served 
as independent predictors of completion status (Completion = 1 vs. Non-Completion = 0).   
 
  
 
 
 
CHAPTER 3 
 
RESULTS 
Demographics: 
As seen in Table 1, analyses revealed no group differences based on PMDD status in 
age, BMI, race, or abuse history (ps > .05).  PMDD women had slightly higher state anxiety 
scores (F(1, 37) = 2.4, p = .13) and significantly greater trait anxiety scores (F(1, 37) = 16.4, 
p < .001) than non-PMDD women.  PMDD women also showed higher BDI scores than non-
PMDD women (F(1, 37) = 14.1, p < .001), results that would be expected during the 
symptomatic luteal phase of the menstrual cycle when the inventory was administered.   
 
9 : 89 : 12Abuse History (Yes : No)
1.67 (.35)1.86 (.33)Prior Episodes of MDD
106 (32.9)72.3 (30.5)Months in Remission from MDD
12 : 515 : 6Race (Non-Hispanic Whites : Minorities)
34.4 (2.0)32.6 (1.8)Age
7.1 (1.0)2.0 (0.9)A Beck Depression Inventory (BDI)
38.2 (1.7)28.9 (1.5)A Trait Anxiety
25.1 (1.4)25.5 (1.3)Body Mass Index (BMI)
32.5 (2.2)27.9 (2.0)B State Anxiety
Non-PMDD     PMDD                                                   
(N = 21)       (N = 17)
Table 1. Mean (+SEM) Demographic Factors as a Function of PMDD Status
A PMDD  > non-PMDD , p < .001
B PMDD  > non-PMDD , p = .13
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As seen in Table 2, analyses revealed no group differences based on Prior MDD 
status in age, BMI, BDI, state anxiety, or abuse history (ps > .05).  However, women with a 
history of MDD had greater trait anxiety (F(1, 37) = 5.0, p < .05) compared to women with 
no history of MDD.   In addition, a greater proportion of non-Hispanic Whites (N=27) had a 
history of MDD than participants categorized as Minorities (N=11; African American, 
Hispanic, Asian, or Multi-racial) (χ2 = 4.3, p< .05), while the proportion of women with 
abuse histories did not significantly differ based on Prior MDD status (p > .05).  Lastly, in 
analyses performed in women with prior MDD only, PMDD and non-PMDD women did not 
differ in number of prior episodes of MDD or months in remission from MDD (all ps >.05). 
 
12 : 115 : 10B Race (Non-Hispanic Whites : Minorities)
7 : 611 : 14Abuse History (Yes : No)
33.2 (2.3)33.4 (1.7)Age
5.2 (1.3)3.8 (1.0)Beck Depression Inventory (BDI)
37.1 (2.2)31.0 (1.6)A Trait Anxiety
24.9 (1.6)25.5 (1.2)Body Mass Index (BMI)
28.5 (2.6)30.7 (1.9)State Anxiety
No Prior MDD   Prior MDD
(N = 25)        (N = 13)
Table 2. Mean (+SEM) Demographic Factors as a Function of Prior MDD Status
A Prior MDD  > No Prior MDD,  p < .05
B Percentage with Prior MDD Diagnosis: Non-Hispanic Whites  > Other , p < .05
 
Pain Sensitivity to Cold Pressor and Tourniquet ischemic Tasks1: 
Cold Pressor Task: 
As anticipated, PMDD women displayed lower threshold and tolerance to the cold 
pressor task than non-PMDD women (F(1, 35) = 7.1, p< .05) (see Figure 1).   However, a 
PMDD x Period interaction (F(1, 35) = 5.8, p< .05) was also present, with simple effects 
                                                 
1
 Figure legend: ± p < .0001; † = p < .001; ‡ = p < .01; * = p < .05; # = p < .10; + = p < .15 
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analyses conducted separately by Period revealing that this PMDD diagnosis-related 
difference in pain sensitivity was more evident at tolerance (F(1, 37) = 5.8, p< .05) than at 
threshold (F(1, 36) = 2.4, p = .13).  Also as expected, women with a history of MDD 
displayed greater cold pressor threshold and tolerance than women with no history of MDD 
(F(1, 35) = 8.2, p < .01) (see Figure 2).  However, a Prior MDD x Period interaction (F(1, 35) 
= 7.3, p < .05) was also present, with simple effects analyses conducted separately by Period 
indicating that this prior MDD diagnosis-related difference in cold pressor pain sensitivity 
was only present at tolerance (F(1, 37) = 8.6, p < .01). 
 
Cold Threshold Cold Tolerance
0
15
30
45
60
75
90
105
120
135
150
Se
co
n
ds
Non-PMDD
(N = 21)
PMDD
(N = 17)
Figure 1: Cold Pressor Threshold and Tolerance as a Function of PMDD Status
+
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Figure 2: Cold Pressor Pain Threshold and Tolerance as a 
Function of Prior MDD Status
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Tourniquet Ischemic Task: 
 As depicted in Figures 3 and 4, no significant main effects or interactions were 
present for the tourniquet ischemic task in either diagnostic group.  
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Figure 3: Tourniquet Ischemic Threshold and Tolerance as a Function of PMDD Status
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Figure 4: Tourniquet Ischemic Pain Threshold and 
Tolerance as a Function of Prior MDD Status
 
 
Pain Task Assessments and Intensity and Unpleasantness Ratings: 
Cold Pressor Task: 
 As seen in Figure 5, PMDD women reported somewhat greater difficulty during the 
cold pressor task than did non-PMDD women (F(1, 37) = 2.9, p = .10).  No other significant 
main effects or interactions were present for cold pressor pain task assessments (see Figures 
5 and 6) or pain intensity and unpleasantness ratings in either diagnostic category (see Table 
3) (ps > .15). 
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Figure 5: Cold Pressor Task Assessments as a Function of PMDD Status
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Figure 6: Cold Pressor Task Assessments as a Function of Prior MDD Status
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Table 3. Mean (+SEM) Cold Pressor and Tourniquet Ischemic Pain Intensity and 
Unpleasantness Ratings as a Function of PMDD and Prior MDD Status
30.5 (4.6)36.0 (3.3)34.3 (4.1)34.0 (3.7)Tourniquet Intensity
40.8 (4.8)42.1 (3.4)42.4 (4.2)41.1 (3.7)Tourniquet Unpleasantness
42.9 (5.6)48.2 (4.0)48.7 (4.9)44.5 (4.4)Cold Pressor Intensity
50 (6.5)48.2 (4.7)53.6 (5.6)44.9 (5.0)Cold Pressor Unpleasantness
Non-PMDD PMDD No Prior MDD Prior MDD
 
 
Tourniquet Ischemic Task: 
No significant main effects or interactions were present for the tourniquet ischemic 
pain task assessments (see Figures 7 and 8) or pain intensity and unpleasantness ratings in 
any diagnostic category (see Table 3) (ps > .15). 
Difficulty Tenseness Inability to Concentrate Effort
1.20
2.20
3.20
4.20
5.20
6.20
7.20
8.20
To
u
rn
iq
u
e
t I
sc
he
m
ic
 
Ta
sk
 
As
se
ss
m
e
n
t
Non-PMDD
(N = 21)
PMDD
(N = 17)
Figure 7: Tourniquet Ischemic Task Assessments as a Function of PMDD Status
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Figure 8: Tourniquet Ischemic Task Assessments as a Function of Prior MDD Status
 
 
Daily Symptom Ratings: 
Daily Symptom Ratings as a Function of PMDD Status (N=53): 
 A total of 53 women successfully completed their daily mood ratings and met either 
PMDD or non-PMDD criteria.  Thus, analyses were conducted for symptom severity as a 
function of PMDD status in this group, as depicted in Figure 9.  As anticipated, PMDD x 
Menstrual Cycle Phase interactions were present for somatic symptom severity (F(1, 51) = 
42.7, p < .0001), depression (F(1, 51) = 49.0, p < .0001), anger/irritability (F(1, 51) = 93.0, p 
< .0001), anxiety (F(1, 51) = 93.4, p < .0001), and impairment (F(1, 51) = 45.1, p < .0001).  
Simple effect analyses conducted separately by Phase revealed that although PMDD women 
reported greater symptom severity than non-PMDD women in both menstrual cycle phases, 
these PMDD-related differences were greater in the luteal phase [somatic (F(1, 52) = 104.9, p 
< .0001), depression (F(1, 52) = 106.7, p < .0001), anger/irritability (F(1, 51) = 154.5, p < 
.0001), anxiety (F(1, 52) = 213.4, p < .0001), and impairment (F(1, 51) = 89.4, p < .0001)] 
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than in the follicular phase [somatic (F(1, 52) = 9.4, p < .01), depression (F(1, 52) = 17.5, p < 
.0001), anger/irritability (F(1, 51) = 9.3, p < .01), anxiety (F(1, 52) = 13.6, p < .001), and 
impairment (F(1, 51) = 8.1, p < .01)] (see Figure 9).  
 
Figure 9: Daily Mood Ratings Core Symptom Categories 
as a Function of PMDD Status
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Daily Symptom Ratings as a Function of Prior MDD Status (N=89): 
 Although there were no main effects present based on prior MDD status for any core 
symptom category, Prior MDD x Menstrual Cycle Phase interactions were found for 
depression (F(1, 87) = 8.5, p < .01) and impairment (F(1, 87) = 7.2, p < .01).  Simple effects 
analyses conducted separately by phase revealed that women with a history of MDD reported 
greater severity of depression (F(1, 88) = 3.1, p = .08) and impairment (F(1, 88) = 4.0, p < 
.05) than women with no history of MDD only in the luteal phase (see Figure 10).  Trends for 
Prior MDD x Menstrual Cycle Phase interactions were also found for anger/irritability (F(1, 
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87) = 2.8, p = .10) and anxiety symptoms (F(1, 87) = 2.9, p = .09), since women with prior 
MDD reported greater severity of these symptoms only in the luteal phase (see Figure 10).  
No significant main effect or interactions were found for the core somatic symptoms (all ps > 
.05).  
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Figure 10: Daily Mood Ratings Symptom Categories as a 
Function of Prior MDD Status
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Hypothalamic Pituitary Adrenal Axis: 
Our results indicated that there were no differences in baseline cortisol or β-endorphin 
(see Table 4) between PMDD and non-PMDD women (all ps > .05).  Similarly, no 
differences in baseline cortisol or β-endorphin (see Table 5) were observed between women 
with and without prior MDD (all ps > .05). 
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7.7 (.90)8.2 (.80)Baseline cortisol (ng/ml)
0.081 (0.008)0.067 (0.007)Baseline β-endorphin (ng/ml)
112.2 (3.0)110.6 (2.1)Baseline systolic blood pressure (SBP)
65.4 (3.2)65.0 (2.3)Baseline heart rate (HR)
68.8 (2.2)67.5 (1.6)Baseline diastolic blood pressure (DBP)
328.7 (48.9)420.4 (34.6)Baseline norepinephrine (NE) (pg/ml)
Non-PMDD           PMDD
(N = 21)             (N = 17)
Table 4. Mean (+SEM) Baseline SNS and HPA-axis 
Factors as a Function of PMDD Status
 
8.3 (1.0)7.8 (0.73)Baseline cortisol (ng/ml)
0.08 (0.012)0.07 (0.008)Baseline β-endorphin (ng/ml)
110.7 (2.5)111.4 (2.3)Baseline systolic blood pressure (SBP)
63.9 (2.8)66.1 (2.5)Baseline heart rate (HR)
67.4 (1.9)68.3 (1.7)Baseline diastolic blood pressure (DBP)
403.1 (43.7)379.2 (39.1)Baseline norepinephrine (NE) (pg/ml)
No Prior MDD      Prior MDD
(N = 25)             (N = 13)
Table 5. Mean (+SEM) Baseline SNS and HPA-axis 
Factors as a Function of Prior MDD Status
 
 
Sympathetic Nervous System: 
 Despite a lack of differences in SBP, DBP, HR, or NE based on PMDD or Prior 
MDD status at baseline (ps > .15) (see Tables 4 and 5), PMDD women showed a blunted HR 
(F(1, 36 = 5.6, p < .05), SBP (F(1, 35 = 4.8, p < .05), DBP (F(1, 35 = 6.4, p < .05), and NE 
(F(1, 34 = 7.8, p < .01) response to stress compared to non-PMDD women (see Figures 11 
and 12).  In addition, women with a history of MDD tended to show a greater increase in 
DBP from baseline to speech stress than women with no history of MDD (F(1, 35 = 2.5, p = 
.13) (see Figure 13), although no other delta SNS factor differed by prior MDD status (see 
Figures 13 and 14). 
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Figure 11: Change in SNS factors from Baseline to Speech 
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Figure 12: Change in Norepinephrine from Baseline to 
Speech Stress as a Function of PMDD Status
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Figure 13: Change in HR and BP from Baseline to Speech 
Stress as a Function of Prior MDD Status
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Figure 14: Change in Norepinephrine from Baseline to 
Speech Stress as a Function of Prior MDD Status
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Speech and Math Task Assessments: 
Speech Task Assessments: 
As depicted in Figure 15, PMDD women reported more difficulty (F(1, 36) = 2.7, p = 
.11), more tension (F(1, 36) = 5.5, p < .05), and a greater inability to concentrate (F(1, 36) = 
7.0, p < .05) during speech stress than non-PMDD women.  Women with or without prior 
MDD did not differ on any measure of the speech task assessment (ps > .15) (see Figure 16). 
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Figure 15: Speech Task Assessments as a Function of PMDD Status
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Figure 16: Speech Task Assessments as a Function of Prior MDD Status
 
 
Math Task Assessments: 
During the math stressor, PMDD women reported a marginally greater impairment in 
concentration than non-PMDD women (F(1, 36) = 3.4, p = .07) (see Figure 17), and there 
was also a trend for women with prior MDD to have reported greater difficulty than women 
with no prior MDD (F(1, 36) =2.8, p = .10) (see Figure 18). 
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Figure 17: Math Task Assessments as a Function of PMDD Status
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Relationship Between Hypothalamic Pituitary Adrenal Axis and Sympathetic Nervous 
System Factors and Pain Factors of Threshold, Tolerance, Intensity, and 
Unpleasantness: 
As a Function of PMDD Status: 
For PMDD women, although no measures of pain sensitivity were associated with 
baseline cortisol in PMDD women (ps > .15) (see Table 6), the higher baseline β-endorphin 
group showed trends for decreased cold pressor (F(1, 15) = 3.3, p = .09) pain sensitivity than 
the lower baseline β-endorphin group.  However, a Group x Period interaction was observed 
(F(1, 14) = 3.0, p = .10), and simple effects analyses conducted separately by Period revealed 
that the difference in the cold pressor pain sensitivity based on baseline β-endorphin group 
status was only present at pain tolerance (p = .08) (see Figure 19).  Additionally, the lower 
baseline β-endorphin group reported somewhat greater cold pressor intensity than the higher 
baseline β-endorphin group (F(1, 16) = 2.4, p = .14) (see Figure 20).  Furthermore, the higher 
baseline β-endorphin group showed trends for decreased tourniquet ischemic pain sensitivity 
(F(1, 14) = 2.8, p = .12), and this difference was an overall effect of threshold and tolerance.   
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Table 6. Relationship Between HPA-axis and SNS Factors and Mean (+SEM) Cold Pressor and      
Tourniquet Ischemic Pain Threshold, Tolerance, Intensity, and Unpleasantness in PMDD Women
194 (28.3)+ 164 (28.3)218 (27.5)148 (24.2)Tourniquet 
Threshold
698 (123)+ 412 (123)621 (142)504 (125)Tourniquet 
Tolerance
35.0 (5.8)33.7 (5.4)35.0 (5.7)33.7 (5.4)Tourniquet 
Intensity
46.9 (5.3)38.3 (5.3)48.1 (5.2)37.2 (5.1)Tourniquet 
Unpleasantness
47.1 (6.7)
46.3 (7.0)
29.2 (6.4)
13 (2.7)
Higher
59.4 (6.3)
50.9 (6.6)
35.1 (6.0)
13.9 (2.6)
Lower
Baseline Cortisol
41.3 (6.6)+ 55.3 (6.2)Cold Pressor 
Intensity
47.5 (6.7)59.1 (6.3)Cold Pressor 
Unpleasantness
Baseline β-endorphin
Lower Higher
Cold Pressor 
Threshold
11.2 (2.5) 16 (2.6)
Cold Pressor 
Tolerance
# 25.3 (5.5) 40.3 (5.8)
36.1 (5.0)49.4 (5.3)37.8 (5.2)47.5 (5.5)
31.4 (5.3)37.5 (5.6)29.8 (5.1)39.4 (5.5)
670 (128)440 (128)702 (123)+ 408 (123)
154 (27.3)204 (27.3)193 (28.7)169 (28.7)
50 (6.5)57.8 (6.9)47.8 (6.3)60.3 (6.7)
49.2 (6.7)48.1 (7.1)47.0 (6.6)50.6 (7.0)
31.1 (6.1)31.5 (6.4)37 (5.8)27.1 (6.2)
13.1 (2.6)13.9 (2.7)15.2 (2.5)11.5 (2.7)
HigherLowerHigherLower
Speech SBPBaseline SBP
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Figure 19: Cold Pressor Pain Threshold and Tolerance as a Function of 
High vs. Low Baseline Beta-Endorphin in PMDD Women 
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Figure 20: Cold Pressor Pain Intensity as a Function of High vs. Low 
Baseline Beta-Endorphin in PMDD Women
 
Also in PMDD women, the higher baseline SBP group was somewhat less sensitive 
to pain than the lower baseline SBP group (F(1, 14) = 2.8, p = .12) during the tourniquet 
ischemic task, although a weak trend for a Group x Period interaction (F(1, 14) = 2.7, p = 
.13) revealed that this difference was only evident at tourniquet ischemic tolerance (p = .11), 
while no SBP-status related differences were found at threshold.  In addition, a trend for a 
Group x Period interaction was observed for speech stress SBP-status during the tourniquet 
ischemic task (F(1, 14) = 2.8, p = .11), since only at tolerance was there evidence that stress 
SBP status influenced pain sensitivity.  However, neither baseline nor speech stress SBP-
status was associated with cold pressor pain sensitivity nor any measure of pain intensity or 
unpleasantness (ps > .15) (see Table 6). 
For non-PMDD women, the lower baseline cortisol group had reported somewhat 
greater cold pressor intensity (F(1, 20) = 2.4, p = .13) and marginally greater tourniquet 
ischemic unpleasantness (F(1, 20) = 4.1, p = .06) than the higher cortisol group.  Cold pressor 
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and tourniquet ischemic threshold and tolerance did not differ based on baseline β-endorphin 
or cortisol group status, and no measure of pain sensitivity differed based on baseline β-
endorphin group status (all ps > .05) (see Table 7). 
Table 7. Relationship Between HPA-axis and SNS Factors and Mean (+SEM) Cold Pressor and      
Tourniquet Ischemic Pain Threshold, Tolerance, Intensity, and Unpleasantness in non-PMDD Women
293 (85.9)279 (90.1)268 (89.9)303 (85.7)Tourniquet 
Threshold
713 (135)497 (141)686 (144)541 (137)Tourniquet 
Tolerance
46.4 (5.3)35.3 (5.6)42.5 (5.9)38.9 (5.6)Tourniquet 
Intensity
33.7 (5.5)34.2 (5.8)26.3 (5.2)# 40.9 (5.0)Tourniquet 
Unpleasantness
38.5 (6.4)
36.0 (7.8)
125 (37.8)
23.1 (4.8)
Higher
50.0 (6.1)
+ 52.9 (7.5)
88.2 (37.8)
16.6 (4.8)
Lower
Baseline Cortisol
43.5 (6.4)43.5 (6.7)Cold Pressor 
Intensity
47.7 (7.9)41.7 (8.2)Cold Pressor 
Unpleasantness
Baseline β-endorphin
Lower Higher
Cold Pressor 
Threshold
18.7 (4.9) 21 (4.9)
Cold Pressor 
Tolerance
90.2 (37.9) 123 (37.9)
43.5 (5.8)38.9 (5.5)43.8 (5.3)37.6 (6.1)
32.3 (5.8)35.5 (5.5)27.6 (4.8)# 42.4 (5.5)
875 (119)‡ 370 (114)686 (130)510 (151)
349 (87.9)229 (83.8)370 (76.8)175 (88.7)
48.5 (8.2)41.5 (7.9)42.1 (7.5)48.6 (8.7)
40.3 (6.6)48.4 (6.3)37.8 (5.6)# 53.5 (6.5)
145 (36)+ 67.4 (36)148 (31.4)* 44.5 (38.4)
20.2 (5.0)19.5 (5.0)21.8 (4.5)16.9 (5.5)
HigherLowerHigherLower
Speech SBPBaseline SBP
 
Also in non-PMDD women, the higher baseline SBP group had less cold pressor pain 
sensitivity than the lower baseline SBP group (F(1, 18) = 3.5, p < .05).  However, a Group x 
Period interaction was present for cold pressor pain (F(1, 14) = 4.1, p = .06), with simple 
effect analyses conducted separately by Period indicating that this difference in cold pressor 
pain sensitivity based on baseline SBP group status was only present at pain tolerance (p = 
.05).  The lower baseline SBP group also reported marginally greater cold pressor intensity 
(F(1, 20) = 3.4, p = .08) and greater tourniquet ischemic pain intensity (F(1, 20) = 4.2, p = 
.06) (see Figure 21) than the higher baseline SBP group.  Finally, for non-PMDD women 
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baseline SBP-status was not associated with cold pressor pain threshold or tolerance (ps > 
.15) (See Table 7). 
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Figure 21: Tourniquet Ischemic Intensity as a Function of High vs. Low 
Baseline SBP in non-PMDD Women
 
Finally in non-PMDD women, a weak trend for a Group x Period interaction (F(1, 18) 
= 2.5, p = .13) revealed that the higher speech stress SBP group had somewhat less sensitive 
to cold pressor pain than the lower speech stress SBP group, although only at cold pressor 
tolerance (p = .14).  As seen in Figure 22, the higher speech stress SBP group was less 
sensitive to tourniquet ischemic pain than the lower speech stress SBP group (F(1, 19) = 5.9, 
p < .05), although a Group x Period interaction (F(1, 19) = 8.4, p < .01) revealed that this 
difference was only present at tolerance (p < .01).  No measure of pain intensity or 
unpleasantness was associated with speech SBP-status (ps > .15) (see Table 7). 
In summary, PMDD women showed more robust relationships involving greater β-
endorphin levels and decreased pain sensitivity, while for non-PMDD women, greater BP 
and cortisol were associated with decreased pain sensitivity. 
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Figure 22: Tourniquet Ischemic Pain Threshold and Tolerance as a
Function of High vs. Low Stress SBP in non-PMDD Women 
 
 
As a Function of Prior MDD Status: 
In women with prior MDD, no measures of pain sensitivity differed by baseline 
cortisol group status (all ps > .05) (see Table 8).  However the higher baseline β-endorphin 
group was somewhat less sensitive to cold pressor pain than the lower baseline β-endorphin 
group (F(1, 11) = 2.4, p = .14), although a weak trend for a Group x Period interaction (F(1, 
11) = 2.7, p = .13) indicated that this difference was only present at tolerance (p = .14).  The 
higher baseline β-endorphin group also reported greater tourniquet ischemic pain 
unpleasantness than the lower baseline β-endorphin group (F(1, 12) = 5.0, p < .05).  
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Table 8. Relationship Between HPA-axis and SNS Factors and Mean (+SEM) Cold Pressor and Tourniquet
Ischemic Pain Threshold, Tolerance, Intensity, and Unpleasantness in Women with Prior MDD
229 (27.8)116 (25.8)204 (34.4)137 (31.8)Tourniquet 
Threshold
763 (140)577 (130)746 (142)591 (131)Tourniquet 
Tolerance
33.8 (4.4)27.6 (4.0)31.3 (4.6)29.7 (4.2)Tourniquet 
Intensity
51.7 (6.7)* 31.4 (6.2)45.0 (7.8)37.1 (7.2)Tourniquet 
Unpleasantness
45.0 (8.0)
45.8 (6.3)
97.5 (51.9)
25.3 (5.3)
Higher
54.3 (7.4)
40.4 (5.8)
145 (48)
15.2 (4.9)
Lower
Baseline Cortisol
44.2 (6.3)41.9 (5.9)Cold Pressor 
Intensity
45.8 (8.0)53.6 (7.4)Cold Pressor 
Unpleasantness
Baseline β-endorphin
Lower Higher
Cold Pressor 
Threshold
20.3 (5.3) 19.4 (5.7)
Cold Pressor 
Tolerance
+ 75.1 (44.1) 179 (47.6)
38.6 (7.4)43.3 (7.9)37.9 (7.3)44.2 (7.9)
31.9 (4.5)28.8 (4.5)25.9 (3.7)# 35.8 (4.0)
816 (117)# 484 (126)826 (113)* 472 (123)
178 (34.4)157 (37.1)206 (30.2)* 123 (32.6)
41.4 (6.6)# 60.0 (7.1)41.4 (6.6)# 60.0 (7.1)
43.3 (5.9)42.5 (6.4)36.9 (5.2)+ 50.0 (5.7)
156 (46.8)84.5 (50.5)156 (46.8)85.2 (50.6)
18.3 (5.3)21.7 (5.7)25.3 (4.7)13.5 (5.1)
HigherLowerHigherLower
Speech SBPBaseline SBP
 
 
Also in women with a history of MDD, the lower baseline SBP group reported 
somewhat greater cold pressor intensity (F(1, 12) = 2.9, p = .12) and cold pressor 
unpleasantness (F(1, 12) = 3.7, p = .08) (see Figure 23) than the higher baseline SBP group.  
Also, the higher baseline SBP group had greater tourniquet ischemic threshold and tolerance 
(F(1, 11) = 5.6, p < .05) (see Figure 24), and lower tourniquet ischemic intensity (F(1, 12) = 
3.3, p = .10), than the lower baseline SBP group.  Furthermore, the lower speech stress SBP 
group reported marginally greater cold pressor unpleasantness than the higher speech stress 
SBP group (F(1, 12) = 3.7, p = .08), and the higher speech stress SBP group had somewhat 
lower tourniquet ischemic pain sensitivity than the lower speech stress SBP group (F(1, 11) = 
3.1, p = .11).  However, a Group x Period interaction (F(1, 11) = 4.1, p = .07) revealed that 
this latter difference based on speech stress SBP-status occurred only at tolerance (p = .08).   
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Figure 23: Cold Pressor Unpleasantness as a Function of High vs. Low 
Baseline SBP in Women With Prior MDD
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Figure 24: Tourniquet Ischemic Threshold and Tolerance as a Function of 
High vs. Low Baseline SBP in Women With Prior MDD
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* Main Effect of Baseline SBP group: p < .05
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In women with no prior MDD, the lower cortisol group reported marginally greater 
cold pressor intensity (F(1, 24) = 3.5  p = .07) (see Figure 25), cold pressor unpleasantness 
(F(1, 24) = 3.4, p = .08), and tourniquet ischemic intensity (F(1, 24) = 2.8, p = .11) than the 
higher cortisol group, although no measure of pain sensitivity differed by β-endorphin or 
baseline SBP group status (all ps > .05) (see Table 9).  Finally, the lower speech stress SBP 
group reported somewhat greater tourniquet ischemic intensity than the higher speech stress 
SBP group (F(1, 24) = 2.4, p = .13).   
To summarize, women with prior MDD displayed stronger relationships between 
greater BP and decreased pain sensitivity, while women with no prior MDD showed a more 
consistent pattern of relationships between increased baseline cortisol and decreased pain 
intensity and unpleasantness than never depressed women.  
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Table 9. Relationship Between HPA-axis and SNS Factors and Mean (+SEM) Cold Pressor and Tourniquet
Ischemic Pain Threshold, Tolerance, Intensity, and Unpleasantness in Women with No Prior MDD
198 (47.8)229 (47.8)189 (49.6)234 (45.7)Tourniquet 
Threshold
645 (128)445 (128)612 (136)489.3 (125)Tourniquet 
Tolerance
35.9 (5.6)36.2 (5.4)29.6 (5.3)+ 41.9 (5.1)Tourniquet 
Intensity
45.4 (4.7)39.1 (4.5)45.0 (4.7)39.5 (45)Tourniquet 
Unpleasantness
39.8 (7.0)
40.0 (6.1)
32.6 
(15.7)
14.8 (3.5)
Higher
# 56.7 (6.7)
# 55.8 (5.8)
54.4 (13.7)
15.1 (3.5)
Lower
Baseline Cortisol
45.0 (6.5)51.2 (6.2)Cold Pressor 
Intensity
49.2 (7.5)47.2 (7.2)Cold Pressor 
Unpleasantness
Baseline β-endorphin
Lower Higher
Cold Pressor 
Threshold
15.5 (3.4) 14.3 (3.7)
Cold Pressor 
Tolerance
47.2 (13.5) 39.2 (14.6)
42.9 (4.4)41.2 (5.0)43.1 (4.6)41.1 (4.8)
30.9 (4.9)+ 42.5 (5.6)31.2 (5.2)41.3 (5.4)
617 (125)460 (135)675.5 (126)415 (126)
217 (46.1)209 (50.1)230.1 (47.8)197 (47.8)
48.2 (6.9)48.1 (7.8)46.5 (7.2)49.9 (7.5)
44.9 (6.0)52.5 (6.7)42.6 (6.2)52.1 (6.4)
45.8 (13)40.4 (15.4)36.0 (13.3)52.5 (14.5)
14.3 (3.3)15.8 (3.9)15.1 (3.4)14.7 (3.7)
HigherLowerHigherLower
Speech SBPBaseline SBP
 
Study Retention: 
Demographic Variables as a Function of Dropout Status (‘Completion’ vs. ‘Dropout’) (N = 
75):  
As depicted in Table 10, multiple stepwise regression analyses revealed that the race 
classification of Minority (R2 = .06), presence of a self-reported psychological history (R2 = 
.06), greater self-reported alcohol consumption (R2 = .05), and presenting as PMDD (R2 = 
.04) were found to be significant predictors of voluntarily dropping out prior to completing 
the laboratory study protocol (Total Model R2 = .19, p < .05) or being a ‘dropout’.   
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R2 =.19 
F(4, 64) =  3.6
p < .05
R2 = .04
β = -.21
R2 = .03
β = -.19
--
R2 = .06
β = -.26
R2 = .06
β = .37
--
--
--
Voluntary Dropout Status         
(N = 75)
Completers = 1  (N = 38) 
Dropouts = 0  (N = 37) 
R2 =.15 
F(4, 97) =  4.3
p < .01
R2 = .02
β = -.17
--
--
R2 = .04
β = -.22
R2 = .04
β = .21
--
--
R2 = .06
β = -.17
Completion Status            
(N = 122)
Completers = 1  (N = 38)     
Non-Completers = 0  (N = 84) 
Alcohol Consumption 
(Drinks per month)
Treatment History
Race                        
Non-Hispanic Whites = 1 
Minorities = 0
Psychological History
Yes = 1; No = 0
Age
PMDD Status
PMDD = 1;                   
Non-PMDD = 0
Total Model R2
Trait Anxiety
BDI
Predictor Variable
Table 10. Predictors of Completion and Voluntary Dropout Status on the 
Basis of Multiple Regression Analyses
-- indicates that the predictor variable did not account for significant variance
 
 
Demographic Variables as a Function of Completion Status (‘Completion’ vs. ‘Non-
Completion’) (N = 122):  
Women who signed a consent form but did not complete the laboratory study 
protocol, irrespective of whether they voluntarily dropped out at any time prior to completion 
or if they were unable to complete the study due to forces outside of their control (i.e. 
presence of medical issues, had not completed at the time of data analysis, and ineligibility 
based on inclusion criteria or daily ratings) were given the title ‘non-completers’.  As seen in 
Table 10, multiple stepwise regression analyses revealed that a higher BDI score reflecting 
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greater depression (R2 = .06), race classification of Minority (R2 = .04), presence of a self-
reported psychological history (R2 = .04), and presenting as PMDD (R2 = .02) were 
significant predictors of non-completion of the laboratory study protocol (Total Model R2 = 
.15, p < .01) or being a ‘non-completer’.  Therefore, even in women who are free of current 
depressive illness, the factors of self-reported psychological history, as well as race and 
PMDD presentation, played a role in decreasing the likelihood of completing the 5-6 month 
study protocol.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
CHAPTER 4 
 
DISCUSSION 
 
 
Summary of Findings in PMDD vs. Non-PMDD Women  
 The present investigation confirms previous literature on heightened laboratory-based 
pain sensitivity and reduced SNS stress reactivity in PMDD versus non-PMDD women, and 
also adds to the field of women’s mood disorder research by being the first to examine the 
relationship between stress-responsive endogenous pain regulators and experimental pain 
sensitivity and stress responsivity in PMDD.  Specifically, we observed decreased threshold 
and tolerance to the cold pressor task (i.e. greater pain sensitivity), and blunted SNS 
reactivity to psychosocial stress when compared to non-PMDD women.  We also found 
PMDD-related differences in endogenous pain regulation, since non-PMDD women showed 
a more consistent relationship involving BP and pain sensitivity, while PMDD women 
showed a more robust relationship involving β-endorphin and pain sensitivity.  In addition to 
blunted SNS reactivity patterns during mental stress, PMDD women also reported more 
difficulty, tension, and impairment in their ability to concentrate during the stressors than 
non-PMDD women.  Thus, PMDD women displayed different physiological and cognitive 
responses to stress, enhanced pain sensitivity, and a different pattern of endogenous pain 
regulation than non-PMDD women.  
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Pain Sensitivity in PMDD vs. Non-PMDD Women 
Although emotional symptoms are the key feature of the disorder, PMDD women 
report a variety of physical symptoms during the luteal phase of the menstrual cycle, playing 
a role in the impairment of social and occupational functioning [228].  For instance, 54% of 
prospectively confirmed PMDD women report moderate to severe somatic symptoms on at 
least 3 of 6 premenstrual days [31], while up to 82% of PMDD women experience some 
degree of physical discomfort premenstrually [231].  Further evidence for the significance of 
somatic symptoms in PMDD comes from SSRI clinical trials which consistently find that, in 
addition to improving mood, SSRIs reduce luteal phase pain symptoms relative to placebo in 
PMDD women [228], and that this reduction in pain symptoms contributes to overall efficacy 
of SSRIs in women with PMDD [69, 228, 281].  Reduction in somatic symptoms as a result 
of SSRI treatment may be due to a secondary effect of a reduction in mood disturbance 
allowing the perception of physical symptoms to seem less severe, to a primary effect of 
increasing serotonin levels, to a general effect of SSRIs on alleviating PMDD as a whole, a 
disorder that encompasses both mood and physical symptoms [228], or to changes in 
hormone-responsive peripheral tissue [66].  The study of experimental pain sensitivity in 
women with PMDD not only yields greater understanding of the biological underpinnings of 
the disorder, but also gives insight into the experience of painful somatic symptoms that 
comprises PMDD.  
Such prior studies from our laboratory have shown that PMDD women exhibit shorter 
ischemic pain threshold and tolerance times in both the follicular [227] and luteal [182, 227] 
phases of the menstrual cycle than non-PMDD women, while others have shown that PMDD 
women endorse higher pressure pain intensity ratings regardless of menstrual cycle phase 
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[204, 205].  The present data support these previous findings for increased pain sensitivity in 
PMDD women, specifically to the cold pressor task.  Since laboratory-based methods of 
assessing pain sensitivity are positively related to clinical pain in both healthy adults [214, 
215] and chronic pain patients [216-218], and predict the onset of clinical pain in initially 
pain free women [282], and since physical, or somatic, symptoms contribute to overall 
dysfunction in PMDD women [228], one would anticipate heightened pain sensitivity in 
PMDD, as we observed in the present study. 
As a caveat to our pain sensitivity findings, our task assessment results indicated that 
the greater pain sensitivity in PMDD women versus non-PMDD women may be related to 
group differences in the subjective experience, since PMDD women reported greater 
difficulty during the cold pressor task than non-PMDD women.  Since PMDD is a disorder 
characterized by heightened mood symptoms during the luteal phase of the menstrual cycle 
when the laboratory study protocol took place, their subjective reports of greater difficulty to 
the pain task may simply be a reflection of this cyclic mood disorder, or may be secondary to 
their greater sensitivity to the cold pressor task. 
 
Symptom Severity in PMDD vs. Non-PMDD Women 
We observed that PMDD women reported greater symptom severity than non-PMDD 
women during the luteal phase of the menstrual cycle, which was expected based on our 
strict diagnostic criteria, and since PMDD is characterized by both somatic and dysphoric 
symptoms occurring in the luteal phase that relinquish at the start of menses.  We did not, 
however, anticipate finding greater symptom severity in PMDD versus non-PMDD women 
during the follicular phase, even though this difference was less robust than during the luteal 
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phase.  One potential explanation for this follicular phase difference in symptom severity 
may be the fact that PMDD women anecdotally report follicular phase guilt regarding their 
actions, behaviors, and mood during the symptomatic luteal phase [43].  The negative 
interpersonal interactions experienced during the luteal phase can carry over into the 
follicular phase when PMDD women must atone for their actions and repair relationships.  
Thus, these feelings of remorse and guilt may have influenced the follicular phase symptom 
ratings in our PMDD sample.   
Another explanation for the greater follicular phase symptom severity in PMDD 
versus non-PMDD women may be that our PMDD sample had a greater proportion of 
women with an abuse history than non-PMDD women (53% vs. 43%).  Although this 
difference was statistically non-significant due to specifically recruiting non-PMDD women 
with prior abuse, it may be clinically meaningful.  Abuse has been robustly associated with 
women’s mood disorders, including MDD [283], and anxiety disorders such as PTSD [284].  
Thus, although no subject met criteria for a current Axis I disorder, residual symptoms 
associated with these disorders may have influenced symptom severity across the menstrual 
cycle.  Consistent with this hypothesis is that PMDD women reported a high level of trait 
anxiety at enrollment, which took place in the follicular phase of the menstrual cycle, and 
therefore may have influenced the heightened follicular phase symptom ratings.  Lastly, 
given the small sample size of our study, the greater percentage of PMDD women with 
abuse, although non-significant, may have carried more weight than in a larger sample.  
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Hypothalamic Pituitary Adrenal Axis and Sympathetic Nervous System Function in 
PMDD vs. Non-PMDD Women 
In addition to greater symptom severity, PMS women also report higher rates of 
traumatic life stress and a greater impact of these stressful events relative to non-PMS 
women [78, 285-288].  Moreover, since stress can trigger or exacerbate PMDD [83], it is 
possible that long-term dysregulation in stress responsive systems associated with greater life 
stress contributes to this disorder [45, 51-55].  Therefore, another goal of the present 
investigation was to examine the major stress axes in PMDD versus non-PMDD women, 
specifically the HPA-axis and SNS.  Although there were no diagnosis-related differences in 
baseline SNS or HPA-axis measures, we observed differences in SNS stress responsivity 
between PMDD and non-PMDD women.  Specifically, PMDD women showed blunted HR, 
DBP, SBP, and NE response to speech stress compared to non-PMDD women, results that 
are in the expected direction based on the literature showing a downregulated SNS in PMDD 
[178].   
Prior studies from our laboratory assessing SNS responses to stress in PMDD found 
no SNS differences at baseline, but blunted HR and DBP reactivity, as well as a trend toward 
reduced cardiac output and systolic BP reactivity to mental stress, in PMDD women relative 
to non-PMDD women [78].  In a separate cohort of women, our laboratory found lower 
stroke volume (i.e. the amount of blood ejected per cardiac cycle) both at baseline and in 
response to psychological stress in PMDD women versus non-PMDD women [227], and in a 
third cohort, never abused PMDD women had lower stress-induced SBP, DBP, and HR than 
never abused non-PMDD women [210].  Despite the consistent research showing a 
hypoactive SNS stress response in PMDD, it is still not clear why this dysregulation occurs.  
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However, the experience of severe and chronic stress in PMDD women may be a pertinent 
factor, particularly the perception of increased stressful events during the luteal phase of the 
cycle [79].  Some studies suggest that it is not the number of stressors that are greater in 
PMDD women, but that it is instead the perception of the impact [80], unpleasantness [289], 
and stressful nature [290] of the stressors that is greater during the luteal phase.  Further 
studies have shown that the cognitive coping strategies are also impaired during the luteal 
phase in PMDD versus non-PMDD women [80].  Our own results showing increased 
perceived difficulty, tension, and impairment in concentration during mental stress in PMDD 
compared to non-PMDD women are consistent with this interpretation, since our laboratory 
protocol occurred in the luteal phase of the menstrual cycle.  Therefore, further studies 
addressing perception, cognitive coping, and other psychosocial and stress-related factors are 
needed to explain the downregulation of the SNS stress response in PMDD women. 
In addition to reflecting altered perceptions/appraisals in the luteal phase in PMDD 
women, our task assessment results may shed light on the blunted SNS response in PMDD 
women versus non-PMDD.  As mentioned above, coping style may not only explain the 
blunted SNS responses to the speech stress task in PMDD, but also may be indicative of the 
reported negative subjective experience during the task in PMDD women.  Passive emotional 
coping is usually induced by stressors that are perceived to be inescapable and 
uncontrollable, such as a speech task in the case of the present study, and cause an individual 
to detach from the environment by using “conservation-withdrawal” strategies.  Such 
disengagement is associated with decreased SNS reactivity [291, 292].  In contrast, active 
emotional coping strategies are usually evoked by escapable, controllable stress and cause 
engagement with the environment, resulting in increased SNS reactivity to the stressor [291, 
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292].  Both animals and humans consistently display this pattern [293] in which passive 
coping involves immobility and quiescence, while active coping is behaviorally manifested 
in confrontation, fight, or escape [292].  The greater reports of task difficulty, tension, and 
inability to concentrate in PMDD women may reflect a passive coping response to the 
stressor.  
Since PMDD women are consistently faced with the uncontrollable stress of 
premenstrual mood changes, they may be prone to passive emotional coping strategies that 
are the most adaptive to this inescapable time of the month.  When PMDD women are 
confronted with a stressor they perceive to be inescapable and uncontrollable, such as the 
speech task, they may revert to familiar passive coping strategies, causing decreased 
sympathetic reactivity.  Future studies assessing active versus passive coping styles or 
cognitive appraisals regarding stressors in PMDD versus non-PMDD women are warranted, 
as they may inform new strategies for cognitive behavioral therapy or other psychological 
intervention methods.  
A further possibility for our findings of hypoactive SNS stress responses in PMDD, 
as well as for the use of passive coping strategies in this disorder, may involve 
downregulated β-adrenergic receptor activity.  Studies have shown that passive coping leads 
to less β-adrenergic receptor activity on both the heart and the vasculature, while active 
coping leads to heightened β-adrenoceptor involvement [294].  Moreover, β-adrenergic 
receptors influence sympathetic responses to stress by mediating the ability of NE to increase 
cardiac activity [295].  Specifically, NE acts on β1- adrenergic receptors in the heart to 
increase myocardial contractility, causing increased HR and BP [94].  Therefore, since 
PMDD women showed blunted sympathetic activity to the speech stressor and may have 
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utilized passive emotional coping mechanisms during the stressor, and since decreased β-
adrenergic activity is associated with both of these phenomena, it is possible that PMDD 
women may have decreased β-adrenergic receptor density.  There have been only a small 
handful of studies assessing β-adrenergic receptor responsivity involvement in PMDD.  In 
one study, heightened β2-adrenergic receptor density on platelets was found in PMDD versus 
non-PMDD women [296], while another found reduced myocardial and vascular β-
adrenergic receptor responsivity in never-abused PMDD women relative to PMDD women 
with an abuse history.  Thus, there may be distinct subgroups of PMDD women based on 
histories of abuse or other factors who show differential β-adrenergic receptor functioning, 
and thus contributing to the currently mixed literature in this area.  Although our study did 
include PMDD women with abuse and MDD histories, our sample sizes were too small to 
test this hypothesis, and thus further study is necessary to truly determine β-adrenergic 
activity in PMDD women.  These studies would have the potential to enlighten the mediating 
role of β-adrenergic receptor responsivity in the relationship between coping style and SNS 
reactivity, as well as inform pharmacological treatments specific to subgroups of PMDD 
women who may differ in β-adrenergic receptor activity.  
 
Relationship Between Hypothalamic Pituitary Adrenal Axis and Sympathetic Nervous 
System Factors and Pain Factors of Threshold, Tolerance, Intensity, and 
Unpleasantness in PMDD vs. Non-PMDD Women 
Although the relationship between pain sensitivity and SNS [233, 235-247] and HPA-
axis factors [182, 233, 234, 243, 245, 249-252] has been robustly reported in the literature, 
most of this work has been done in men, and our study is the first to explore this association 
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in PMDD women.  A consistent pattern emerged in PMDD women for high β-endorphin 
levels to be associated with increased cold pressor pain tolerance and decreased pain 
intensity ratings as well as increased tourniquet ischemic threshold and tolerance.  For non-
PMDD women, however, β-endorphin group status was not related to any measure of pain 
sensitivity.   
The lack of the expected associations between baseline β-endorphin and decreased 
pain threshold and tolerance in non-PMDD women was unanticipated, since many prior 
studies have reported this relationship in healthy subjects [182, 233, 245, 249-252].  Our 
method of obtaining β-endorphin concentrations from plasma as opposed from the central 
nervous system can be ruled out as a potential explanation, since the relationship between 
plasma β-endorphin levels and analgesia has been shown to be mediated by peripheral opioid 
receptors in addition to centrally located receptors.  Plasma β-endorphin binds to peripheral 
opioid receptors and directly decreases pain sensitivity by inhibiting the firing of peripheral 
somatosensory fibers that modulate nociception [297].  In patients with angina, Jarmukli et 
al. [298] administered ketoconazole, which stimulates the release of β-endorphin from the 
pituitary gland into the periphery, and found increased thresholds to heat pain compared to 
control conditions.  Since β-endorphin cannot cross the blood brain barrier, this study 
indicates that this endogenous opioid does not need to be centrally active to exert analgesic-
like effects [298, 299].   
Our lack of findings regarding β-endorphin and pain sensitivity in non-PMDD 
women may instead have resulted from the absence of a stress sample of β-endorphin and our 
reliance instead on exclusively baseline samples.  For example, previous studies showing 
relationships between β-endorphin and pain sensitivity in humans either administered 
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endogenous β-endorphin to participants [300, 301], or measured changes in β-endorphin 
response to a pain procedure [252, 302, 303], exercise test [304], or pharmacological 
manipulation [298].  Two studies did, however, administer a mental stress task and 
subsequently measure β-endorphin levels, but results were inconsistent and possibly reflected 
incorrect timing of the stress sample [305, 306].  Specifically, Bragdon et al. [305] found the 
expected positive relationship between ischemic pain tolerance and stress β-endorphin levels, 
but a negative relationship between ischemic pain tolerance and β-endorphin reactivity from 
baseline to stress in pain free women.  Sheps et al. [306] observed a positive relationship 
between thermal pain threshold and β-endorphin levels at stress, but not at baseline, in 
normotensives and hypertensives.  Furthermore, although not tested in response to mental 
stress, Jarmukli et al. [298] reported no effect of basal β-endorphin levels on angina pain in 
patients with this heart condition.  In fact, only two studies of which we are aware found a 
relationship between baseline levels of β-endorphin and pain sensitivity, one in PMDD and 
non-PMDD women [182], and the other in non-Hispanic Whites [249].   
An additional possibility for the absence of a relationship involving β-endorphin and 
pain sensitivity is that our sample size may not have been large enough to detect such 
associations, since in general, results were in the expected direction in non-PMDD women 
(i.e. higher β-endorphin and lower pain sensitivity), and our sample was smaller than 
previous studies documenting relationships between β-endorphin and pain sensitivity [233, 
234, 243, 249]. 
Although the expected β-endorphin/pain relationship was absent in non-PMDD 
women, they did, however, display a more consistent pattern of associations between high 
SBP and decreased pain sensitivity and reported pain intensity than PMDD women.  
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Increased BP coupled with decreased pain perception can still exist in the absence of the β-
endorphin/pain relationship, since Breuhl et al. [307] reported that endogenous opioids did 
not mediate the relationship between greater baseline BP and decreased pain sensitivity in 
normotensives.  In fact, in a later review, Breuhl and Chung [247] confirmed the lack of 
substantial evidence for the mediation of endogenous opioids such as β-endorphin in the 
BP/pain relationship in humans. 
The relationship between high BP and reduced pain sensitivity, which is the most 
well-documented form of stress-induced analgesia (SIA) [233, 235-246], appears instead to 
be mediated by the activation of arterial baroreceptors [248].  The relationship between 
cardiovascular and pain regulatory systems is thought to be mediated by blood pressure-
induced stimulation of mechanoreceptive afferents (i.e. baroreceptors), which are involved in 
maintaining cardiovascular homeostasis.  Baroreceptors are located in the carotid sinus, 
aortic arch, and cardiopulmonary regions of the cardiovascular system, reflexively 
responding to increases in arterial pressure or blood volume increases and subsequently 
causing an increase in parasympathetic output (i.e. vasodilation and decreases in HR and 
cardiac output) via the vagus nerve, and subsequently decreases in BP [239, 254].   
Stimulation of baroreceptors in animal models has been shown to diminish 
somatomotor reflexes indicative of analgesic-like effects [239, 254, 308] and in humans, 
natural increases in baroreceptor activity are associated with decreased pain sensitivity and 
clinical pain [239, 309-312].  In humans, studies have examined the relationship of pain 
sensitivity to natural variations in baroreceptor activation, such as being more active during 
systole (the active cardiac contraction phase) than during diastole (the passive cardiac filling 
phase) [313].  Breuhl et al. [247] describes the process by which baroreceptors mediate the 
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relationship between pain sensitivity and blood pressure, beginning with pain increasing 
sympathetic arousal through the somatosensory reflex.  Next, increases in blood pressure 
occur, leading to heightened activation of baroreceptors, which stimulates descending pain 
inhibitory pathways and returns the body to homeostatic levels of arousal [247].  More 
specifically, Maixner et al. [239] reviewed the literature on the relationship between 
baroreceptors and pain sensitivity and determined that cardiopulmonary vagal afferent 
stimulation in response to baroreceptor activation impairs the ability of nociceptive dorsal 
horn neurons to respond to noxious stimuli, subsequently causing analgesia.  In summary, 
there is robust evidence suggesting that baroreceptor mechanisms play a significant role in 
the relationship between BP and pain, which may explain the presence of the BP/pain 
relationship non-PMDD women.   
In addition to BP, another biological factor that has been shown to be related to pain 
sensitivity is cortisol [243].  Individuals with low back pain, rheumatoid arthritis, chronic 
pelvic pain, fibromyalgia, headaches, persistent sciatic pain and other pain conditions have 
been shown to display decreased adrenocortical activity [243].  Moreover, previous research 
from our laboratory reported associations between greater cortisol responses to mental stress 
and greater pain tolerance in nonsmokers [233] and in Caucasians [234], and Al’absi et al. 
[243] found that baseline salivary cortisol predicted lower self-reported pain during and after 
the cold pressor task in men, but not in women.   Furthermore, cortisol has been implicated as 
a partial mediator of SIA [233, 234, 243, 249].  Thus, the relationship between increased 
cortisol and decreased pain intensity and unpleasantness found only in non-PMDD women in 
our study supports previous research, and also distinguishes adrenocortical activity on the 
basis of PMDD status.  In summary, PMDD women failed to display the expected 
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associations between decreased pain sensitivity and increased BP and cortisol that were 
observed in non-PMDD women.  This finding in combination with increased pain sensitivity 
and blunted SNS responses to stress compared to non-PMDD women suggest stress- and 
pain-related dysfunction that may contribute to the etiology of PMDD. 
 
Summary of Findings in Prior MDD vs. No Prior MDD  
The present investigation also supports the existing literature suggesting decreased 
laboratory-based pain sensitivity and hyperactive SNS and HPA-axis functioning in euthymic 
women with a history of MDD.  Our study is the first, however, to include women with prior 
MDD who were currently free of medications, including antidepressants, and who had been 
in extended remission from their depressive episodes (mean = 88 months).  We found that 
women who had been free of MDD for, on average, over seven years, showed persistent 
biological disturbances beyond the remission of the depressive episode, reflected in increased 
cold pressor tolerance (i.e. decreased pain sensitivity), increased premenstrual mood 
symptoms, and greater DBP responsivity to stress than never depressed women.  Moreover, 
our study was the first to investigate the association between pain sensitivity and stress-
responsive pain regulatory mechanisms in women in women with and without prior MDD.  
We observed that women with prior MDD displayed more consistent relationships between 
greater BP and decreased pain sensitivity than women with no prior MDD, a group who 
showed a more consistent pattern of relationships between increased baseline cortisol and 
decreased pain intensity and unpleasantness than never depressed women.  These results 
reveal persistent dysfunction in pain mechanisms and stress reactivity, as well as an enhanced 
relationship between BP and pain, in euthymic women with a history of MDD.   
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Pain Sensitivity in Prior MDD vs. No Prior MDD  
Our pain sensitivity results comparing women with and without prior MDD status 
were consistent with prior literature finding lower pain sensitivity in women with both 
current [221-225] and prior MDD [27, 28] compared to controls.  Decreased pain sensitivity 
in both MDD and prior MDD is clinically significant, since a positive correlation between 
clinical pain intensity and the severity of MDD has been reported [213].  Somatic symptoms 
such as headache, fatigue, and back pain are core components of MDD, since approximately 
two-thirds of those with DEP first present to their doctors about physical, not emotional 
symptoms [230].  Additionally, data from the World Health Organization was used to assess 
somatic symptoms in 15 countries on 5 continents, and revealed that the overall prevalence 
of depressed individuals reporting only somatic symptoms as the reason for visiting their 
physician was 69% [230]. 
The importance of somatic symptoms and DEP is also supported by the finding that 
as DEP remits with the use of SSRIs, the severity of physical symptoms also decreases [314].  
Data also suggests that somatic painful symptoms that remain after successful treatment 
predicts future relapse [315].  This phenomenon may occur independently of the positive 
effects on mood, since the analgesic effects of antidepressants have been shown to present 
prior to any changes in the depressed mood state, and at lower starting doses than those 
necessary to bring about a therapeutic effect on DEP [316].  SSRIs may also have positive 
effects on impaired descending inhibition found in DEP, since they increase serotonin, and in 
some cases, NE, neurotransmitters that aid in sending descending peripheral messages that 
inhibit ascending pain signals [317].  Furthermore, and most relevant to the present study, 
Bromberger et al. [256] found that currently euthymic women with prior DEP were more 
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susceptible to reporting high body pain (e.g. headaches, backaches) than women without 
prior DEP, despite being free of DEP for, on average, more than 14 years.  These findings 
reveal that clinical pain in women persists beyond the remission of the depressive episode.   
Only a handful of studies have explored experimental pain sensitivity in DEP.  
Lautenbacher et al. [224] showed support for reduced experimental pain sensitivity in MDD, 
but only for certain pain modalities.  They observed increased pressure pain sensitivity, but 
no difference in ischemic or heat pain sensitivity, in MDD versus controls.  In a similar 
fashion, Bar et al. [222] also show that decreased pain sensitivity depends on pain modality.  
That study compared patients with MDD and controls on heat, electrical and ischemic pain 
sensitivity, finding increased pain threshold and tolerance to electrical and heat pain, but 
decreased threshold and tolerance to ischemic pain in MDD.  These studies provide support 
for our lack of diagnosis-related differences in tourniquet ischemic pain sensitivity in both 
prior MDD and PMDD women, and also for our observations of decreased cold pressor pain 
sensitivity in women with prior MDD.  
A systematic review and meta-analysis examined the effect of current DEP on 
experimental pain perception, concluding that pain threshold was higher (i.e. less sensitive) 
in depressed individuals than healthy controls [219].  However, only 2 of the 6 studies in the 
meta-analysis assessed pain tolerance, which may be especially relevant for mood disorders.   
Pain tolerance reflects the affective experience of pain, while pain threshold reflects the 
sensory experience [220], and this may explain the diagnosis-related differences in pain 
sensitivity that we observed only at cold pressor tolerance.   
Since PMDD and MDD are both depressive disorders characterized primarily by 
emotional symptoms, it follows that women with these disorders would differ on the 
                                                                                                                                        
 116
affective aspects of pain perception (i.e. tolerance).  Studies have shown that DEP is not 
associated with a deficit in perceptual processing of pain, and thus would not differentiate 
women with or without the disorder on the basis of their sensory pain perception (i.e. 
threshold).  For instance, Lautenbacher et al. [221] showed that subjects with current DEP 
had increased heat pain thresholds compared to controls, regardless of whether or not 
subjects were required to rely on perceptual processing speed, and depressed subjects and 
controls did not differ on skin sensitivity to non-noxious warmth, cold, and vibration stimuli 
[221].  Furthermore, Giesecke et al. [226] assessed neural activation to pressure pain 
sensitivity using fMRI in fibromyalgia patients with or without MDD.  Self-reported 
depressive symptoms and diagnosis of MDD were not correlated with pain-evoked neuronal 
activation in brain areas associated with the sensory-discriminative aspects of pain, but were 
associated with neuronal activations in brain regions associated with the motivational-
affective dimension of pain.  Therefore, women with the depressive disorders of PMDD and 
MDD only differed from their respective control groups in pain tolerance, and not threshold, 
possibly due to specific deficits in the affective/motivational aspect of pain.  
Despite the fact that the majority of existing research on experimental pain sensitivity 
and mood disorders have been performed in patients with current mood disorders, studies 
assessing laboratory-based pain in prior MDD are also present.  For instance, Bar et al. [27] 
assessed thermal pain sensitivity in women who were in full clinical recovery from MDD and 
found significantly increased pain threshold and tolerance in women with prior MDD 
compared to controls.  Additionally, a recent study from our laboratory showed that women 
with prior mood disorders were less sensitive to ischemic pain than women with no prior 
mood disorders [28]. 
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Several hypotheses have been proposed to explain the reduced experimental pain 
sensitivity in MDD, such as the presence of a more stoic behavior or affective indifference in 
DEP [318], a true sensory deficit in psychiatric affective illness [319, 320], increased 
somatosensory perception thresholds in DEP [321], impaired descending inhibition [317], 
and increased prefrontal and lateral thalamic activation [322].  The latter was proposed by 
Bar et al. [322], who studied cerebral responses to thermal pain perception in women with 
acute MDD using fMRI.  The study showed that women with MDD had higher thermal pain 
thresholds than healthy controls, which may be related to the additional finding that women 
with MDD had increased activation in the lateral prefrontal cortices (PFC) and lateral 
thalamus during pain perception compared to controls.  The lateral PFCs control the 
continuous monitoring of the external environment, processing aspects of working memory, 
cognitive control, and are important in modulating pain processes, while the lateral thalamus 
regulates sensory discriminative processing of painful stimuli [322].  Activation in the lateral 
PFCs and the thalamus during and after painful stimuli has been repeatedly described in the 
literature, and Bar et al. [322] suggest a strong relationship between hyperactivity in these 
regions and decreased sensitivity to experimental pain in DEP.   
Given the well documented evidence that women have increased clinical pain [323] 
and also show decreased experimental pain tolerance [324, 325], it may seem paradoxical 
that women with DEP, who also have increased clinical pain [256], show increased 
experimental pain tolerance (i.e. reduced pain sensitivity).  Lautenbacher and Krieg [326] 
have addressed this paradox of increased clinical pain complaints and reduced experimental 
pain sensitivity in DEP, hypothesizing that diminished processing of painful stimuli could be 
responsible for both phenomena.  The authors argue that reduced processing of nociceptive 
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stimuli at both spinal and subcortical stages may cause hypoalgesia to phasic experimental 
pain, and at the same time cause hyperalgesia to endogenous clinical pain due to deficient 
activation of inhibitory systems.  This theory is supported by Bar et al. [222] who found 
increased pain sensitivity to ischemic pain (deep somatic pain), but decreased pain sensitivity 
to heat and electric pain (phasic surface pain) in patients with MDD compared to controls.  
Although Lautenbacher et al. [224] failed to find a significant correlation between clinical 
pain complaints and pain threshold in depressed patients, this does not rule out the possibility 
that alterations in central and peripheral pain processing contribute to both phenomena.  
Thus, our results indicating that women with a history of MDD continue to display 
dysfunctions in pain regulation, specifically during cold pressor tolerance, are consistent with 
the vast majority of the literature on experimental pain sensitivity in MDD and may, in fact, 
coincide with the increased clinical pain observed in the disorder.     
 
Symptom Severity in Prior MDD vs. No Prior MDD  
 Further evidence for continued dysfunction beyond the remission of MDD exists in 
our findings for heightened reported symptom severity in women with prior MDD.  Although 
these women with prior MDD were not currently suffering from a depressive episode, this 
symptom perseverance may be indicative of the risk for development of a future MDD 
episode, since it has been shown that over 75% of MDD sufferers will battle with recurrences 
of the disorder at some point in their lifetime [10].  Approximately 54% of women in our 
study had experienced MDD two or more times in the past, and since studies show that after 
an individual experiences a second major depressive episode, the risk of a third becomes 
70% within three years [18], there is a high probability of recurrence of the disorder.  Thus, 
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the current findings, along with previous data from our laboratory [unpublished] showing 
that women with prior DEP experience elevated daily somatic symptoms than never 
depressed women, may predict a high rate of recurrence of the disorder.   
Not only may enduring symptom severity predict future major depressive episodes, 
but persistent disturbance in endogenous stress [20-26] and pain [27, 28]-related factors may 
also be predictive of relapse.  Banki and colleagues [165] showed that patients who relapsed 
within six months of antidepressant treatment had higher CRH levels during remission than 
those who remained asymptomatic.  Additionally, persistent DEX/CRH non-suppression of 
cortisol, indicative of an upregulated HPA-axis and dysregulation in negative feedback 
mechanisms, has been shown to be predictive of MDD relapse, as discussed above [134, 174, 
176, 177].  Finally, a recent animal study shows that HPA-axis dysregulation may be related 
not only to the likelihood of DEP relapse, but also to the persistency of the depressed state 
[327].  Mizoguchi et al. [327] exposed rats to a chronic stressor, which is known to induce 
behavioral depression, followed by a three month rest period, and found that the behaviorally 
depressed state assessed via rotarod test persisted even after the extensive rest period, 
coupled with persistent HPA-axis dysregulation via DEX non-suppression.  These studies 
show that sustained HPA-axis hyperactivity during symptom remission in those with prior 
DEP may be indicative of a subsequent episode of DEP [165, 173], and that CRH 
hypersecretion may be a stable or “trait” indicator of vulnerability to DEP [131].  While we 
did not find evidence for sustained HPA-axis hyperactivity in prior MDD, possibly due to 
our sample size limitations, we did find evidence for sustained SNS upregulation in prior 
MDD, specifically increased DBP responses to speech stress when compared to women with 
no prior MDD.  Alterations in underlying pain pathways, whether manifested as increased 
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clinical pain or decreased experimental pain sensitivity, may be the common denominator 
resulting from persistent disturbance in stress-responsive pain regulatory mechanisms, such 
as heightened SNS activation [233, 235-246], that are also known to affect mood states.  
Sustained clinical pain has also been shown to predict depression outcomes has also 
been observed in the literature [328].  For instance, Von Korff et al. [329] assessed the 
severity of physical disease in patients with MDD at baseline and at 6- and 12-month follow-
ups and found that patients who showed mean improvement in their depressive symptoms 
had decreased physical disease severity at baseline than those patients whose depression 
symptoms did not improve.  Additionally, a review by Von Korff and Simon [330] observed 
that pain-related functional impairment and number of days in pain predicted greater severity 
of depressive disorders.  Our findings of persistent dysregulation in pain sensitivity to cold 
pressor pain in women with prior MDD may be predictive of future depressive episodes.  A 
replication of the current study including longitudinal data on relapse rate would allow future 
studies to determine the predictive nature of persistent symptoms, stress-response 
dysregulation, and pain, on future episodes of MDD. 
 
Role of Endogenous Steroid Hormones in Current and Prior MDD 
 Our results indicating that women with prior MDD reported more severe depression, 
impairment, anger/irritability, and anxiety than women with no history of MDD only in the 
luteal phase of the menstrual cycle might lead one to speculate that greater luteal phase 
symptoms in women with prior MDD may be due to a disproportionately high percentage of 
PMDD women compared to non-PMDD in this group.  However, our data shows that the 
percentage of women diagnosed as PMDD did not differ between women with or without 
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prior MDD (46% vs. 44%), and suggest an alternative explanation.  Therefore, these results 
may be better explained by previous data showing that an estimated 64% of women with 
current MDD experience premenstrual exacerbation of their depressive symptoms [331], and 
studies showing that women demonstrate increased rates of DEP and suicide attempts 
premenstrually [54, 331, 332].  Furthermore, despite remission due to effective treatment, 
DEP may recur only during the luteal phase [61].  Thus, our findings may support the notion 
that premenstrual magnification of mood symptoms may remain beyond the remission of the 
depressive episode. 
 The exclusively premenstrual presence of symptoms in women with a history of 
MDD may also reflect the pathophysiological link between female gonadal hormones and 
depressive disorders.  MDD is the leading cause of disease-related disability in women, 
affecting approximately 21.3% of females, while only 12.7% of males [12].  However, some 
estimates of the gap between the genders are even greater, finding prevalence rates in women 
to be 1.5 - 3 times greater than men [17].  Endocrine control of the reproductive system and 
hormonal fluctuations throughout the menstrual cycle play key roles in the development of 
certain mood disturbances in women and therefore contribute to this gender gap.  Although 
the explanatory abilities of sex hormones are not sufficient to explain gender differences in 
the prevalence of MDD since the pathogenic mechanism of action is not well understood 
[16], the importance of gonadal hormones in women’s mood disorders may provide a partial 
explanation for the increase in luteal phase mood symptoms in our prior MDD women.   
Distinct time periods in the female life cycle when hormonal changes arise, such as 
during the menstrual cycle, after the birth of a child, and during the menopausal transition, 
are associated with increased vulnerability to dysphoric states [1, 3, 4].  Mood disturbances 
                                                                                                                                        
 122
associated with these hormonal changes such as PMS, PMDD, postpartum depression, and 
perimenopausal depression, all require the female brain to adapt to fluctuating hormones or 
to a new baseline hormone level.  If the brain does not properly respond and adjust its 
function accordingly, this may lead to the development of mood disorders such as MDD 
[333].  For example, women are more likely to develop MDD, including new onset MDD, in 
the menopausal transition period than when premenopausal [334, 335], and this MDD risk is 
no longer present in the postmenopausal stage [336].  Therefore, it may not be the absolute 
levels of gonadal hormones, but the premenstrual change in the levels of these hormones that 
contribute to the increase in mood symptoms observed exclusively during the luteal phase.   
Support for this comes from research suggesting that aberrant reactions to normal 
fluctuations in hormone levels throughout the menstrual cycle may be a cause of PMDD [66, 
71] and that PMDD women may be more sensitive to the mood modulatory effects of 
gonadal hormones [72].  For example, using a GnRH agonist to suppress ovarian function, 
Schmidt et al. [71] showed that within the context of ovarian suppression [and symptom 
elimination] in PMDD women, the addition of either progesterone or estradiol precipitates 
(within 1-2 weeks) the return of symptoms comparable in severity to those seen at baseline.  
Moreover, that study [71] also showed that the same manipulation was without effect in 
women without PMDD, demonstrating for the first time a differential sensitivity to gonadal 
steroid hormones in PMDD.  The importance of changes in gonadal steroids in PMDD was 
suggested by an early observational study of Halbreich et al. [337], who found that the 
strongest predictor of premenstrual symptom severity in PMDD women was the rate of 
change in luteal phase progesterone and estradiol following peak levels, and not the absolute 
hormone levels per se.  This observation provides further evidence that the dysphoric mood 
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states in women with PMDD are consequent to changes in normal ovarian steroid hormone 
concentrations across the menstrual cycle, similar to pathophysiological mechanisms 
postulated for the induction of postpartum depression [338, 339].   
Further evidence implicating changes in hormone levels in the onset of DEP comes 
from a study assessing the effect of hormone manipulations in currently euthymic women 
with and without a history of postpartum depression, Bloch et al. [339] administered GnRH 
agonist leuprolide acetate in order to produce a hypogonadal state, added back high doses of 
estradiol and progesterone to mimic pregnancy, and then withdrew both steroids in order to 
induce a simulated post-partum period.  The study observed that only women with a history 
of postpartum depression reported increased mood symptoms during hormone add-back and 
withdrawal, indicating that women with a history of postpartum depression have a 
differential response to changes in gonadal steroids than women with no history of 
postpartum depression.  The results of these studies [71, 337, 339] indicate that not only may 
women with PMDD be more sensitive to fluctuations in gonadal steroid levels, but a history 
of DEP may confer a heightened state of vulnerability in certain subgroups of PMDD 
women.   
Further studies that may explain the exclusively premenstrual increase in mood 
symptoms in our sample of women with prior MDD are those showing a higher likelihood 
for women to develop depressive symptoms during perimenopause than when premenopausal 
[334, 340].  Freeman et al. [334] followed premenopausal women with no histories of DEP 
throughout the transition to menopause, and found that the variability and not the absolute 
levels of hormones during perimenopause mediated increased depressive symptoms as well 
as MDD.  Thus, it is not surprising that women who are free of current depressive illness, but 
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who have a history of MDD, continue to experience symptoms associated with their former 
depressive state in accordance with hormone fluctuations during the menstrual cycle.  
 
Hypothalamic Pituitary Adrenal Axis and Sympathetic Nervous System Function in 
Prior MDD vs. No Prior MDD  
Although we observed no diagnosis-related differences in HPA-axis factors at 
baseline, women with prior MDD showed somewhat greater increases in DBP from baseline 
to speech stress than women with no history of MDD.  The latter supports previous research 
for an upregulated SNS stress-response in current MDD patients [117, 120, 121], and those 
displaying current depressive symptoms [104, 157].  For example, Lechin et al. [117] found 
increased NE at baseline, as well as heightened NE and HR in response to orthostatic and 
exercise stress in patients with MDD compared to control subjects, and Udupa and 
colleagues [119] reported increased SNS activity in MDD patients, reflected in baseline 
systolic BP and measures of HRV.  Additionally, a recent animal study found SNS 
upregulation in rats during a chronic stress-induced depressive state, finding heightened 
resting HR and MAP, and reduced HRV compared to non-depressed rats [248].   
Even elevated depressive symptoms in the absence of clinical DEP are associated 
with increased 24 hour urinary NE and HR in daily life [156], as well as increased BP, HR, 
CO, and NE in response to a speech stressor [157], and heightened systolic BP in response to 
an exercise challenge [104].  A study by Hamer and colleagues  [121] supports the positive 
relationship between DEP and SNS factors, finding that subjects with high depression scores 
displayed greater HR and 3-methoxy-phenylglycol (the major metabolite of NE) reactivity to 
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anger and depression-inducing speech stressors than those low on the depression scale, 
although these measures did not differ at baseline.   
Although previous studies have observed a hyperactive SNS in patients in remission 
from MDD at baseline [23, 24], ours is the first study, to our knowledge, to assess stress-
induced SNS factors in euthymic women not taking antidepressant medications.  Although 
our results for a hyperactive SNS in women with prior MDD were not as robust as the 
literature in current MDD [117, 120, 121], we were able to extend and support previous 
research suggesting that the upregulation in BP stress reactivity persists beyond the remission 
of the depressive episode [23]. 
 
Relationship Between Hypothalamic Pituitary Adrenal Axis and Sympathetic Nervous 
System Factors and Pain Factors of Threshold, Tolerance, Intensity, and 
Unpleasantness in Prior MDD vs. No Prior MDD 
The BP/pain relationship was also present in women with a history of MDD, since the 
high SBP groups had consistently decreased pain sensitivity and subjective pain ratings than 
the low SBP groups, while women with no history of MDD failed to show any consistent 
relationship involving BP and pain.  Although these results in women with no prior MDD 
were unanticipated due to robust literature reporting the positive association between BP and 
pain, [233, 235-247], the majority of the work was conducted in men or mixed gender 
samples without separate analyses in women.   
Moreover, a recent study that suggests distinct biological underpinnings of the 
relationship between BP and pain sensitivity in MDD versus non-depressed individuals that 
may shed light on the observations of the present investigation [255].  Frew and Drummond 
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[255] assessed cold pressor pain tolerance, intensity, and unpleasantness ratings both before 
and after administration of the opioid antagonist naltrexone or placebo in subjects with and 
without current MDD.  They discovered that in non-depressed controls, the BP/pain 
relationship was present in the placebo group, but not in the naltrexone group, indicating that 
endogenous opioids are necessary to maintain the association between BP and pain in 
controls.  In contrast, in MDD patients, the BP/pain relationship existed in the naltrexone 
group, but not in the placebo group, indicating that endogenous opioids may block the 
association between BP and pain in MDD [255].  This study shows that the biological 
mechanisms underlying the association between high BP and reduced sensitivity to acute 
pain may differ between those with and without MDD.  Furthermore, since our cohort failed 
to show greater β-endorphin levels in MDD that have previously been supported [101, 104], 
levels that have been shown to block the BP/pain relationship, it is possible that in our 
sample of women with prior MDD, the lack of heightened β-endorphin typically found in 
other MDD samples resulted in the emergence of this relationship between BP and pain in 
the present study (i.e. a functional blockade of opioid tone associated with lower levels).  
Another potential explanation for stronger and more consistent relationships between 
heightened SBP and decreased pain sensitivity and perception in women with prior MDD 
compared to never depressed women may involve upregulated baroreceptor mechanisms.  
Evidence for enhanced baroreceptor stimulation in prior MDD comes from our findings for 
hyperactive BP responses to stress coupled with decreased sensitivity to pain in this 
population.  Since individuals with remitted MDD show persistently heightened levels of 
perceived daily stress [81], as well as persistent SNS reactivity to stress as seen in our study, 
baroreceptor mechanisms must be consistently stimulated in order to activate homeostatic BP 
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control mechanisms, subsequently causing an enhancement of the BP/pain sensitivity 
relationship over time.   
Heightened baroreceptor stimulation causing a stronger link between stress responses 
and pain may be advantageous in the sense of allowing heightened SNS reactivity to stress 
[21-24] to combat increased acute pain during the defense reaction, but may be, under certain 
circumstances, a maladaptive adaptation that serves to sustain the disorder that may last 
beyond the remission of the depressive episode.  A clinical example comes from patients 
with silent myocardial ischemia, where increased baroreceptor activation influences a strong 
relationship between BP and pain and is thought to be maladaptive.  Since individuals with 
this disorder are asymptomatic, the hypertensive-associated hypoalgesia serves not only to 
sustain the disorder, but to keep it hidden from the patient who is in need of medical attention 
[341].   
A case in addition to MDD in which a stronger BP/pain relationship in women with a 
psychiatric disorder might be maladaptive is in bulimia nervosa (BN).  Women with BN have 
been shown to display a strong association between BP and pain sensitivity not seen in 
controls [342], since a study from our laboratory reported BP-related hypoalgesia in response 
to the tourniquet ischemic pain task in women with BN that was absent in healthy controls.  
Given this association, increases in BP as a result of bingeing and purging may reduce the 
physical discomfort that coincides with these behaviors, serving as a maladaptive mechanism 
for the individual in the sense of maintaining the disorder [342].  Since both MDD and BN 
are highly associated with depressive symptomatology [343] and heightened SNS 
responsivity (i.e. binging and purging in BN [342]), it is possible that enhancement of 
baroreceptor activation occurs during their development as a maladaptive mechanism, 
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decreasing the pain associated with both disorders, but also acting as a rewarding mechanism 
contributing to their maintenance.  
The results of our study indicate that dysregulation in pain and stress mechanisms 
found in patients with current MDD persist beyond the remission of the depressive episode, 
and thus are key underlying components of the disorder that may contribute to the etiology of 
MDD.   
 
Comparisons and Contrasts Between PMDD and Prior MDD 
Although the majority of our findings support divergent physiological profiles 
involving pain and stress mechanisms between women with prior MDD compared to women 
with PMDD, certain similarities in our data did in fact exist.  For instance, only the cold 
pressor pain task was able to elicit the greater pain sensitivity found in PMDD and the 
decreased pain sensitivity present in prior MDD compared to their respective control groups, 
while the tourniquet ischemic pain task did not uncover any diagnostic differences in pain 
sensitivity based on either PMDD or prior MDD status.  An explanation for the absence of 
the expected diagnosis-related differences in pain sensitivity during the tourniquet task may 
come from the fact that experimental pain tests have been shown to activate different 
endogenous pain mechanisms.  Sensitivity to tourniquet ischemic pain involves endogenous 
opioid mechanisms [265, 266]], whereas sensitivity to cold pressor pain may be mediated by 
systemic vascular resistance and noradrenergic mechanisms, or in other words, the SNS 
[233].   
A recent study from our laboratory lends support for cold pressor pain sensitivity to 
be mediated by SNS factors, finding that NE was an independent predictor of cold pressor 
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pain tolerance, but not tourniquet ischemic tolerance, in non-smokers [233].  Furthermore, 
studies have shown that the selective opioid receptor antagonist naloxone increases 
tourniquet ischemic [265, 344], but not thermal [345, 346], pain sensitivity.  The current 
study observed greater SNS reactivity in prior MDD and blunted SNS reactivity in PMDD 
compared to their respective control groups, but no diagnosis-related differences in baseline 
β-endorphin.  Thus, since the anticipated diagnosis-related differences are only present for 
SNS factors, one would expect differences in pain sensitivity only for the laboratory-based 
test that is mediated by sympathetic mechanisms.  In summary, our findings for exclusively 
SNS dysregulation in women with PMDD and a history of MDD correspond to our 
observation of pain dysregulation in the SNS-mediated cold pressor pain task, but not in the 
opioid-mediated tourniquet ischemic task.  
Another similarity between all women in our study was the lack of diagnostic-related 
differences in the HPA-axis factors of baseline β-endorphin and cortisol.  Due to logistical 
reasons, our laboratory study protocol was restricted to early morning hours, which may 
explain the lack of diagnosis related differences in our HPA-axis factors.  Our decision to 
sample β-endorphin only at baseline was due to the lack of an established time course for 
capturing a β-endorphin response to mental stress, and to the lack of reliability of stress-
induced HPA-axis measures during the early morning hours when our study took place.  
Research has shown that cortisol levels show only small spontaneous fluctuations in the late 
afternoon as compared to the morning [347], and that cortisol levels rise for approximately 
the first hour an individual is awake and then decline steadily throughout the rest of the day 
[348, 349].  Specifically, the lowest concentration of the plasma cortisol circadian rhythm is 
at midnight, rising to a peak between 6:00 and 8:00am, and falling until day’s end [350].  
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Therefore, many studies that aim to observe a cortisol response to stress have been conducted 
in the late afternoon to early evening [270, 272, 351], since the ability to detect a stress 
response is diminished in the morning when cortisol levels are at their most rapid decline and 
stress perturbation is acting against the strong diurnal decline [350].  Thus, since stress-
responsive β-endorphin concentrations mimic that of cortisol [95], measurements of both 
HPA-axis factors in response to stress are unreliable in the early morning when our study 
was conducted.  Thus, we restricted our HPA-axis measurement to occur strictly at baseline 
rest, and since prior studies assessing baseline levels of cortisol and β-endorphin in both 
PMDD and prior MDD do not consistently support diagnostic related differences, our ability 
to detect diagnosis-related differences may have been stronger if stress-responsive factors 
were assessed.   
The literature on baseline β-endorphin levels in PMDD women has not been well 
established, and earlier studies reporting decreased β-endorphin levels in PMDD [60, 180, 
181] have been questioned in terms of their accuracy by PMDD experts participating in a 
roundtable discussion of the biological determinants of the disorder [60].   Similarly, 
evidence regarding decreased baseline cortisol concentrations in PMDD versus non-PMDD 
women has been described as scant, inconsistent, and mainly focused on cortisol responses to 
neuroendocrine challenge tests [352].  In contrast, women with PMS, a syndrome that is less 
strictly defined clinically and less severe than PMDD, have been shown to display reduced 
peripheral β-endorphin levels during the luteal phase of the menstrual cycle compared to 
non-PMS women during the luteal [179-181] and follicular [182] phases, and a recent study 
from our laboratory found decreased peripheral baseline β-endorphin levels in PMDD versus 
non-PMDD women [182].  Comparable evidence for a hypoactive HPA-axis in PMDD 
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comes from two separate studies from our laboratory, finding decreased baseline cortisol in 
PMDD versus non-PMDD women [79, 182].  In light of the latter findings for a hypoactive 
HPA-axis at baseline in PMDD women, our lack of support for these findings may be 
spurious and a reflection of our small sample size.  
A similar explanation may be given for our lack of prior MDD-related differences in 
HPA-axis factors.  Although prior studies assessing β-endorphin in patients with current DEP 
have mostly focused on responses to challenge, finding increased β-endorphin levels 
compared to healthy controls, or on responses to successful treatment, observing a concurrent 
decrease in depressive symptoms and β-endorphin concentrations [95, 101, 104, 170, 183], 
the majority of studies in current and prior MDD have shown support for a hyperactive HPA-
axis.   For instance, increased levels of cortisol at baseline [95-102] and diurnal (i.e. mean 
daily concentrations assessing fluctuations due to circadian rhythm) [105, 106] cortisol levels 
in women with current MDD compared to non-depressed subjects have been reported, and in 
research assessing individuals with histories of MDD, results have shown higher diurnal 
salivary cortisol [21], and greater diurnal mean urinary cortisol [22] compared to those with 
no history of MDD.   Moreover, Goodwin et al. [101] found greater β-endorphin levels in 
patients with MDD at rest compared to non-depressed controls, and Krittayaphong et al. 
[104] reported that coronary artery disease patients with high depression scores had higher 
resting β-endorphin levels than those patients with low depression scores.  Therefore, the 
lack of differences in baseline HPA-axis factors based on prior MDD status, similar to that 
found in our PMDD women, may be due to our small sample sizes.  Thus, future studies that 
include larger samples may enlighten our potentially spurious findings in women with 
PMDD and prior MDD.   
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The null findings regarding cortisol levels in our study are not likely due to issues 
regarding the reliability of our plasma measurement.  Cortisol exists in two forms, free 
cortisol, and total cortisol, the latter of which comprises free plus bound cortisol.  Plasma 
concentrations reflect only total cortisol concentrations, and thus has been criticized for its 
lack of clinical relevance, since only free cortisol is biologically active [350, 353, 354].  
However, Wedekind et al. [355] assessed salivary, free plasma, and total plasma (free and 
bound) at baseline in patients with panic disorder and healthy controls, and found elevated 
cortisol concentrations in patients compared to controls irrespective of cortisol measurement.  
Similarly, Carroll and colleagues [356] assessed individuals with and without current mood 
disorders for cerebrospinal fluid cortisol, total cortisol in plasma, and urinary free cortisol, 
and found that regardless of the measurement used, mood disorder patients showed higher 
cortisol concentrations compared to healthy controls.  The results of these studies indicate the 
plasma total cortisol is an accurate biological measure and allows for the differentiation of 
HPA-axis dysfunction in affective disorders.  
An important distinction between PMDD and prior MDD may be differences in 
baroreceptor regulation of BP and pain sensitivity.  In PMDD women, despite showing 
decreased SNS responsivity to mental stress coupled with increased sensitivity to cold 
pressor pain, we found no evidence for consistent relationships between BP and pain 
sensitivity.  Thus, the less persistent baroreceptor stimulation resulting from decreased SNS 
activation in PMDD women may contribute to the absence of the BP/pain relationship.  A 
similar explanation can be utilized to explain the contrasting relationship in prior MDD.  
Women with prior MDD in our study showed increased BP responses to the speech stressor 
coupled with decreased sensitivity to cold pressor pain, as well as a strong relationship 
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between BP and pain.  The chronically heightened SNS found in women with prior MDD 
may result in more persistent baroreceptor activity, thus explaining the robust association 
between BP and pain in these women.  In summary, differential activation of baroreceptor 
pathways influenced by opposing SNS activation in PMDD versus prior MDD may explain 
the presence of the BP/pain relationship in prior MDD, but not PMDD. 
 
Study Limitations 
There are several limitations to this study that should be acknowledged.  First, due to 
logistical issues surrounding time of day of testing, we were unable to assess the stress-
induced HPA-axis factors of cortisol and β-endorphin, factors that would be expected to 
differ based on both PMDD [178] and prior MDD [127] status.  The ability to measure these 
HPA-axis factors in response to mental stress in our study would have enabled us to not only 
replicate prior findings for diagnostic related differences in cortisol and β-endorphin, but to 
be the first to find differences in the relationship between these measures and experimental 
pain sensitivity in both women with PMDD and women with prior MDD.  Future research 
assessing stress-responsive measures of cortisol and β-endorphin during the late afternoon 
are warranted in order to determine any diagnosis-related dysregulation in the HPA-axis/pain 
relationship.  
Furthermore, future studies assessing additional HPA-axis measures such as ACTH 
and CRH would further enlighten the exact mechanisms involved in the downregulation of 
the HPA-axis in PMDD and the hyperactive HPA-axis in current and prior MDD.  Since the 
majority of the evidence for HPA-axis dysregulation in MDD comes from studies showing 
increased CRH levels in MDD [122, 166, 168, 170-172], levels that have been shown to 
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cause decreased ACTH but normal to elevated cortisol in response to CRH [10, 130, 137, 
138], the assessment of all components of the HPA-axis in women with a history of MDD is 
necessary in order to paint a full picture of persistent HPA-axis dysfunction.  Since chronic 
CRH hypersecretion and overall hyperactivity of the HPA-axis in MDD are strongly related 
to impairment in negative feedback to the hypothalamus [131, 132, 137, 139], the assessment 
of CRH and ACTH would allow for the measurement of HPA-axis factors that are responsive 
to negative feedback mechanisms.  
Impairment of HPA-axis negative feedback has indeed been assessed in euthymic 
individuals with a history of MDD, finding normalization after successful treatment [103, 
148, 169, 171].  Although Ising and colleagues [128] argued that normalization of HPA-axis 
negative feedback is a key factor in the success of antidepressant drugs, and studies show that 
the degree of normalization correlates with and predicts clinical efficacy of antidepressants 
[173], a limitation of many of the existing studies is the relatively short length of time 
between baseline and post-treatment testing, with the majority of studies retesting 6 weeks or 
less after baseline [112, 148, 169].  Normalization of HPA-axis after treatment may be a 
short-term phenomenon that initially overrides the “trait” characteristic of heightened HPA-
axis activity, but may return over time and become uncoupled from symptom improvement.  
Thus, further studies are needed to determine if impairment in HPA-axis negative feedback 
shows long-term persistence in euthymic women with prior MDD. 
Another limitation that deserved mention is the small sample size for women with 
prior MDD (N = 13).  We were thus unable to explore interactions involving PMDD and 
prior MDD, which limited our ability to investigate the potential interplay in the underlying 
mechanisms of PMDD and prior MDD.  Further studies including a larger sample of women 
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with prior MDD may have the analytic capacity to observe interactions between PMDD and 
prior MDD, and possibly concluding that PMDD does not stand alone in its biological and 
psychosocial determinants, but instead occurs in the context of MDD.  As Rubinow and 
Schmidt [67] asked when attempting to understand why gonadal steroids play a role in the 
manifestation of PMDD in some women, but not others, “What is the context of 
susceptibility?”  They determined that the answers to this question lie within a tangled web 
of individual differences that may cause gonadal steroids to trigger PMDD in some women, 
but not others.  Future research may discover that another “context of susceptibility” for 
PMDD may in fact involve the presence or absence of a history of MDD.  
 Another limitation of the small sample size is that we were unable to control for 
differences in baseline anxiety and depression, differences that may have contributed to our 
stress responsivity and pain sensitivity results.  However, mood disturbances are significant 
aspects of both PMDD and MDD, especially during the luteal phase of the menstrual cycle 
when state anxiety and depression were assessed, and thus the more negative mood found in 
PMDD and prior MDD was likely a manifestation of the disorder, as opposed to an 
extraneous variable.  Thus, controlling for these baseline differences may have resulted in the 
masking of critical aspects of the disorders, and subsequently hindering our ability to 
determine diagnosis related differences in stress and pain sensitivity.  
 
Study Retention 
Due to the need for strict PMDD diagnostic criteria involving 2-3 months of daily 
ratings and long-term commitment necessary to complete the laboratory study protocol, 
many women who were enrolled and signed a consent form did not remain through the 
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study’s completion.  Thus, another goal of our study was to determine if certain demographic 
factors were predictive of voluntarily dropping out of the laboratory study protocol at any 
time prior to completion, or being classified as a ‘dropout’.  We found that race classification 
of Minority, presence of a self-reported psychological history, greater self-reported alcohol 
consumption, and presenting as PMDD were found to be significant predictors of voluntarily 
dropping out of the study.   
These results are logical, since women who have experienced depression symptoms 
either currently or in the past, who think they have PMDD, or consume higher amounts of 
alcohol per month may be more likely to drop out due to lack of dedication, time, motivation, 
and emotional stability necessary to complete the multiple visits involved in the study 
protocol.  Furthermore, only approximately 8% of women who presented as PMDD and 
voluntarily dropped out of the study actually met diagnostic criteria for PMDD.  Thus, the 
vast majority of women presenting as PMDD did not in fact suffer from the disorder, 
consistent with numerous other reports [45, 46, 78].  Most likely, these women were 
suffering from a sub-threshold psychiatric disorder other than PMDD, and thus may have 
contributed to PMDD presentation predicting dropout status in our model. 
We also assessed the predictive value of the abovementioned demographic variables 
in a larger group of women called ‘non-completers’ that included the ‘dropouts’, or those 
who voluntarily dropped out of the study, and also included women who signed a consent 
form but either had not completed the study at the time of data analysis, or were withdrawn 
from the study due to forces outside of their control, such as medical concerns or failing to 
meet diagnostic or inclusion criteria.  We determined that a higher BDI score, self-identified 
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Minority race, presence of a self-reported psychological history, and presenting as PMDD 
were predictors of non-completion of the laboratory study protocol.  
The finding for the presentation of PMDD to be a predictor of being a ‘non-
completer’ is a reflection or our strict diagnostic criteria for PMDD, since many women who 
believe they have PMDD do not meet criteria upon daily ratings inspection.  Instead, while 
some have simply overestimated the severity of their symptoms, a sizeable proportion of 
these women are those with chronic, phase-independent dysphoria.  Thus, the presentation of 
PMDD may likely reflect current mood disturbance and is consistent with the ability of high 
BDI scores to predict non-completion.  Moreover, the ability of depression scores and self-
reported psychological history to predict non-completion of the laboratory study protocol is 
understandable, since women who currently feel depressed or anxious, or have suffered from 
a psychological disorder in the past, are less likely meet non-PMDD as well as PMDD 
criteria due to ongoing symptoms, irrespective of the menstrual cycle.  
Although there were no demographic factors distinguishing non-Hispanic Whites 
from Minorities that could potentially explain the ability of Minority status to predict both 
non-completion and voluntarily dropping out of the laboratory study protocol, other factors 
that were not measured in the current study, such as daily life stress and chronic stressors, 
may have played a role.  It is well established that African Americans experience more 
psychosocial stress such as racism, and experience more chronic stress due to unemployment, 
low socioeconomic status (SES), and lower social status than Caucasians [357].  Although 
there were no race-related differences in SES in our study, African Americans generally 
experience more chronic stress in the form of discrimination compared to Caucasians, 
regardless of SES [358].  Therefore, since African American women made up the most of our 
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Minority sample, had we measured these stress-related factors, we may have seen that they 
negatively impacted our Minority sample in a way that would decrease the likelihood of 
completing our laboratory protocol.     
In order to obtain a true sense of the final sample of women in our study, it is 
important to compare the factors that distinguish ‘completers’ from ‘non-completers’ to the 
factors that distinguish ‘completers from ‘dropouts’.  Greater alcohol consumption predicted 
dropping out of the study, but did not predict non-completion of the study, indicating that 
alcohol use contributed to voluntarily dropping out prior to laboratory study protocol 
completion, but did not contribute to meeting diagnostic or inclusion criteria.  This implies 
that alcohol consumption may be related to non-compliance with the study in terms of 
missing visits to the laboratory, forgetting to complete the daily ratings, etc., but does not 
necessarily affect PMDD symptomatology.  On the other hand, greater BDI scores predicted 
non-completion of the study, but did not predict dropping out of the study.  This finding 
suggests that the higher depressive symptoms may be a factor that made women less likely to 
complete the laboratory study protocol due to failing to meet inclusion or diagnostic criteria 
(due to the chronic nature of depressive symptoms), instead of due to voluntarily dropping 
out of the study.  
 
Summary of Primary Findings and Hypotheses Regarding Differential Adaptation to 
Stress in PMDD and MDD 
In the present investigation, we determined that women with PMDD displayed 
heightened cold pressor pain sensitivity and reduced SNS stress reactivity in addition to 
reporting more difficulty, tension, and inability to concentrate during mental stress than non-
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PMDD women.  Furthermore, non-PMDD women showed a more consistent relationship 
between BP and pain sensitivity, while PMDD women showed a more robust relationship 
between β-endorphin and pain sensitivity.  In contrast to the profile of PMDD women, 
euthymic women with prior MDD showed decreased cold pressor pain sensitivity and greater 
DBP responsivity to stress than never depressed women.  Since women with a history of 
MDD were free of the disorder for, on average, over seven years, our study has documented 
persistent biological disturbances beyond the remission of the depressive episode.  Lastly, we 
observed that women with prior MDD displayed a more consistent pattern of relationships 
between greater BP and decreased pain sensitivity, while women with no prior MDD showed 
more consistent associations between increased baseline cortisol and decreased pain intensity 
and unpleasantness.   
Based on the results of the present investigation, one may argue that downregulation 
of the stress axes in PMDD women may have developed as an adaptive mechanism to 
combat the heightened experience of stress, whereas this adaptation failed to occur in 
individuals with current and prior MDD.  However, the MDD literature suggests viewing the 
dysregulation of the stress axes as a pre-cursor to the development of MDD as opposed to a 
failure to adapt to a heightened stress experience.  For example, as mentioned above, CRH 
causes symptoms of MDD in animals [144], normalization of HPA-axis and SNS parameters 
upon remission following antidepressant treatments haven been robustly reported [103, 146, 
149, 166, 168-171], and persistent HPA-axis upregulation following treatment of MDD 
predicts relapse [134].  Moreover, since euthymic first degree relatives of depressed patients 
show persistently intermediate levels of cortisol release in response to the DEX/CRH test that 
is between healthy controls and currently depressed patients [114, 164], there may also be a 
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stable genetic component contributing to HPA-axis dysregulation in MDD.  Finally, since 
our study found a heightened DBP stress response in currently euthymic women with prior 
MDD compared to never depressed women, it may be argued that if the upregulation of the 
HPA-axis and the SNS found in MDD reflects the failure of the organism to adapt to the 
disorder, the hyperactivity would not persist beyond remission.  Thus, upregulation of the 
stress axes in current and prior MDD seems to be a contributor to, rather than an effect of, the 
depressive disorder.  
 A similar argument for pre-existing biological disturbances contributing to the onset 
of MDD can be made regarding the decreased experimental pain sensitivity found in current 
and prior MDD.  Painful somatic symptoms that remain after successful treatment of MDD 
have been shown to predict future relapse [315], and since increased somatic pain and 
decreased sensitivity to experimental pain share a common biological origin (i.e. 
downregulation in central pain processing in MDD [326]), it can be inferred that decreased 
sensitivity to laboratory-based pain found in current and prior MDD may be an underlying 
mechanism serving as a physiological precursor to the development of the disorder.  
Moreover, although it may be argued that decreased pain sensitivity would logically be an 
adaptive mechanism in patients with MDD in order to cope with the heightened painful 
symptoms associated with the disorder [212], the persistence of pain dysregulation in the 
absence of current MDD can be viewed as evidence against this argument, since the 
adaptation would no longer be necessary beyond the remission of the disorder.  However, it 
is also possible that the decreased pain sensitivity found in women with a history of MDD 
may be viewed as a persistent adaptation to heightened somatic symptoms associated with 
MDD that has become a permanent remnant of the disorder.  Further longitudinal studies, 
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such as those examining high risk family members of patients with MDD, are necessary to 
determine the extent to which the decreased pain sensitivity in MDD is an antecedent or 
consequence of the disorder.  
The viewpoint that the dysregulation of the stress axes and pain sensitivity found in 
current and prior MDD reflects a physiological precursors to the development of MDD 
parallels the diathesis-stress model of psychology and psychiatry.  Diatheses in the 
psychological realm are considered relatively stable individual differences (i.e. genetic 
dispositions, cognitive style, biological dysfunction, or deficient social skills) that make 
people vulnerable to depression when confronted with stressful life events [357].  The pain 
and stress axes dysregulation in MDD may function as a diathesis, or biological substrate, on 
which a significant life stressor acts to trigger the onset of the disorder.  Research in the 
diathesis-stress model of depression shows that stressful life events interact with this 
substrate or vulnerability, triggering distress that affects the individual’s resilience and drives 
the individual toward the depressive condition [358].  Further understanding of the 
biopsychosocial diathesis-stress model of MDD will inform the development of future 
integrative treatments focusing on biological vulnerabilities and the life stressors that 
contribute to the onset of the disorder. 
 Since differential sensitivity to the fluctuations in female gonadal hormones in 
PMDD have been designated as the foremost underlying mechanisms associated with the 
disorder [71], there have been no studies to date examining the ability of the hypoactive 
stress axes or increased sensitivity to pain to predict or contribute to the development of 
PMDD.  However, these studies implicating menstrual cycle-related hormone changes as a 
precipitating factor in PMDD may not only play a role in the emotional symptoms associated 
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with the disorder, but to the physical somatic symptoms as well.  Since estrogen has been 
shown to have both analgesic as well as pain-inducing properties [359], the fluctuation in 
estrogen and other hormones throughout the menstrual cycle may play a role in the increased 
somatic symptoms reported by PMDD women.  Furthermore, since clinical pain has been 
associated with laboratory-based pain in healthy controls [214, 215] and chronic pain patients 
[216-218], these hormone fluctuations may also affect sensitivity to experimental pain in 
women with PMDD [360].  Thus, as opposed to considering increased sensitivity to pain as a 
consequence of PMDD, it is more likely that it is a contributing factor of the disorder, 
although studies addressing the causal nature of pain mechanisms in PMDD are warranted in 
order to further understand the underlying mechanisms of the disorder.  
In contrast to our hypothesis for MDD, it is possible that the downregulated HPA-axis 
and SNS found in PMDD did in fact develop as a homeostatic adaptation to the disorder, 
allowing women with PMDD to physiologically cope with their heightened subjective 
experience of stress.  Supporting evidence comes from post-traumatic stress disorder 
(PTSD), an illness that is also associated with a hypoactive HPA-axis [361].  Since both 
PMDD and PTSD share a high prevalence of abuse histories [361], the adaptive HPA-axis 
dysregulation may have arisen via similar mechanisms in both disorders.  The hypothesis that 
the hypoactive stress axes found in PMDD developed as an adaptation to the heightened 
stress associated with the disorder is accordance with the overall conclusion of the present 
study that PMDD and MDD each have a distinct pathophysiology.  The hypothesis suggests 
that the dysregulation of the stress axes serves not as an underlying mechanism and 
biological substrate in MDD, but as a homeostatic adaptation to the disorder in PMDD.  
Unlike MDD, PMDD is not a recurrent disorder, and thus research investigating the ability of 
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certain psychophysiological variables to predict PMDD relapse is not applicable.  Therefore, 
longitudinal studies are necessary to determine whether downregulated stress axes precipitate 
the development of PMDD or arise in response to certain stress-related biological or 
psychological manifestations of the disorder.   
 
Conclusions 
The results of the present study revealed distinct pathophysiology between women 
with prior MDD and women with PMDD.  Despite the fact that our results support the 
dichotomy of PMDD from MDD, PMDD women are more likely to have a history of DEP 
[45, 51-54] as well as develop a future depressive episode [56-59].  Thus, since we observed 
that women with prior MDD displayed decreased pain sensitivity, increased premenstrual 
symptom severity, increased SNS stress responsivity, and a stronger relationship between 
pain sensitivity and BP compared to women with no history of MDD, these results may have 
special relevance to PMDD women.  The present investigation underscores the need to assess 
DEP histories in women who present with PMDD in the clinical setting as well as in future 
research.  Since PMDD women with prior MDD may represent a biologically and clinically 
distinct subgroup of PMDD women, assessing psychological history may serve to inform 
treatment options in terms of stress and pain management in addition to refining the 
inconsistent PMDD literature in these areas.  
Furthermore, since histories of DEP are more common in PMDD, and since PMDD 
and prior MDD show opposing SNS stress reactivity, pain sensitivity, and pattern of 
endogenous pain regulation factors, histories of MDD may have special relevance for 
PMDD, and women with prior MDD should be recognized as a distinct subgroup of the 
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disorder.  Although our small sample size did not allow us to reliably determine the distinct 
physiological profile of co-morbid PMDD and prior MDD, we conducted preliminary 
analyses to investigate if in fact PMDD women with a history of MDD showed differential 
patterns of pain sensitivity, baseline HPA-axis factors, stress-responsive SNS factors, 
subjective ratings of pain and stress tasks, and severity of daily mood ratings (see Appendix 
B).  PMDD women with prior MDD showed biological profiles that more closely resembled 
that of PMDD (i.e. greater pain sensitivity, decreased cortisol, blunted NE response to stress, 
heightened effort and increased negative subjective experiences during the pain and stress 
tasks), indicating that the current pathophysiology predominates over the prior depressive 
disorder.  However, this co-morbid subgroup did differ from PMDD women with no prior 
MDD, and thus may still represent a distinct subgroup of PMDD women.  Although further 
research is necessary to determine the reliability of our preliminary findings, the entirety of 
our results implicate MDD and PMDD as two distinctive disorders, and show that a history 
of MDD may have special physiological and clinical relevance for women with PMDD. 
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APPENDIX A 
Enrollment Statistics 
 
Met Phone Screen criteria 
and signed Consent 
122 
*PMDD (76) 
*Non-PMDD (46) 
Did not complete 
study protocol 
84 
*PMDD (59) 
*Non-PMDD (25) 
Completed study 
protocol 
38 
PMDD (17) 
Non-PMDD (21) 
Received PMDD or 
CTL diagnosis 
15 
PMDD (8) 
Non-PMDD (7) 
 
Did not receive PMDD 
or CTL diagnosis 
69 
*PMDD (51) 
*Non-PMDD (18) 
 
Had not 
completed 
laboratory study 
protocol at time 
of data analysis 
2 
PMDD (2) 
Non-PMDD (0) 
 
Dropped out 
before 
completing 
study protocol 
8 
PMDD (3) 
Non-PMDD (5) 
 
Dropped out before 
providing the 2-3 
months of daily 
ratings required for 
diagnosis 
29 
*PMDD (20) 
*Non-PMDD (9) 
Did not meet 
enrollment 
criteria and thus 
did not begin 
daily ratings 
8 
*PMDD (6) 
*Non-PMDD (2) 
 
Completed 
BOTH the 
psychiatric 
interview and 
at least one 
month of 
daily ratings 
13 
 
Did not 
complete 
BOTH the 
psychiatric 
interview 
and at least 
one month of 
daily ratings 
16 
Did not 
complete 
BOTH the 
psychiatric 
interview and 
at least one 
month of 
daily ratings  
9 
Completed 
BOTH the 
psychiatric 
interview 
and at least 
one month of 
daily ratings 
23 
 
Did not meet 
PMDD 
(N=25) or 
non-PMDD 
(N=7) criteria 
based on daily 
ratings 
32 
Did not meet Phone 
Screen criteria 
359 
*PMDD (108) 
*Non-PMDD (251) 
Completed Phone Screen 
479 
*PMDD (325) 
*Non-PMDD (154) 
Did not 
complete the 
laboratory study 
protocol due to 
medical issues 
5 
PMDD (3) 
Non-PMDD (2) 
 
* = presented as PMDD or non-PMDD 
N = 53: women given a 
PMDD or CTL diagnosis 
N = 89: women who completed 
both the psychiatric interview and 
at least one month of daily ratings 
N = 75: women used in 
the analyses comparing 
dropouts and completers 
N = 122: women used in the 
analyses to compare dropouts, 
non-completers, and completers 
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Visual Analog Intensity Scale 
 
 
 
 
 
Strongest imaginable pain 
intensity of any kind 
Very strong pain intensity 
Strong pain intensity 
Moderate pain intensity 
Weak pain intensity 
Barely detectable pain intensity 
No pain intensity 
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Visual Analog Unpleasantness Scale 
 
 
 
 
 
 
 
Most unpleasant pain 
of any kind imaginable 
Very unpleasant pain 
Unpleasant pain 
Moderately unpleasant pain 
Weakly unpleasant pain 
Barely unpleasant pain 
No unpleasantness 
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Task Assessment Scale 
 
 
1.  Indicate on each of the scales below, by circling a number on the number line, your 
experience during the preceding task. 
 
 
Not Difficult______________________________________________________Very 
Difficult 
                       0        1        2        3        4        5        6        7        8        9        10 
 
 
     Not Tense   ____________________________________________________ Very Tense 
                       0        1        2        3        4        5        6        7        8        9        10 
 
 
Able to         ______________________________________________________  Not Able to                        
Concentrate    0        1        2        3        4        5        6        7        8        9        10   Concentrate 
 
 
2. Indicate on the scale before, by circling a number on the number line, how much effort 
you put into the preceding task. 
 
 
   Very Low  ___________________________________________________        Very High         
   Effort           0        1        2        3        4        5        6        7        8        9        10     Effort 
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ID# ________                               DAILY RATING FORM 
INSTRUCTIONS 
 
There are 24 items listed on the following pages.  Additionally, there are four blank columns 
where you may add items describing other changes that trouble you premenstrually.  This is 
where you can notify us of any symptoms that you wish to add. 
 
1. Rate each item every evening, preferably before bed.  It is usually a good idea to "post" 
the ratings where you will see them each night (e.g., the closet door, the mirror on the 
medicine cabinet), or to keep them on your nightstand. 
 
2.   The levels of severity for rating each item are given at the top of each page.  The ratings 
should indicate the degree to which you experienced the feelings or behaviors described 
in the item for that particular day. See attached form for descriptions of each rating. The 
severity ratings you select should reflect the average   intensity for that feeling for the 
whole day. 
 
3. Start with the correct day of the week for the first day's ratings (the same day as your 
screening visit). 
 
4. Continue to the end of all the pages (page 8) each day. 
 
5. In the column indicated, note only those days on which you are menstruating with an X. 
Remember that spotting is also considered menstruating and that you make symptom 
ratings every day, regardless of whether  or not you are menstruating. 
 
6. Comment on the last page if there have been unusual events that have affected your 
feelings or behavior for  that day (e.g., illness, very bad news), and make sure to write 
down the date. 
 
7. If you forget to complete the ratings on any evening, try to do it as early as possible on 
the next day, but do not complete more than one day’s ratings from memory.  If you miss 
a day, skip the column, but indicate that it  was a missed day. 
 
8. When you have completed each packet (each is good for 7 days) please place it in an 
envelope and mail it to us EVERY MONDAY.  It is very important for our record 
keeping that the calendars are returned in a timely fashion.  We will keep records of when 
each calendar is due. 
 
9. Call Becky at 919-966-2547 at the start of each period and for any additional questions 
you may have. 
 
TURN EACH PAGE EACH DAY, RATING A TOTAL OF AT LEAST 24 ITEMS. 
 
All information contained on this form and data summarized from it will be kept confidential.                             
Any written or verbal reports will be done in a way which precludes identification of individuals. 
 
_________________________________________________________________________________________ 
*Developed by Jean Endicott, Ph.D., Sybil Schacht, M.S.W., and Uriel Halbreich, M.D., Research 
Assessment and Training Unit, 722 West 168th Street, New York, New York  10032. 
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Severity Ratings: 1 = Not at all, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, 6 = Extreme 
 
Day of     Date      Menstruating? Felt depressed, sad,    Felt hopeless      Felt worthless    Felt anxious, keyed      Comments on 
Week                                 “down”, or “blue”                                   or guitly             up or  “on edge”           back page? 
                                                               
 
Mon   /                    1 2 3 4 5 6             1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Tue   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Wed   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Thu   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Fri   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sat   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sun   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No                                                                                               
 
Mon   /                     1 2 3 4 5 6            1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Tue   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Wed   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Thu   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Fri   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sat   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sun   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
 
Mon   /                      1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Tue   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Wed   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Thu   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Fri   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sat   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sun   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
 
Mon   /                      1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Tue   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Wed   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Thu   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Fri   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sat   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sun   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
 
Mon   /                      1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Tue   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Wed   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Thu   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Fri   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sat   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sun   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
 
Mon   /                      1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Tue   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Wed   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Thu   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Fri   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sat   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
Sun   /           1 2 3 4 5 6           1 2 3 4 5 6     1 2 3 4 5 6     1 2 3 4 5 6             Yes  No 
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Severity Ratings: 1 = Not at all, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, 6 = Extreme 
 
Day of     Date     Menstruating? Had mood swings,     Was more sensitive      Felt angry,        Had conflict or      Comments on 
Week                                 (e.g. suddenly felt       to rejection or my         irritable             problems with          back page? 
                                                          sad or tearful)             feelings were easily                                people 
                                                        hurt 
     
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No   
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No    
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No    
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No    
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No    
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6          1 2 3 4 5 6      1 2 3 4 5 6         Yes  No                                                                                               
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Severity Ratings: 1 = Not at all, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, 6 = Extreme 
 
Day of     Date    Menstruating?         Had less interest         Had difficulty          Felt lethargic,       Had increased        Comments   
Week                                 in usual activities       concentrating           tired, fatigued,     appetite or              on back page? 
    (e.g., work, school,                                     or had a lack        overate 
    friends, hobbies)                                         of energy   
                                                              
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No   
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No   
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No   
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No   
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No   
 
Mon   /                      1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Tue   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Wed   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Thu   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Fri   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sat   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No 
Sun   /           1 2 3 4 5 6          1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6         Yes  No  
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Severity Ratings: 1 = Not at all, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, 6 = Extreme 
 
Day of    Date     Menstruating?       Had cravings for      Slept more, took        Had trouble          Felt overwhelmed,    Comments on 
Week                       specific foods           naps, found it hard    getting to sleep     that I couldn’t cope   back page?   
     
Mon   /                      1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No  
  
Mon   /                      1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No  
 
Mon   /                      1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No  
 
Mon   /                      1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No  
  
Mon   /                      1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No  
 
Mon   /                      1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6         1 2 3 4 5 6         1 2 3 4 5 6      1 2 3 4 5 6          Yes  No  
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Severity Ratings: 1 = Not at all, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, 6 = Extreme 
 
Day of    Date     Menstruating?     Felt out of              Had breast             Had breast              Had headache          Comments 
Week                     control                   tenderness              swelling, felt                        on back page? 
                  “bloated” or had  
             weight gain  
 
Mon   /                      1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No  
                                                                                                
Mon   /                      1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No  
 
Mon   /                      1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No  
 
Mon   /                      1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No  
 
Mon   /                      1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No  
 
Mon   /                      1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Tue   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Wed   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Thu   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Fri   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sat   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No 
Sun   /           1 2 3 4 5 6       1 2 3 4 5 6       1 2 3 4 5 6        1 2 3 4 5 6          Yes  No  
 
                                                                                                
  
Severity Ratings: 1 = Not at all, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, 6 = Extreme 
 
Day of    Date    Menstruating?     Had joint or      At work, school, home     At least one of the    At least one of the     Comments  
Week                                              muscle pain      or in daily routine, at       above problems        problems above          on back                                              
                                                                                least on of the above        interfered with          interfered with            page? 
                                                                                problems caused less        hobbies or social      relationships  
                                                                                less productivity               activities 
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
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Severity Ratings: 1 = Not at all, 2 = Minimal, 3 = Mild, 4 = Moderate, 5 = Severe, 6 = Extreme 
 
Day of    Date    Menstruating?    Other symptom     Other symptom            Other symptom         Other symptom      Comments on                                                                     
Week                                             ___________       ____________            ____________           ____________       back page? 
      
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
 
Mon   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Tue   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Wed   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Thu   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Fri   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sat   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No 
Sun   /                  1 2 3 4 5 6       1 2 3 4 5 6            1 2 3 4 5 6          1 2 3 4 5 6          Yes  No  
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Comments: 
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APPENDIX B 
SUPPLEMENTARY RESULTS: ANALYSES AS A FUNCTION                                               
OF PMDD AND PRIOR MDD STATUS 
 
 
 
PMDD       Non-PMDD
Prior MDD
(n = 6)
No Prior MDD
(n = 11)
Prior MDD
(n = 7)
No Prior MDD
(n = 14)
Age 33.8 (3.5) 34.6 (2.6) 32.7 (3.2) 32.5 (2.3)
BMI 22.8 (2.4) 26.4 (1.8) 26.7 (2.2) 24.9 (1.6)
A BDI 7.5 (1.7) 6.8 (1.3) 3.1 (1.6) 1.4 (1.1)
State Anxiety 27.8 (3.7) 35.1 (2.7) 29.1 (3.4) 27.3 (2.4)
B Race (Non-Hispanic 
White : Other)
5 : 1 7 : 4 7 : 0 8 : 6
Abuse History 2 7 5 4
Prior Episodes of 
MDD
1.67 (0.35) 0 1.86 (0.33) 0
Months in Remission 
from MDD
106 (33) NA 72.3 (30) NA
Mean (+SEM) Demographic Factors as a Function of PMDD Status and Prior MDD
 
A
 PMDD > Non-PMDD, p < 0.01 
B
 MDD Diagnosis: Non-Hispanic Whites  > Other , p < 0.05 
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B
A
 
A
  Non-PMDD women with prior MDD > all other groups, ps < .09 
B
 Non-PMDD women with prior MDD > all other groups, ps < .06 
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Tourniquet Ischemic Pain Threshold and Tolerance as a Function 
of PMDD and Prior MDD Status
p < .05p = .11
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Difficulty Tenseness Inability to Concentrate Effort
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No Prior MDD
PMDD
Prior MDD
p = .06
Cold Pressor Task Assessments as a Function of PMDD and Prior MDD Status
*
p = .12
 
* PMDD women with prior MDD > all other groups, ps < .06 
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Difficulty Tenseness Inability to Concentrate Effort
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Daily Mood Ratings Core Symptom Categories as a Function of PMDD and Prior MDD Status
Follicular Luteal
Somatic Dep Ang/Irr Anx Impair Somatic Dep Ang/Irr Anx Impair
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(1-
6) 
(N
=
53
)
Non-PMDD
No Prior MDD
Non-PMDD
Prior MDD
PMDD
No Prior MDD
PMDD
Prior MDD
A B
A
A
A
A
C
C
 
A
 PMDD with no prior MDD > all other groups, ps < .05 
B
 non-PMDD with prior MDD > non- PMDD with no prior MDD, p = .06 
C PMDD with prior MDD > non-PMDD with no prior MDD, p < .05 
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Change in Norepinephrine from Baseline to Speech Stress as a 
Function of PMDD and Prior MDD Status
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Baseline Beta-Endorphin
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p = .12p < .05
p < .05
*
 
* PMDD women with prior MDD > all other groups; ps < .05 
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